0001822479-26-000015 | 10-K | XBRL Viewer

Print Document

Share-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Mar. 31, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
2020 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 30.5	$ 35.2	$ 30.4
Number of shares authorized (in shares)		27,900,000
Number of shares available for grant (in shares)		13,800,000
Restricted Stock \| Restricted Stock - Pre-IPO B-1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		5 years
Share-based compensation expense		$ 0.5	1.6	2.0
Restricted Stock \| Restricted Stock - Pre-IPO B-1 \| Year One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		20.00%
Restricted Stock \| Restricted Stock - Pre-IPO B-1 \| Year Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		20.00%
Restricted Stock \| Restricted Stock - Pre-IPO B-1 \| Year Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		20.00%
Restricted Stock \| Restricted Stock - Pre-IPO B-1 \| Year Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		20.00%
Restricted Stock \| Restricted Stock - Pre-IPO B-1 \| Year Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		20.00%
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		0
Contractual term		10 years
Period for recognition		1 year 1 month 6 days
Total unrecognized compensation expense		$ 4.9
Fair value of stock options vested		$ 9.8	16.3	10.6
Stock options \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		2 years
Stock options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Stock options \| 2020 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 7.3	16.4	14.4
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period for recognition		1 year 8 months 12 days
Total unrecognized compensation expense		$ 18.6
Fair value of stock options vested		$ 17.3	$ 15.4	$ 14.1
Granted (in dollars per share)		$ 13.48	$ 14.05	$ 16.95
RSUs \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
RSUs \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
RSUs \| 2020 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 20.4	$ 18.8	$ 16.0
Phantom Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Phantom Share Units (PSUs) \| 2020 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Share-based compensation expense		$ 2.8

Segment and Geographic Information - Schedule of Reconciliation of Reportable Segment Amounts (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($) claim	Dec. 31, 2023 USD ($)	Jul. 23, 2025 claim	Mar. 28, 2023 claim
Segment Reporting Information [Line Items]
Share-based compensation	$ 30,878	$ 36,777	$ 32,238
Loss on refinancing of debt	1,462	24,168	0
Accretion of asset retirement obligation	2,321	2,638	2,413
Income before income taxes	147,506	$ 113,874	106,027
GEORGIA \| Pending Litigation \| Personal Injury And Wrongful Death
Segment Reporting Information [Line Items]
Number of pending claims \| claim		79
Illinois EO litigation settlements \| Pending Litigation
Segment Reporting Information [Line Items]
Number of pending claims \| claim				129
Illinois EO litigation settlements \| Pending Litigation \| Personal Injury And Wrongful Death
Segment Reporting Information [Line Items]
Number of pending claims \| claim					97
Operating Segments
Segment Reporting Information [Line Items]
Segment income	593,801	$ 548,574	528,029
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
Segment Reporting Information [Line Items]
Interest expense, net	155,722	164,691	142,878
Depreciation and amortization	136,428	161,797	157,925
Share-based compensation	31,068	36,896	32,364
Loss on refinancing of debt	1,462	24,168	0
Loss (gain) on foreign currency and derivatives not designated as hedging instruments, net	58	2,448	(1,552)
Business optimization project expenses	8,068	9,368	7,662
Professional services relating to EO sterilization facilities	46,225	32,694	45,312
Accretion of asset retirement obligation	2,321	2,638	2,413
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment \| Illinois EO litigation settlements
Segment Reporting Information [Line Items]
Litigation settlement	64,943	0	0
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment \| Georgia EO litigation settlement
Segment Reporting Information [Line Items]
Litigation settlement	$ 0	$ 0	$ 35,000

Employee Benefits - Schedule of a One-Percentage Point Change in Assumed Health Care Cost Trend Rates (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)
Retirement Benefits [Abstract]
Change in net periodic benefit cost, 1% Increase	$ 21
Change in net periodic benefit cost, 1% Decrease	(18)
Change in projected benefit obligation, 1% Increase	510
Change in projected benefit obligation, 1% Decrease	$ (434)

Asset Retirement Obligations (“ARO”) (Tables)

12 Months Ended

Dec. 31, 2025

Asset Retirement Obligation Disclosure [Abstract]

Schedule of Asset Retirement Obligations

The following table describes changes to our ARO liability during the years presented:


(thousands of U.S. dollars)
For the years ended December 31,	2025		2024
ARO – beginning of period	$	49,319	$	47,944
Changes in estimates	191		1,240
Accretion expense	2,321		2,638
Foreign currency exchange and other	1,665		(2,503)
ARO – end of period	$	53,496	$	49,319

Leases - Schedule of Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Operating lease costs	$ 13,207	$ 13,267	$ 13,920
Finance lease costs:
Amortization of right of use assets	6,474	8,438	8,152
Interest on lease liabilities	6,105	6,064	4,394
Total finance lease costs	12,579	14,502	12,546
Total lease costs	25,786	27,769	26,466
Short-term lease costs	$ 1,700	$ 1,500	$ 1,400

Consolidated Statements of Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Deficit	Accumulated Other Comprehensive (Loss) Income
Beginning Balance (in shares) at Dec. 31, 2022		282,421
Beginning Balance at Dec. 31, 2022	$ 350,238	$ 2,860	$ (29,775)	$ 1,189,622	$ (705,816)	$ (106,653)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation plans (in shares)		409
Share-based compensation plans	28,149		2,593	25,556
Comprehensive income (loss):
Pension and post-retirement plan adjustments, net of tax	(10,506)					(10,506)
Foreign currency translation	40,174					40,174
Interest rate derivatives, net of tax	(15,697)					(15,697)
Net income (loss)	51,376				51,376
Ending Balance (in shares) at Dec. 31, 2023		282,830
Ending Balance at Dec. 31, 2023	443,734	$ 2,860	(27,182)	1,215,178	(654,440)	(92,682)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation plans (in shares)		636
Share-based compensation plans	32,348		3,748	28,600
Comprehensive income (loss):
Pension and post-retirement plan adjustments, net of tax	8,462					8,462
Foreign currency translation	(118,635)					(118,635)
Interest rate derivatives, net of tax	(5,396)					(5,396)
Net income (loss)	44,398				44,398
Ending Balance (in shares) at Dec. 31, 2024		283,466
Ending Balance at Dec. 31, 2024	404,911	$ 2,860	(23,434)	1,243,778	(610,042)	(208,251)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation plans (in shares)		905
Share-based compensation plans	24,762		6,421	18,341
Comprehensive income (loss):
Pension and post-retirement plan adjustments, net of tax	2,386					2,386
Foreign currency translation	98,115					98,115
Interest rate derivatives, net of tax	(2,088)					(2,088)
Net income (loss)	77,949				77,949
Ending Balance (in shares) at Dec. 31, 2025		284,371
Ending Balance at Dec. 31, 2025	$ 606,035	$ 2,860	$ (17,013)	$ 1,262,119	$ (532,093)	$ (109,838)

Income Taxes - Schedule of Total Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Current
Federal U.S.	$ 8,975	$ 708	$ (3,809)
State U.S.	1,108	1,100	924
Foreign	59,452	58,235	54,087
Total current provision	69,535	60,043	51,202
Deferred
Federal U.S.	(328)	13,645	6,933
State U.S.	670	(837)	(619)
Foreign	(320)	(3,375)	(2,865)
Total deferred provision	22	9,433	3,449
Total provision for income taxes	$ 69,557	$ 69,476	$ 54,651

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Jul. 04, 2025
Operating Loss Carryforwards [Line Items]
Tax benefit recognized from the reduction of the valuation allowance			$ 16,600,000
Deferred income taxes	$ 71,075,000	$ 69,500,000
Tax benefit attributable to holiday	1,100,000	1,300,000
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	155,400,000	164,100,000
Operating loss carryforwards, valuation allowance	800,000
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	299,500,000	293,800,000
Operating loss carryforwards, not subject to expiration	64,100,000	89,600,000
Operating loss carryforwards, valuation allowance	17,200,000	12,500,000
Foreign
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	32,600,000	21,400,000
Operating loss carryforwards, valuation allowance	5,400,000	3,600,000
Deferred income taxes	$ 7,800,000	$ 3,800,000

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2025

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Prepaid taxes	$	5,212	$	4,993
Prepaid business insurance	3,974		6,993
Prepaid rent	4,466		1,223
Customer contract assets	24,410		15,213
Current deposits	283		807
Prepaid maintenance contracts	490		638
Value added tax receivable	4,527		3,614
Prepaid software licensing	2,661		2,590
Stock supplies	5,012		4,025
Embedded derivatives	1,162		2,689
Other	13,053		8,246
Prepaid expenses and other current assets	$	65,250	$	51,031

Goodwill and Other Intangible Assets - Schedule of Weighted-Average Remaining Amortization (Details)	Dec. 31, 2025
Customer relationships
Goodwill [Line Items]
Weighted average remaining amortization period	9 years 3 months 18 days
Proprietary technology
Goodwill [Line Items]
Weighted average remaining amortization period	9 years 9 months 18 days
Trade names
Goodwill [Line Items]
Weighted average remaining amortization period	9 months 18 days
Land-use rights
Goodwill [Line Items]
Weighted average remaining amortization period	30 years 8 months 12 days
Sealed source and supply agreements
Goodwill [Line Items]
Weighted average remaining amortization period	9 years
Other
Goodwill [Line Items]
Weighted average remaining amortization period	9 months 18 days

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

Stockholders’ Equity	12 Months Ended
Stockholders’ Equity	Dec. 31, 2025
Equity [Abstract]
Stockholders’ Equity	Stockholders’ Equity Common Stock The Company completed its IPO in the fourth quarter of 2020 and shares began trading on Nasdaq on November 20, 2020. Prior to the completion of the IPO, the Company amended and restated its certificate of incorporation to authorize 1,200,000,000 shares of common stock, par value $0.01 per share, and reclassify all 3,000 shares of its common stock then outstanding as 232,400,200 shares. Upon completion of the IPO, 284,421,755 shares of common stock were outstanding. Voting Rights. Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, subject to certain restrictions described in the certificate of incorporation. Dividends. Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. Liquidation, Dissolution, and Winding Up. In the event of liquidation, dissolution or winding up, the holders of the Company’s common stock will be entitled to share equally and ratably in the net assets legally available for distribution to stockholders after the payment of all of debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Preferred Stock In addition, prior to the completion of the IPO, the Company’s amended and restated certificate of incorporation authorized 120,000,000 shares of preferred stock, par value $0.01 per share. The board of directors may issue preferred stock, without stockholder approval, in such series and with such designations, preferences, conversion or other rights, voting powers and qualifications, limitations or restrictions thereof, as the board of directors deems appropriate.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Share-Based Compensation - Schedule of Performance Shares, Activity (Details) - Performance Shares	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Number of Shares
Beginning balance (in shares) \| shares	0
Granted (in shares) \| shares	865,256
Forfeited (in shares) \| shares	(5,604)
Ending balance (in shares) \| shares	859,652
Weighted-average Grant Date Fair Value
Beginning balance (in dollars per share) \| $ / shares	$ 0
Granted (in dollars per share) \| $ / shares	10.86
Forfeited (in dollars per share) \| $ / shares	11.68
Ending balance (in dollars per share) \| $ / shares	$ 10.86

Long-Term Debt - Schedule of Maturities of Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Debt Disclosure [Abstract]
2026	$ 14,230
2027	14,230
2028	14,230
2029	14,230
2030	14,230
Thereafter	2,098,322
Total	$ 2,169,472	$ 2,255,577

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

Changes to goodwill during the years ended December 31, 2025 and 2024 were as follows:


(thousands of U.S. dollars)	Sterigenics		Nordion		Nelson Labs		Total
Goodwill at January 1, 2024	$	659,888	$	276,929	$	174,373	$	1,111,190
Changes due to foreign currency exchange rates	(6,666)		(21,444)		(2,007)		(30,117)
Goodwill at December 31, 2024	653,222		255,485		172,366		1,081,073
Changes due to foreign currency exchange rates	5,697		12,286		4,176		22,159
Goodwill at December 31, 2025	$	658,919	$	267,771	$	176,542	$	1,103,232

Schedule of Acquired Finite-Lived Intangible Assets

Other intangible assets consisted of the following:


(thousands of U.S. dollars)	Gross Carrying Amount		Accumulated Amortization
As of December 31, 2025
Finite-lived intangible assets
Customer relationships	$	167,313	$	84,083
Proprietary technology	37,775		19,253
Trade names	2,400		2,000
Land-use rights	8,861		2,313
Sealed source and supply agreements	168,740		91,405
Other	900		790
Total finite-lived intangible assets	385,989		199,844

Indefinite-lived intangible assets
Regulatory licenses and other(a)	76,064		—
Trade names / trademarks	26,018		—
Total indefinite-lived intangible assets	102,082		—
Total	$	488,071	$	199,844


As of December 31, 2024	Gross Carrying Amount		Accumulated Amortization
Finite-lived intangible assets
Customer relationships	$	646,965	$	537,871
Proprietary technology	73,464		52,976
Trade names	2,531		1,651
Land-use rights	8,493		2,008
Sealed source and supply agreements	192,630		110,668
Other	4,344		3,655
Total finite-lived intangible assets	928,427		708,829

Indefinite-lived intangible assets
Regulatory licenses and other(a)	72,550		—
Trade names / trademarks	25,505		—
Total indefinite-lived intangible assets	98,055		—
Total	$	1,026,482	$	708,829

(a)Includes certain transportation certifications, a class 1B nuclear license and other intangibles related to obtaining such licensure. These assets are considered indefinite-lived as the decision for renewal by the CNSC is highly based on a licensee’s previous assessments, reported incidents, and annual compliance and inspection results. New applications for license can take a significant amount of time and cost; whereas an existing licensee with a historical record of compliance and current operating conditions is generally expected to obtain renewal, as Nordion has demonstrated over its 75 years of history. In September 2025, the CNSC renewed Nordion’s Class 1B nuclear license for a 25-year term.

Schedule of Acquired Indefinite-lived Intangible Assets

Other intangible assets consisted of the following:


(thousands of U.S. dollars)	Gross Carrying Amount		Accumulated Amortization
As of December 31, 2025
Finite-lived intangible assets
Customer relationships	$	167,313	$	84,083
Proprietary technology	37,775		19,253
Trade names	2,400		2,000
Land-use rights	8,861		2,313
Sealed source and supply agreements	168,740		91,405
Other	900		790
Total finite-lived intangible assets	385,989		199,844

Indefinite-lived intangible assets
Regulatory licenses and other(a)	76,064		—
Trade names / trademarks	26,018		—
Total indefinite-lived intangible assets	102,082		—
Total	$	488,071	$	199,844


As of December 31, 2024	Gross Carrying Amount		Accumulated Amortization
Finite-lived intangible assets
Customer relationships	$	646,965	$	537,871
Proprietary technology	73,464		52,976
Trade names	2,531		1,651
Land-use rights	8,493		2,008
Sealed source and supply agreements	192,630		110,668
Other	4,344		3,655
Total finite-lived intangible assets	928,427		708,829

Indefinite-lived intangible assets
Regulatory licenses and other(a)	72,550		—
Trade names / trademarks	25,505		—
Total indefinite-lived intangible assets	98,055		—
Total	$	1,026,482	$	708,829

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

The estimated aggregate amortization expense for finite-lived intangible assets for each of the next five years and thereafter is as follows:


(thousands of U.S. dollars)
2026	$	22,161
2027	21,084
2028	20,537
2029	20,427
2030	20,427
Thereafter	81,509
Total	$	186,145

Schedule of Weighted-Average Remaining Amortization Periods

The weighted-average remaining amortization periods of the finite-lived intangible assets by major intangible asset class as of December 31, 2025 were as follows:


(in years)			Weighted average remaining amortization period
Customer relationships			9.3
Proprietary technology			9.8
Trade names			0.8
Land-use rights			30.7
Sealed source and supply agreements			9.0
Other			0.8

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

Financial Instruments and Financial Risk - Schedule of Derivative Instruments (Details) - USD ($)	Dec. 31, 2025	Mar. 31, 2025	Dec. 31, 2024	Mar. 31, 2023
Derivative [Line Items]
Notional Amount	$ 664,400,000		$ 894,500,000
Derivative Assets	1,162,000		3,236,000
Derivative Liabilities	4,218,000		4,296,000
Derivatives designated as hedging instruments \| Interest rate swaps
Derivative [Line Items]
Notional Amount	400,000,000.0	$ 400,000,000.0	400,000,000.0	$ 400,000,000.0
Derivative Assets	0		459,000
Derivative Liabilities	2,346,000		0
Derivatives not designated as hedging instruments \| Foreign currency forward contracts
Derivative [Line Items]
Notional Amount	0		263,700,000
Derivative Assets	0		88,000
Derivative Liabilities	0		198,000
Derivatives not designated as hedging instruments \| Embedded derivatives
Derivative [Line Items]
Notional Amount	264,400,000		230,800,000
Derivative Assets	1,162,000		2,689,000
Derivative Liabilities	$ 1,872,000		$ 4,098,000

- Definition

Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.

+ References + Details

- Definition

Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.

+ References + Details

Financial Instruments and Financial Risk - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2025	Mar. 31, 2023
Derivative [Line Items]
Notional amount	$ 664,400,000	$ 894,500,000
Interest rate derivatives, net of tax	(2,088,000)	(5,396,000)	$ (15,697,000)
Allowance for uncollectible accounts	2,968,000	2,532,000
Derivatives designated as hedging instruments
Derivative [Line Items]
Interest rate derivatives, net of tax	1,000,000.0
Derivatives designated as hedging instruments \| Interest rate swaps
Derivative [Line Items]
Notional amount	$ 400,000,000.0	$ 400,000,000.0		$ 400,000,000.0	$ 400,000,000.0

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Pre-IPO Restricted Stock Units Activity

A summary of the activity for the years ended December 31, 2025, 2024 and 2023 related to the restricted stock distributed in respect of the pre-IPO awards (Class B-1 and B-2) is presented below:


	Restricted Stock - Pre-IPO B-1	Restricted Stock - Pre-IPO B-2
At January 1, 2023	716,091	1,098,415
Forfeited	(16,243)	(111,304)
Vested	(347,401)	—
At December 31, 2023	352,447	987,111
Forfeited	(2,651)	—
Vested	(278,345)	(987,111)
At December 31, 2024	71,451	—

Vested	(71,451)	—
At December 31, 2025	—	—

Schedule of Stock Options, Valuation Assumptions

Weighted-average grant-date fair values of stock options and the assumptions used in estimating the fair values are as follows. No stock options were granted during the year ended December 31, 2025.


For the year ended December 31,	2024			2023
Weighted average grant date fair value per option	$	7.35		$	7.13
Expected term (years)	6 years			6 years
Risk-free interest rate	4.2		%	4.2		%
Expected volatility	46.8		%	50.0		%

Schedule of Stock Option Activity

The following table summarizes our stock option activity for the year ended December 31, 2025:


	Number of Shares	Weighted-average Exercise Price		Remaining Contractual Life	Aggregate Intrinsic Value (millions of U.S. dollars)
Outstanding at the beginning of the year	8,328,051	$	14.94

Forfeited	(113,221)	18.92
Exercised	(30,949)	14.59
Outstanding at the end of the year	8,183,881	$	14.89	6.6 years	$	35.3
Exercisable at the end of the year	6,841,193	$	14.80	6.3 years	$	32.2
Unvested at the end of the year	1,342,688	$	15.32	7.9 years	$	3.1

Schedule of Restricted Stock Activity

The following table summarizes our unvested RSUs activity for the year ended December 31, 2025:


	Number of Shares	Weighted-average Grant Date Fair Value
Unvested at the beginning of the year	2,278,537	$	13.73
Granted	1,583,130	13.48
Forfeited	(89,892)	12.87
Vested	(1,365,684)	12.74
Unvested at the end of the year	2,406,091	$	14.16

Schedule of Performance Shares, Activity

The following table summarizes our unvested PSUs for the year ended December 31, 2025:


	Number of Shares	Weighted-average Grant Date Fair Value
Unvested at December 31, 2024	—	—
Granted	865,256	10.86
Forfeited	(5,604)	$	11.68
Unvested at December 31, 2025	859,652	$	10.86

Revenue Recognition (Details) - USD ($) $ in Thousands	12 Months Ended
Revenue Recognition (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Total net revenues	$ 1,163,617	$ 1,100,441	$ 1,049,288
Deferred revenue	17,999	15,100
Point in time
Disaggregation of Revenue [Line Items]
Total net revenues	938,602	869,138	820,877
Over time
Disaggregation of Revenue [Line Items]
Total net revenues	225,015	231,303	228,411
Sterigenics
Disaggregation of Revenue [Line Items]
Total net revenues	755,780	697,853	667,130
Sterigenics \| Point in time
Disaggregation of Revenue [Line Items]
Total net revenues	755,780	697,853	667,130
Sterigenics \| Over time
Disaggregation of Revenue [Line Items]
Total net revenues	0	0	0
Nordion
Disaggregation of Revenue [Line Items]
Total net revenues	187,618	173,355	160,459
Nordion \| Point in time
Disaggregation of Revenue [Line Items]
Total net revenues	182,822	171,285	153,747
Nordion \| Over time
Disaggregation of Revenue [Line Items]
Total net revenues	4,796	2,070	6,712
Nelson Labs
Disaggregation of Revenue [Line Items]
Total net revenues	220,219	229,233	221,699
Nelson Labs \| Point in time
Disaggregation of Revenue [Line Items]
Total net revenues	0	0	0
Nelson Labs \| Over time
Disaggregation of Revenue [Line Items]
Total net revenues	$ 220,219	$ 229,233	$ 221,699

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

+ Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Earnings:
Net income	$ 77,949	$ 44,398	$ 51,376
Less: Allocation to participating securities, basic	4	59	287
Less: Allocation to participating securities, diluted	4	59	287
Net income attributable to Sotera Health Company common stockholders, basic	77,945	44,339	51,089
Net income attributable to Sotera Health Company common stockholders, diluted	$ 77,945	$ 44,339	$ 51,089
Weighted Average Common Shares:
Weighted-average common shares outstanding - basic (in shares)	283,956,000	282,784,000	281,008,000
Dilutive effect of potential common shares (in shares)	2,465,000	2,122,000	2,213,000
Weighted-average common shares outstanding - diluted (in shares)	286,421,000	284,906,000	283,222,000
Earnings per Common Share:
Net income (loss) per common share attributable to Sotera Health Company common stockholders - basic (in dollars per share)	$ 0.27	$ 0.16	$ 0.18
Net income (loss) per common share attributable to Sotera Health Company common stockholders - diluted (in dollars per share)	$ 0.27	$ 0.16	$ 0.18
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	5,559,000	5,503,000	4,399,000
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	9,000	34,000	291,000
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	5,550,000	5,469,000	4,108,000

Revenue Recognition

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Abstract]

Revenue Recognition

The following table shows disaggregated net revenues from contracts with external customers by timing of revenue and by segment for the years ended December 31, 2025, 2024 and 2023:


	Year Ended December 31, 2025
	Sterigenics		Nordion		Nelson Labs		Consolidated
Point in time	$	755,780	$	182,822	$	—	$	938,602
Over time	—		4,796		220,219		225,015
Total	$	755,780	$	187,618	$	220,219	$	1,163,617


	Year Ended December 31, 2024
	Sterigenics		Nordion		Nelson Labs		Consolidated
Point in time	$	697,853	$	171,285	$	—	$	869,138
Over time	—		2,070		229,233		231,303
Total	$	697,853	$	173,355	$	229,233	$	1,100,441


	Year Ended December 31, 2023
	Sterigenics		Nordion		Nelson Labs		Consolidated
Point in time	$	667,130	$	153,747	$	—	$	820,877
Over time	—		6,712		221,699		228,411
Total	$	667,130	$	160,459	$	221,699	$	1,049,288

When we receive consideration from a customer prior to transferring goods or services under the terms of a sales contract, we record deferred revenue, which represents a contract liability. Deferred revenue totaled $18.0 million and $15.1 million at December 31, 2025 and 2024, respectively. We recognize deferred revenue after we have transferred control of the goods or services to the customer and all revenue recognition criteria are met.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Schedule of Property, Plant and Equipment

Depreciation is computed using the assets’ estimated useful lives as presented below:


Buildings and building improvements			15–44 years
Machinery and equipment			3–30 years
Leasehold improvements			2–20 years
Furniture and fixtures			3–10 years
Computer hardware and software			1–7 years

Property, plant, and equipment, net, consisted of the following:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Land and buildings	$	470,905	$	418,038
Leasehold improvements	128,313		98,028
Machinery, equipment, including Co-60	853,195		757,568
Furniture and fixtures	9,472		9,118
Computer hardware and software	72,694		58,767
Asset retirement costs	7,925		7,368
Construction-in-progress	259,919		250,418
	1,802,423		1,599,305
Less accumulated depreciation	(671,859)		(562,413)
Property, plant and equipment, net	$	1,130,564	$	1,036,892

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

Long-term debt consisted of the following:


(thousands of U.S. dollars)
As of December 31, 2025	Gross Amount		Unamortized Debt Issuance Costs		Unamortized Debt Discount		Net Amount
Secured notes due 2031	$	750,000	$	(3,129)	$	—	$	746,871
Term loan due 2031	1,419,472		(6,618)		(19,028)		1,393,826
	2,169,472		(9,747)		(19,028)		2,140,697
Less current portion	14,230		(66)		(191)		13,973
Long-term debt	$	2,155,242	$	(9,681)	$	(18,837)	$	2,126,724


(thousands of U.S. dollars)
As of December 31, 2024	Gross Amount		Unamortized Debt Issuance Costs		Unamortized Debt Discount		Net Amount
Secured notes due 2031	$	750,000	$	(3,707)	$	—	$	746,293
Term loan due 2031	1,505,577		(6,508)		(22,459)		1,476,610
	2,255,577		(10,215)		(22,459)		2,222,903
Less current portion	15,094		(65)		(226)		14,803
Long-term debt	$	2,240,483	$	(10,150)	$	(22,233)	$	2,208,100

Schedule of Maturities of Long-term Debt

Aggregate maturities of the Company’s long-term debt, excluding debt issuance costs and discounts, as of December 31, 2025, are as follows:


(thousands of U.S. dollars)
2026	$	14,230
2027	14,230
2028	14,230
2029	14,230
2030	14,230
Thereafter	2,098,322
Total	$	2,169,472

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

Leases - Schedule of Non-Cash Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$ 10,822	$ 10,550	$ 4,559
Finance leases	$ 431	$ 36,016	$ 14,770

Share-Based Compensation - Schedule of Stock Options Activities (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($) $ / shares shares
Number of Shares
Beginning balance (in shares) \| shares	8,328,051
Forfeited (in shares) \| shares	(113,221)
Exercised (in shares) \| shares	(30,949)
Ending balance (in shares) \| shares	8,183,881
Weighted-average Exercise Price
Beginning balance (in shares) \| $ / shares	$ 14.94
Forfeited (in dollars per share) \| $ / shares	18.92
Exercised (in dollars per share) \| $ / shares	14.59
Ending balance (in shares) \| $ / shares	$ 14.89
Outstanding at the end of the year, Remaining Contractual Life	6 years 7 months 6 days
Outstanding at the end of the year, Aggregate Intrinsic Value \| $	$ 35,300
Exercisable at the end of the year, Number of Shares (in shares) \| shares	6,841,193
Exercisable at the end of the year, Weighted-average Exercise Price (in dollars per share) \| $ / shares	$ 14.80
Exercisable at the end of the year, Remaining Contractual Life	6 years 3 months 18 days
Exercisable at the end of the year, Aggregate Intrinsic Value \| $	$ 32,200
Unvested at the end of the year, Number of Shares (in shares) \| shares	1,342,688
Unvested at the end of the year, Weighted-average Exercise Price (in dollars per share) \| $ / shares	$ 15.32
Unvested at the end of the year, Remaining Contractual Life	7 years 10 months 24 days
Unvested at the end of the year, Aggregate Intrinsic Value \| $	$ 3,100

Asset Retirement Obligations (“ARO”) - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Asset Retirement Obligation Disclosure [Abstract]
Depreciation expense	$ 0.6	$ 0.4	$ 0.4
Decommissioning obligation, letters of credit and surety bonds outstanding	$ 50.3	$ 49.1

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2025
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation – Sotera Health Company (also referred to herein as the “Company,” “we,” “our,” “us” or “its”), is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry with operations primarily in the Americas, Europe and Asia. The accompanying consolidated financial statements include the assets, liabilities, operating results, and cash flows of the Company and its wholly owned subsidiaries prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). We operate and report in three segments, Sterigenics, Nordion and Nelson Labs. We describe our reportable segments in Note 21, “Segment and Geographic Information.” All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates – In preparing our consolidated financial statements in conformity with GAAP, we make estimates and assumptions that affect the amounts reported and the accompanying notes. We regularly evaluate the estimates and assumptions used and revise them as new information becomes available. Actual results may vary from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents – We consider all highly liquid investments purchased with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents may include various deposit accounts and money market funds.
Accounts Receivable	Accounts Receivable – Accounts receivable consists of amounts billed and currently due from customers. The amounts due are stated net of the allowance for uncollectible accounts. The Company maintains an allowance for uncollectible receivables to provide for the estimated amount of receivables that will not be collected.
Allowance for Uncollectible Accounts Receivable	Allowance for Uncollectible Accounts Receivable – We maintain an allowance for uncollectible accounts receivable for estimated losses in the collection of amounts owed to us by customers. We estimate the allowance based on analyzing a number of factors, including amounts written off historically, customer payment practices, customer financial information and credit ratings, current market conditions as well as the expected future economic conditions that may impact the collection of accounts receivable. We also analyze significant customer accounts on a regular basis and record a specific allowance when we become aware of a specific customer’s inability to pay. We generally do not charge interest on accounts receivable or require collateral from our customers. We record write-offs against the allowance for uncollectible accounts receivable when all reasonable efforts for collection have been exhausted. As a result, the related accounts receivable are reduced to an amount that we reasonably believe is collectible. These analyses require judgment. If the financial condition of our customers worsens, or economic conditions change, we may be required to make changes to our allowance for uncollectible accounts receivable.
Inventories	Inventories – Inventories as of December 31, 2025 and 2024 are held at Nordion. Inventories are stated at the lower of cost or net realizable value. Cost of material, labor, and manufacturing overhead are determined using standard cost, which approximates average cost. We review inventory on an ongoing basis, considering factors such as deterioration and obsolescence. We record a reserve for excess and obsolete inventory, which was immaterial at December 31, 2025 and 2024, when the facts and circumstances indicate that particular inventories will not be usable. If future market conditions vary from those projected, and our estimates prove to be inaccurate, we may be required to write-down inventory values and record an adjustment to cost of revenues.
Property, Plant, and Equipment	Property, Plant, and Equipment – Property, plant, and equipment is carried at cost, or initially at fair value if acquired in an acquisition, less accumulated depreciation and amortization. Except for Co-60, a radioactive isotope used in gamma radiation sterilization, all property, plant, and equipment depreciation is computed using the straight-line method over estimated useful lives. Leasehold improvements are amortized over their estimated useful lives or the term of the related lease, whichever is shorter. Co-60 is amortized using an accelerated method, which relates to the natural radioactive decay of the isotope over its estimated useful life which is approximately twenty years. Amortization of Co-60 is included within depreciation expense as a cost of revenue. Expenditures for major software purchases and software developed for internal use are capitalized and depreciated using the straight-line method over the estimated useful lives of the related assets, which are generally one to five years. From time to time, we build or expand facilities. The cost of construction of these facilities is reflected as construction-in-progress until the asset is ready for its intended use, at which time the costs are reclassified to the appropriate depreciable category of property, plant, and equipment and depreciation commences. Fixed asset projects requiring one or more years to complete construction qualify for capitalization of interest costs in accordance with our policy. Interest related to property, plant and equipment projects with a construction period of less than one year are not capitalized and are immaterial. Repairs and maintenance costs that do not extend the useful life of an asset are expensed as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation is removed from the Consolidated Balance Sheets, and the resulting gain or loss is reflected as a component of operating income.
Leases	Leases – We determine if an agreement contains a lease and classify our leases as operating or finance at the lease commencement date. Leases with an initial term of twelve months or less are recognized as lease expense on a straight-line basis over the lease term and are not recorded on the Consolidated Balance Sheets. Non-lease components are accounted for separately from the lease components for all asset classes. Finance leases are those in which we will pay substantially all the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. Lease assets arising from finance leases are included in “Property, plant and equipment, net” and the liabilities are included in “Finance lease obligations” on the Consolidated Balance Sheets. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the lease asset over the shorter of the lease term or the useful life of asset. Finance leases are accounted for as if the assets were owned and financed, with associated expense recognized in “Interest expense, net” and “Cost of revenues” or “Selling, general and administrative expenses” within the Consolidated Statements of Operations and Comprehensive Income (Loss) depending on the nature of the underlying asset. Operating lease assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. As most leases do not provide an implicit interest rate, we estimate an incremental borrowing rate to determine the present value of lease payments. Our estimated incremental borrowing rate reflects a secured rate based on recent debt issuances, our estimated credit rating, and lease term. We recognize operating lease costs on a straight-line basis over the term of the lease in “Cost of revenues” or “Selling, general and administrative expenses” on the Consolidated Statements of Operations and Comprehensive Income (Loss) depending on the nature of the underlying asset. We lease certain facilities and equipment under various non-cancelable leases. Most of our real property leases provide for renewal periods and rent escalations and stipulate that we pay taxes, maintenance, and certain other operating expenses applicable to the leased premises.
Goodwill and Other Indefinite-Lived Intangibles	Goodwill and Other Indefinite-Lived Intangibles – Goodwill and other indefinite-lived intangible assets, primarily certain regulatory licenses and tradenames, are tested for impairment annually as of October 1. If circumstances change during interim periods between annual tests that would indicate that the carrying amount of such assets may not be recoverable, the Company tests such assets at an interim date for impairment. Factors that necessitate an interim impairment assessment include prolonged negative industry or economic trends and significant underperformance relative to historical or projected future operating results. We performed a quantitative assessment of all reporting units (Sterigenics, Nordion and Nelson Labs) as of October 1, 2025. The fair value of each reporting unit was calculated using a discounted cash flow analysis which was dependent on subjective market participant assumptions determined by management. We further corroborated these discounted cash flow analyses utilizing a market approach to determine the estimated enterprise fair value. Assumptions used in the analyses included discount rates, revenue growth rates and projected operating cash flows. Estimates of future cash flows are based upon relevant data at a point-in-time, are subject to change, and could vary from actual results. The estimated fair value of each reporting unit exceeded its carrying amount by a sufficient margin to support a positive assertion that goodwill is not impaired. We performed a qualitative impairment assessment to evaluate any potential impairment to the indefinite-lived intangible assets. We considered significant events and circumstances that could affect the significant inputs used to determine the estimated fair value of the indefinite-lived intangible assets, and determined, after considering the totality of evidence that it is not more likely than not that the indefinite-lived intangible assets are impaired. There have been no other significant events or circumstances that occurred since the annual assessment date of October 1 that would change the conclusions reached above.
Derivative Instruments	Derivative Instruments – We may enter into derivative instruments and hedging activities to manage, where possible and economically efficient, commodity price risk, foreign currency exchange rate risk and interest rate risk related to borrowings. We also have identified embedded derivatives in certain supply and customer contracts. Certain interest rate derivatives are designated as cash flow hedges allowing for changes in fair value to be recorded through “Other comprehensive income (loss).” Amounts in accumulated other comprehensive income (loss) will be reclassified into earnings in the same periods during which the hedged transaction affects earnings and are presented in “Interest expense, net” within the Consolidated Statements of Operations and Comprehensive Income (Loss). Derivatives not designated as hedges are recorded at fair value on the Consolidated Balance Sheets, with any changes in the value being recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss) in the same line item as the corresponding hedged item. We classify cash flows from derivative instruments and hedging activities as cash flows from operating activities in the Consolidated Statements of Cash Flows. To the extent derivative arrangements are with the same counterparty and contractual right of offset exists under applicable master agreements, we offset assets and liabilities for reporting on the Consolidated Balance Sheets.
Pension, Post-Retirement and Other Post-Employment Benefit Plans	Pension, Post-Retirement and Other Post-Employment Benefit Plans – We sponsor a defined-contribution retirement plan that covers substantially all U.S. employees. We also sponsor various post-employment benefit plans at our Nordion business in Canada, including defined benefit and defined contribution pension plans, retirement compensation arrangements and plans that provide extended health care coverage to retired employees. In addition, we provide other benefit plans at our foreign subsidiaries, including a supplemental retirement arrangement, a retirement and termination allowance and post-retirement benefit plans, which include contributory healthcare benefits and contributory life insurance coverage. All non-pension post-employment benefit plans are unfunded. These costs and obligations are affected by assumptions including the discount rate, the expected long-term rate of return on plan assets, the annual rate of change in compensation for eligible employees, estimated changes in costs of healthcare benefits, and other demographic and economic factors. We review the assumptions used on an annual basis. We recognize the over/under funded status of defined benefit pension and post-retirement benefits plans in our Consolidated Balance Sheets. This amount is measured as the difference between the fair value of plan assets and the projected benefit obligation (“PBO”). Changes in the funded status of the plans are recorded in other comprehensive income (loss) in the year they occur. We measure plan assets and obligations as of the balance sheet date. We provide additional information about our pension and other post-retirement benefits plans in Note 11, “Employee Benefits.” Amortization of net gain or loss included in accumulated other comprehensive income (loss) is reclassified to net periodic pension cost if, as of the beginning of the year, that gain or loss exceeds 10% of the greater of the PBO or the market related value of the plan assets (the ‘corridor’). As most of the plan’s participants are no longer actively accruing benefits, the average remaining life expectancy is used.
Asset Retirement Obligations (“ARO”)	Asset Retirement Obligations (“ARO”) – ARO are legal obligations associated with the retirement of long-lived assets or the exit of a leased facility. We recognize a liability for an ARO in the period in which it is incurred if a reasonable estimate of fair value can be made, and the associated asset retirement costs are then capitalized as part of the carrying amount of the long-lived asset. We lease various facilities where sterilization and ionization services are performed. Under the lease agreements, we are required to return the facilities to their original condition and to perform decommissioning activities. In addition, certain of our owned facilities are required to be decommissioned when we vacate the facility. Accretion expense is recognized in “Cost of Revenues” in the Consolidated Statements of Operations and Comprehensive Income (Loss) over time as the discounted liability is accreted to its expected settlement value.
Debt Issuance Costs, Premiums and Discounts	Debt Issuance Costs, Premiums and Discounts – We have incurred costs in connection with obtaining financing as well as premiums and discounts associated with our long-term debt. The portion of these fees that are capitalized are recorded as a reduction of debt on the Consolidated Balance Sheets and amortized into interest expense over the term of the debt agreement. Debt issuance costs associated with the Company’s revolving credit facilities are classified as assets unless there are outstanding borrowings under such arrangements.
Concentration of Credit Risk, Other Risks and Uncertainties	Concentration of Credit Risk, Other Risks and Uncertainties – We maintain cash and cash equivalents in the form of demand deposits in accounts with major financial institutions in the U.S. and in countries where our subsidiaries operate. Deposits in these institutions may exceed amounts of insurance provided on such accounts. We have not experienced any losses on our deposits of cash and cash equivalents.
Income Taxes	Income Taxes – We use the liability method of accounting for income taxes whereby we recognize deferred tax assets and liabilities for the future tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets will be reduced by a valuation allowance if, based on management’s estimate, it is more likely than not that a portion of the deferred tax assets will not be realized in a future period. The estimates used in the recognition of deferred tax assets are subject to revision in future periods based on new facts and circumstances. We determine whether it is more likely than not that a tax position will be sustained upon examination, including resolution of related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, we presume that the position will be examined by the appropriate taxing authority and that the taxing authority will have full knowledge of all relevant information. A tax position that meets the more-likely-than-not recognition threshold is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Determining what constitutes an individual tax position and whether the more-likely-than-not recognition threshold is met for a tax position are matters of judgment based on the individual facts and circumstances of that position evaluated in light of all available evidence. We review and adjust tax estimates periodically because of ongoing examinations by, and settlements with, the various taxing authorities, as well as changes in tax laws, regulations, and precedent. We are subject to a tax on global intangible low taxed income (“GILTI”) which we record as a period cost. Our policy is to recognize interest and penalties related to income tax matters as a component of the provision for income taxes in our Consolidated Statements of Operations and Comprehensive Income (Loss).
Foreign Currency Translation	Foreign Currency Translation – The functional currency of our foreign subsidiaries is generally the local currency. Accordingly, assets and liabilities are generally translated into U.S. dollars at the current rates of exchange as of the balance sheet date, and revenues and expenses are translated using weighted-average rates prevailing during the period. Adjustments from foreign currency translation are included as a separate component of accumulated other comprehensive income (loss). Gains or losses arising from foreign currency transactions are recognized in the Consolidated Statements of Operations and Comprehensive Income (Loss) as foreign exchange loss (gain). The Company routinely enters into foreign currency forward contracts to manage foreign currency exchange rate risk of our intercompany loans in certain of our international subsidiaries and non-functional currency assets and liabilities. The foreign currency forward contracts expire on a monthly basis. For the years ended December 31, 2025, 2024 and 2023, foreign exchange loss related primarily to short-term losses (offset by short-term gains) on sales denominated in currencies other than the functional currency of our operating entities.
Revenue Recognition	Revenue Recognition – Revenue is recognized when control of promised goods or services is transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The majority of our sales agreements contain performance obligations satisfied at a point-in-time when control of promised goods or services have transferred to our customers. Sales recognized over time are generally accounted for using an input measure to determine progress completed as of the end of the period. Refunds, returns, warranties and other related obligations are not material to any of our segments and we do not incur material incremental costs to secure customer contracts. Our Sterigenics segment provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets. We typically have multiyear service contracts with our significant customers, and these sales contracts are primarily based on customers’ purchase orders. Given the relatively short turnaround times, performance obligations are generally satisfied at a point-in-time upon the completion of sterilization or irradiation processing and approval by our quality assurance process. Sterigenics segment revenues are included in service revenues in our Consolidated Statements of Operations and Comprehensive Income (Loss). Our Nordion segment is a global provider of Co-60 and gamma irradiation systems, which are key components to the gamma sterilization process. Revenue from the sale of Co-60 sources is recognized as product revenue at a point-in-time upon satisfaction of our performance obligations for delivery of existing sources. Revenue from the sale of gamma irradiation systems is recognized as product revenue over time using an input measure of costs incurred and is immaterial to the overall business. Revenues from Co-60 installation and disposal and gamma irradiation systems refurbishments and installations are recognized as service revenue. Our Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. We provide our customers mission-critical lab testing services, which assess the product quality, effectiveness, patient safety and end-to-end sterility of products. These services are necessary for our customers’ regulatory approvals, product releases and ongoing product performance evaluations. Nelson Labs services are generally provided on a fee-for-service or project basis, and we recognize revenues over time using an input measure of time incurred to determine progress completed at the end of the period. Nelson Labs segment revenues are included in service revenues in our Consolidated Statements of Operations and Comprehensive Income (Loss). We do not capitalize sales commissions because substantially all of our sales commission programs have an amortization period of one year or less. Furthermore, costs to fulfill a contract are not material. Provisions for discounts, rebates to customers, and other adjustments are provided for as reductions in net revenues in the period the related sale is recorded. Shipping and handling charges billed to customers are included in net revenues, and the related shipping and handling costs are included in “Cost of Revenues” on the Consolidated Statements of Operations and Comprehensive Income (Loss). Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from net revenue. Payment terms vary by the type and location of the customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.
Share-Based Compensation	Share-Based Compensation – Equity-based awards issued to employees under the Sotera Health Company 2020 Omnibus Incentive Plan (“2020 Plan”) include restricted stock units (“RSUs”), performance stock units (“PSUs”) and stock options that vest over time. Prior to our initial public offering (the “IPO” as described in Note 14, “Stockholders' Equity”), equity-based awards were issued to employees and non-employee directors in the form of partnership interests in our predecessor, Sotera Health Topco Parent, L.P. (“Topco Parent”), which vested based on either time (“time vesting awards”) or the achievement of certain performance and market conditions (“performance awards” and, together with the time vesting awards, the “pre-IPO awards”). In connection with the IPO, Topco Parent made in-kind distributions of restricted shares of our common stock to holders of pre-IPO awards as described in Note 14, “Stockholders' Equity.” The restricted shares of our common stock distributed in respect of pre-IPO time vesting awards vested through August 2025; expense related to these unvested awards was recognized over the remaining vesting period. Expense attributable to the performance awards was recognized in its entirety in the year ended December 31, 2020 as the related performance conditions were considered probable of achievement and the implied service condition was met. Share-based compensation expense is recognized in the Consolidated Statements of Operations and Comprehensive Income (Loss) within “Selling, general and administrative expenses” at the grant date fair value over the requisite service period (one to three years for awards granted under the 2020 Plan and five years for time vesting pre-IPO awards on a straight-line basis). We use the Black-Scholes option pricing model to measure the grant date fair value of stock options awarded under the 2020 Plan using certain valuation assumptions. Certain RSUs and PSUs contain a performance modifier based on the achievement of growth targets of the market value of the Company’s common stock price. The fair value of these awards is estimated using a Monte Carlo simulation valuation model, as these awards are subject to a market condition. Share-based compensation expense for all awards recognizes forfeitures as they occur.
Earnings Per Share	Earnings Per Share – In periods in which the Company has net income, earnings per share information is determined using the two-class method, which includes the weighted-average number of common shares outstanding during the period and securities that participate in dividends (“participating securities”). Our unvested restricted common stock distributed in respect of partnership interests in Topco Parent (“pre-IPO Class B-1 restricted stock awards”) has the right to receive non-forfeitable dividends or dividend equivalents if the Company declares dividends on its common stock. Under the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period. Diluted earnings per common share incorporates the dilutive effect of common stock equivalents on an average basis during the period, if dilutive, in which case the dilutive effect of such securities is calculated using the more dilutive of (a) the two-class method, or (b) treasury stock method, as applicable, to the potentially dilutive instruments. Unvested restricted common stock is not included in the weighted average common shares outstanding figure within earnings per share until the period in which the vesting condition is satisfied. In periods in which the Company has a net loss, the two-class method is not applicable because the pre-IPO Class B-1 restricted stock awards do not participate in losses. Refer to Note 16, “Earnings Per Share” for additional information.
Treasury Stock	Treasury Stock – The Company records repurchases of its own common stock at cost. Repurchased common stock is presented as a reduction of equity in the Consolidated Balance Sheets. The difference between the repurchase and reissue price of the Company’s own stock is added to or deducted from additional paid-in capital. The cost of treasury stock reissued is calculated using a weighted average cost method.
Commitments and Contingencies	Commitments and Contingencies – Certain conditions may exist as of the date of the consolidated financial statements which may result in a loss to the Company but will only be resolved when one or more future events occur or fail to occur. Such liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, settlement agreements, and other sources, are recorded when management assesses that it is probable that a future liability has been incurred and the amount can be reasonably estimated. Recoveries of costs from third parties, which management assesses as being probable of realization, are recorded to the extent related contingent liabilities are accrued. Legal costs incurred in connection with matters relating to contingencies are expensed in the period incurred. We record gain contingencies when realized.
Adoption of Accounting Standard Updates and Accounting Standards Updates (“ASUs”) Issued But Not Yet Adopted	Adoption of Accounting Standard Updates In the year ended December 31, 2025, we adopted Accounting Standards Update (“ASU”) 2023-09-Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this ASU require entities to disclose, on an annual basis, specific categories in the reconciliation of the provision (benefit) for income taxes to the statutory rate and provide additional information for reconciling items that meet a quantitative threshold. Additionally, the ASU requires entities to disclose a disaggregation of taxes paid by category (federal, state and foreign taxes) as well as individual jurisdictions. ASUs Issued But Not Yet Adopted In November 2024, the FASB issued ASU 2024-03-Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in this ASU requires entities to disaggregate certain expense captions into specified categories in disclosures within the footnotes to the financial statements. In January 2025, the FASB issued ASU 2025-01, which revises the effective date of ASU 2024-03 and clarifies that entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. The Company expects that this ASU will increase disclosures in the annual and interim periods when adopted.

Employee Benefits - Schedule of Weighted Average Assumptions Used in the Measurement of Benefit Obligation (Details)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Defined benefit pension plan
Projected benefit obligation
Discount rate	4.82%	4.65%
Rate of compensation increase	3.00%	3.00%
Periodic benefit
Discount rate	4.65%	4.65%
Expected return on plan assets	6.00%	6.25%
Rate of compensation increase	3.00%	3.00%
Other post-retirement benefits plans
Projected benefit obligation
Discount rate	4.82%	4.65%
Rate of compensation increase	3.00%	3.00%
Initial health care cost trend rate	7.00%	7.00%
Ultimate health care cost trend rate	4.00%	4.00%
Years until ultimate trend rate is reached	15 years	15 years
Periodic benefit
Discount rate	4.65%	4.65%
Rate of compensation increase	3.00%	3.00%

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,802,423	$ 1,599,305
Less accumulated depreciation	(671,859)	(562,413)
Property, plant and equipment, net	1,130,564	1,036,892
Land and buildings
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	470,905	418,038
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	128,313	98,028
Machinery, equipment, including Co-60
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	853,195	757,568
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	9,472	9,118
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	72,694	58,767
Asset retirement costs
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	7,925	7,368
Construction-in-progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 259,919	$ 250,418

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Operating activities:
Net income	$ 77,949	$ 44,398	$ 51,376
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation	94,908	84,260	76,577
Amortization of intangible assets	41,798	79,377	81,348
Loss on refinancing of debt	1,462	24,168	0
Deferred income taxes	22	9,433	3,449
Share-based compensation expense	30,878	36,777	32,238
Accretion expense	2,321	2,638	2,413
Unrealized foreign exchange loss (gain)	9,517	(18,337)	6,057
Unrealized (gain) loss on derivatives not designated as hedging instruments	(863)	2,213	(1,637)
Amortization of debt issuance costs	5,434	7,238	9,051
Other	(4,275)	(5,367)	(5,319)
Changes in operating assets and liabilities:
Accounts receivable	7,151	2,216	(21,724)
Inventories	(2,377)	(4,753)	(9,972)
Other current assets	(12,902)	3,598	4,003
Accounts payable	5,185	(6,644)	(5,333)
Accrued liabilities	1,941	7,114	3,500
Income taxes payable / receivable, net	(5,461)	1,470	924
Other liabilities	295	(3,793)	(1,733)
Other long-term assets	212	(6,842)	(238)
Net cash provided by (used in) operating activities	287,195	224,164	(147,732)
Investing activities:
Purchases of property, plant and equipment	(138,018)	(179,070)	(214,975)
Other investing activities	2,874	74	69
Net cash used in investing activities	(135,144)	(178,996)	(214,906)
Financing activities:
Proceeds from long-term borrowings	0	2,259,350	500,000
Payment of revolving credit facility	0	0	(200,000)
Payments of debt issuance costs and debt discount	(4,374)	(32,071)	(25,645)
Payments of long-term borrowings	(86,104)	(2,264,373)	(2,500)
Buyout of leased facility	0	(6,736)	0
Shares withheld for employee taxes on equity awards	(6,568)	(4,428)	(4,089)
Other financing activities	(3,488)	(2,306)	(1,807)
Net cash (used in) provided by financing activities	(100,534)	(50,564)	265,959
Effect of exchange rate changes on cash and cash equivalents	16,074	(17,393)	2,039
Net increase (decrease) in cash and cash equivalents, including restricted cash	67,591	(22,789)	(94,640)
Cash and cash equivalents, including restricted cash, at beginning of period	278,865	301,654	396,294
Cash and cash equivalents, including restricted cash, at end of period	346,456	278,865	301,654
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	164,015	179,924	173,842
Cash paid during the period for income taxes, net of tax refunds received	60,873	65,829	50,210
Purchases of property, plant and equipment included in accounts payable	25,330	10,180	16,720
Illinois EO litigation settlements
Changes in operating assets and liabilities:
Litigation settlement	34,000	0	(407,712)
Georgia EO litigation settlement
Changes in operating assets and liabilities:
Litigation settlement	$ 0	$ (35,000)	$ 35,000

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table shows disaggregated net revenues from contracts with external customers by timing of revenue and by segment for the years ended December 31, 2025, 2024 and 2023:


	Year Ended December 31, 2025
	Sterigenics		Nordion		Nelson Labs		Consolidated
Point in time	$	755,780	$	182,822	$	—	$	938,602
Over time	—		4,796		220,219		225,015
Total	$	755,780	$	187,618	$	220,219	$	1,163,617


	Year Ended December 31, 2024
	Sterigenics		Nordion		Nelson Labs		Consolidated
Point in time	$	697,853	$	171,285	$	—	$	869,138
Over time	—		2,070		229,233		231,303
Total	$	697,853	$	173,355	$	229,233	$	1,100,441


	Year Ended December 31, 2023
	Sterigenics		Nordion		Nelson Labs		Consolidated
Point in time	$	667,130	$	153,747	$	—	$	820,877
Over time	—		6,712		221,699		228,411
Total	$	667,130	$	160,459	$	221,699	$	1,049,288

Leases - Schedule of Term and Rate (Details)	Dec. 31, 2025	Dec. 31, 2024
Weighted average remaining lease term:
Operating leases	11 years 1 month 6 days	7 years 3 months 18 days
Finance leases	14 years 10 months 24 days	15 years 2 months 12 days
Weighted average discount rate:
Operating leases	6.90%	6.57%
Finance leases	6.55%	6.55%

Employee Benefits - Schedule of Amounts in Accumulated Other Comprehensive Income Loss (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Defined Benefit Plan Disclosure [Line Items]
Net actuarial loss amount expected to be reclassified in the next twelve month in accumulated other comprehensive income	$ 0
Defined benefit pension plan
Defined Benefit Plan Disclosure [Line Items]
Net actuarial gain	2,196,000	$ 107,000
Deferred income taxes	(510,000)	(27,000)
Accumulated other comprehensive income – net of tax	1,686,000	80,000
Other post-retirement benefits plans
Defined Benefit Plan Disclosure [Line Items]
Net actuarial gain	1,870,000	1,549,000
Deferred income taxes	(593,000)	(444,000)
Accumulated other comprehensive income – net of tax	$ 1,277,000	$ 1,105,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (k)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (m)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

+ Details

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenues:
Total net revenues	$ 1,163,617	$ 1,100,441	$ 1,049,288
Cost of revenues:
Total cost of revenues	518,083	498,146	472,130
Gross profit	645,534	602,295	577,158
Selling, general and administrative expenses	252,762	242,630	236,667
Amortization of intangible assets	30,738	62,039	63,799
Interest expense, net	155,722	164,691	142,878
Loss on refinancing of debt	1,462	24,168	0
Foreign exchange loss	947	199	159
Other income, net	(8,546)	(5,306)	(7,372)
Income before income taxes	147,506	113,874	106,027
Provision for income taxes	69,557	69,476	54,651
Net income	77,949	44,398	51,376
Other comprehensive income (loss) net of tax:
Pension and post-retirement benefits (net of taxes of $600, $2,804 and $(3,420), respectively)	2,386	8,462	(10,506)
Interest rate derivatives (net of taxes of $(718), $(1,856) and $(5,467), respectively)	(2,088)	(5,396)	(15,697)
Foreign currency translation	98,115	(118,635)	40,174
Comprehensive income (loss)	$ 176,362	$ (71,171)	$ 65,347
Earnings per share:
Basic (in dollars per share)	$ 0.27	$ 0.16	$ 0.18
Diluted (in dollars per share)	$ 0.27	$ 0.16	$ 0.18
Weighted average number of shares outstanding:
Basic (in shares)	283,956	282,784	281,008
Diluted (in shares)	286,421	284,906	283,222
Georgia EO litigation settlement
Cost of revenues:
Litigation settlement	$ 0	$ 0	$ 35,000
Illinois EO litigation settlements
Cost of revenues:
Litigation settlement	64,943	0	0
Service
Revenues:
Total net revenues	995,756	941,822	905,598
Cost of revenues:
Total cost of revenues	456,311	439,543	418,611
Product
Revenues:
Total net revenues	167,861	158,619	143,690
Cost of revenues:
Total cost of revenues	$ 61,772	$ 58,603	$ 53,519

Schedule II - Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2025

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts

Schedule II – Valuation and Qualifying Accounts

(in thousands)


Description	Balance at Beginning of Period		Charges (credits) to costs and expense		Deductions(1)		Translation Adjustments(2)		Balance at End of Period

Year Ended December 31, 2025
Deducted from asset accounts:
Allowance for uncollectible accounts receivable	$	2,532	$	2,119	$	(1,746)	$	63	$	2,968
Deferred tax asset valuation allowance	160,595		11,135		—		564		172,294
Year Ended December 31, 2024
Deducted from asset accounts:
Allowance for uncollectible accounts receivable	$	4,689	$	(435)	$	(1,580)	$	(142)	$	2,532
Deferred tax asset valuation allowance	125,435		35,660		—		(500)		160,595
Year Ended December 31, 2023
Deducted from asset accounts:
Allowance for uncollectible accounts receivable	$	1,871	$	4,313	$	(1,502)	$	7	$	4,689
Deferred tax asset valuation allowance	105,600		19,682		—		153		125,435

(1)Uncollectible accounts written off, net of recoveries.

(2)Change in foreign currency exchange rates.

Employee Benefits -Schedule of Expected Future Benefit Payments (Details) $ in Thousands	Dec. 31, 2025 USD ($)
Defined benefit pension plan
Estimated Future Benefit Payments
2026	$ 13,813
2027	14,168
2028	14,339
2029	14,506
2030	14,617
2031 - 2035	74,377
Total	145,820
Other post-retirement benefits plans
Estimated Future Benefit Payments
2026	550
2027	585
2028	510
2029	511
2030	514
2031 - 2035	2,628
Total	$ 5,298

Long-Term Debt

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Abstract]

Long-Term Debt

Long-term debt consisted of the following:


(thousands of U.S. dollars)
As of December 31, 2025	Gross Amount		Unamortized Debt Issuance Costs		Unamortized Debt Discount		Net Amount
Secured notes due 2031	$	750,000	$	(3,129)	$	—	$	746,871
Term loan due 2031	1,419,472		(6,618)		(19,028)		1,393,826
	2,169,472		(9,747)		(19,028)		2,140,697
Less current portion	14,230		(66)		(191)		13,973
Long-term debt	$	2,155,242	$	(9,681)	$	(18,837)	$	2,126,724


(thousands of U.S. dollars)
As of December 31, 2024	Gross Amount		Unamortized Debt Issuance Costs		Unamortized Debt Discount		Net Amount
Secured notes due 2031	$	750,000	$	(3,707)	$	—	$	746,293
Term loan due 2031	1,505,577		(6,508)		(22,459)		1,476,610
	2,255,577		(10,215)		(22,459)		2,222,903
Less current portion	15,094		(65)		(226)		14,803
Long-term debt	$	2,240,483	$	(10,150)	$	(22,233)	$	2,208,100

Debt Facilities

Under the debt agreements summarized below, at December 31, 2025 we and SHH, our wholly owned subsidiary, had debt payment obligations under (a) a term loan in the amount of $1,419.5 million, (b) a revolving credit facility, which supported operationally-related letters of credit but was otherwise undrawn, and which provides to us capacity up to $600.0 million for future potential borrowings, and (c) $750.0 million of senior secured notes. Our debt agreements also include additional covenants, conditions and rights to request additional debt, as summarized below.

Senior Secured Credit Facilities and Indenture

On December 13, 2019, SHH entered into senior secured first lien credit facilities (the “Senior Secured Credit Facilities”), consisting of both a prepayable senior secured first lien term loan (the “Term Loans”) and a senior secured first lien revolving credit facility (the “Revolving Credit Facility”) pursuant to a first lien credit agreement (as amended through Amendment No. 6

(as defined below), the “Credit Agreement”). The Senior Secured Credit Facilities also provide SHH the right at any time and under certain conditions to request incremental term loans or incremental revolving credit commitments based on a formula defined in the Senior Secured Credit Facilities.

On September 17, 2025, the Company and SHH entered into Amendment No. 6 (“Amendment No. 6”) to the Credit Agreement. Among other changes, Amendment No. 6 provides for the refinancing lenders to provide term loans (the “Repriced Term Loans”) to SHH in an aggregate principal amount of $1,419.5 million, which reflects the balance after the Company’s application of $75.0 million of available cash to repay outstanding borrowings under its term loan facility. Amendment No. 6 also reduced the interest rate spread by 0.50% across term loans under the facility, such that the Repriced Term Loans have an applicable interest rate margin equal to the Adjusted Term SOFR (as defined in the Credit Agreement) plus 2.50%, with a 0.00% floor (with optionality for the Company to elect Alternate Base Rate (“ABR”) plus 1.50% or Adjusted Daily Simple SOFR plus 2.50% (each as defined in the Credit Agreement)). This pricing reflects both the 0.50% reduction implemented through Amendment No. 6 and a 0.25% contractual pricing step-down that was triggered in August 2025. The Repriced Term Loans are also subject to a “soft call” premium of 1.00% for certain repricing transactions with respect to the Repriced Term Loans that occur within the six-month period after the effective date of Amendment No. 6. The Repriced Term Loans amortize at a rate of 1.00% per annum and mature on May 30, 2031.

On April 30, 2025, the Company and SHH entered into Amendment No. 5 (“Amendment No. 5”) to the Credit Agreement. Among other changes, Amendment No. 5 provides (i) for an increase in the commitments under the existing Revolving Credit Facility in an aggregate principal amount of $176.2 million, (ii) that certain lenders providing revolving credit commitments shall also provide additional commitments for the issuance of letters of credit under the Revolving Credit Facility in an aggregate principal amount of $186.3 million and (iii) for the extension of the maturity date of the Revolving Credit Facility to April 30, 2030. Amendment No. 5 does not give effect to any other material changes to the terms and conditions of the Credit Agreement, including with respect to the representations and warranties, events of default and the affirmative or negative covenants.

On May 30, 2024, the Company and SHH entered into Amendment No. 4 (“Amendment No. 4”) to the Senior Secured Credit Facilities. Among other changes, Amendment No. 4 provides for term loans (the “Refinancing Term Loans”) to SHH in an aggregate principal amount of $1,509.4 million. Pursuant to Amendment No. 4, the Refinancing Term Loans shall have an applicable interest rate margin per annum equal to (i) ABR plus 2.25% for ABR Loans (as defined in the Credit Agreement), (ii) daily simple Secured Overnight Financing Rate (“SOFR”) plus 3.25% for RFR Loans (as defined in the Credit Agreement) and (iii) Term SOFR plus 3.25% for Term Benchmark Loans (as defined in the Credit Agreement), in each case with a 0.00% applicable floor and the applicable interest rate margin shall be subject to a pricing step-down of 0.25% when the Senior Secured Leverage Ratio (as defined in the Credit Agreement) is less than or equal to 3.30:1.00. The Refinancing Term Loans amortize at a rate of 1.00% per annum and mature on May 30, 2031.

The weighted average interest rates on borrowings under the Refinancing Term Loans for the years ended December 31, 2025 and 2024 was 7.25% and 8.29%, respectively.

On May 30, 2024, SHH, the Company, certain subsidiaries of the Company (the “Guarantors”), and Wilmington Trust, National Association, as trustee, paying agent, registrar, transfer agent and notes collateral agent, entered into an Indenture (the “Indenture”) governing SHH’s $750.0 million aggregate principal amount of 7.375% senior secured notes due 2031 (the “Secured Notes”) issued in May 2024. The Secured Notes pay interest semiannually in arrears on June 1 and December 1 of each year, which began on December 1, 2024, at a rate of 7.375% per year, and will mature on June 1, 2031. The Secured Notes may be redeemed, at any time or from time to time, in whole or in part, on or after June 1, 2027 at the redemption prices specified in the Indenture, together with accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. At any time or from time to time, prior to June 1, 2027, the Secured Notes may be redeemed, in whole or in part, at a redemption price equal to 100% of the aggregate principal amount thereof plus a make-whole premium, together with accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. In addition, at any time or from time to time, prior to June 1, 2027, SHH may redeem up to 40% of the aggregate principal amount of the Secured Notes (including any additional Secured Notes issued under the Indenture) with an amount not to exceed the net cash proceeds from certain equity offerings at a redemption price equal to 107.375% of the aggregate principal amount thereof plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date. Further, at any time or from time to time, on or before June 1, 2027, SHH may redeem up to 10% of the then outstanding aggregate principal amount of Secured Notes (including any additional Secured Notes issued under the Indenture) during each of the twelve-month periods ending after the issue date, at a redemption price equal to 103%

of the aggregate principal amount thereof, plus accrued and unpaid interest, if any, thereon to, but excluding, the redemption date.

The obligations under the Indenture are secured on a first-lien basis by security interests in substantially all of the assets of SHH, the Company and the Guarantors (other than any excluded assets) that secure the Credit Agreement on a pari passu basis, subject to certain limitations, exceptions and permitted liens. These obligations are secured pursuant to a security agreement, dated as of May 30, 2024, by and among SHH, the Company, the other grantors party thereto, and Wilmington Trust, National Association (the “Security Agreement”), as may be amended from time to time, and related financing statements.

The Company used the combined net proceeds from the Refinancing Term Loans and Secured Notes, along with cash on hand, to refinance its previously outstanding $1,763.1 million Term Loan due 2026 and $496.3 million Term Loan B due 2026.

The Senior Secured Credit Facilities and the Indenture contain additional covenants that, among other things, restrict, subject to certain exceptions, limitations and qualifications, our ability and the ability of our restricted subsidiaries to engage in certain activities, such as incur additional indebtedness or permit to exist any lien on any property or asset now owned or hereafter acquired, as specified in the Senior Secured Credit Facilities and the Indenture. The Senior Secured Credit Facilities and the Indenture also contain certain customary affirmative covenants and events of default, including upon a change of control. In addition, an event of default under the Senior Secured Credit Facilities and the Indenture would occur if the Company or certain of its subsidiaries received one or more enforceable judgments for payment in an aggregate amount in excess of the greater of (i) $162.6 million or (ii) 30.0% of consolidated EBITDA or LTM EBITDA (as defined in the Credit Agreement and the Indenture, respectively) and the judgments were not stayed or remained undischarged for a period of 60 consecutive days. As of December 31, 2025, we were in compliance with all of the covenants under the Senior Secured Credit Facilities and the Indenture.

All of SHH’s obligations under the Senior Secured Credit Facilities and the Indenture are unconditionally guaranteed by the Company and each existing and subsequently acquired or organized direct or indirect wholly-owned domestic restricted subsidiary of the Company, with customary exceptions including, among other things, where providing such guarantees is not permitted by law, regulation or contract or would result in material adverse tax consequences. All obligations under the Senior Secured Credit Facilities and the Indenture, and the guarantees of such obligations, are secured by substantially all assets of SHH and the guarantors, subject to permitted liens and other exceptions and exclusions, as outlined in the Senior Secured Credit Facilities, the Indenture and the Security Agreement.

Outstanding letters of credit are collateralized by encumbrances against the Revolving Credit Facility and the collateral pledged thereunder, or by cash placed on deposit with the issuing bank. As of December 31, 2025, the Company had $8.2 million of letters of credit issued against the Revolving Credit Facility, resulting in total availability under the Revolving Credit Facility of $591.8 million.

Term Loan Interest Rate Risk Management

The Company utilizes interest rate derivatives to reduce the variability of cash flows in the interest payments associated with our variable rate debt due to changes in SOFR. For additional information on the derivative instruments described above, refer to Note 20, “Financial Instruments and Financial Risk”, “Derivative Instruments.”

Debt Maturities

Aggregate maturities of the Company’s long-term debt, excluding debt issuance costs and discounts, as of December 31, 2025, are as follows:


(thousands of U.S. dollars)
2026	$	14,230
2027	14,230
2028	14,230
2029	14,230
2030	14,230
Thereafter	2,098,322
Total	$	2,169,472

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Segment and Geographic Information - Additional Information (Details) - segment	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting [Abstract]
Number of operating segments	3
Number of reportable segments	3
Operating Segments \| Nordion \| Revenue from Contract with Customer Benchmark \| Customer Concentration Risk \| Customer One
Segment Reporting Information [Line Items]
Percentage	34.80%	34.30%	34.90%
Operating Segments \| Nordion \| Revenue from Contract with Customer Benchmark \| Customer Concentration Risk \| Customer Two
Segment Reporting Information [Line Items]
Percentage	11.00%		13.90%

Income Taxes - Schedule of Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
U.S.	$ (69,357)	$ (116,049)	$ (100,635)
Foreign	216,863	229,923	206,662
Income before income taxes	$ 147,506	$ 113,874	$ 106,027

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Leases (Tables)

12 Months Ended

Dec. 31, 2025

Leases [Abstract]

Schedule of Lease Expense

The components of lease expense were as follows:


	Year Ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Operating lease costs (a)	$	13,207	$	13,267	$	13,920
Finance lease costs:
Amortization of right of use assets	6,474		8,438		8,152
Interest on lease liabilities	6,105		6,064		4,394
Total finance lease costs	12,579		14,502		12,546
Total lease costs	$	25,786	$	27,769	$	26,466

(a)Includes $1.7 million, $1.5 million, and $1.4 million of short-term lease costs in the years ended December 31, 2025, 2024, and 2023, respectively.

Supplemental cash flow information related to leases was as follows:


	Year Ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	7,917	$	7,382	$	10,067
Operating cash flows for finance leases	6,332		6,277		3,988
Finance cash flows for finance leases	3,903		8,088		1,823

Supplemental non-cash information was as follows:


	Year Ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	10,822	$	10,550	$	4,559
Finance leases	431		36,016		14,770

Schedule of Lease Term and Discount Rate

Lease terms and discount rates were as follows:


	Year Ended December 31,
	2025		2024
Weighted average remaining lease term:
Operating leases	11.1 years		7.3 years
Finance leases	14.9 years		15.2 years
Weighted average discount rate:
Operating leases	6.90	%	6.57	%
Finance leases	6.55	%	6.55	%

Schedule of Maturity of Operating Lease

Maturities of lease liabilities as of December 31, 2025 are as follows:


(thousands of U.S. dollars)	Operating Leases		Finance Leases		Total
2026	$	8,134	$	9,689	$	17,823
2027	7,187		9,968		17,155
2028	5,760		10,263		16,023
2029	4,717		9,933		14,650
2030	3,767		9,634		13,401
2031 and Thereafter	22,069		108,811		130,880
Total lease payments	51,634		158,298		209,932
Less imputed interest	(15,978)		(60,998)		(76,976)
Total lease liabilities	$	35,656	$	97,300	$	132,956

Schedule of Maturity of Finance Lease

Maturities of lease liabilities as of December 31, 2025 are as follows:


(thousands of U.S. dollars)	Operating Leases		Finance Leases		Total
2026	$	8,134	$	9,689	$	17,823
2027	7,187		9,968		17,155
2028	5,760		10,263		16,023
2029	4,717		9,933		14,650
2030	3,767		9,634		13,401
2031 and Thereafter	22,069		108,811		130,880
Total lease payments	51,634		158,298		209,932
Less imputed interest	(15,978)		(60,998)		(76,976)
Total lease liabilities	$	35,656	$	97,300	$	132,956

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

Our basic and diluted earnings per common share are calculated as follows:


	Year Ended December 31,
in thousands of U.S. dollars and share amounts (except per share amounts)	2025		2024		2023
Earnings:
Net income	$	77,949	$	44,398	$	51,376
Less: Allocation to participating securities	4		59		287
Net income attributable to Sotera Health Company common stockholders	$	77,945	$	44,339	$	51,089
Weighted Average Common Shares:
Weighted-average common shares outstanding - basic	283,956		282,784		281,008
Dilutive effect of potential common shares	2,465		2,122		2,213
Weighted-average common shares outstanding - diluted	286,421		284,906		283,222
Earnings per Common Share:
Net income per common share attributable to Sotera Health Company common stockholders - basic	$	0.27	$	0.16	$	0.18
Net income per common share attributable to Sotera Health Company common stockholders - diluted	0.27		0.16		0.18

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Diluted earnings per shares does not consider the following potential common shares as the effect would be anti-dilutive:


	Year Ended December 31,
in thousands of share amounts	2025	2024	2023
RSUs	9	34	291
Stock options	5,550	5,469	4,108
Total anti-dilutive securities	5,559	5,503	4,399

Financial Instruments and Financial Risk - Schedule of Activities of Derivative Instruments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized (gain) loss on embedded derivatives recorded in other income, net	$ (863)	$ 2,213	$ (1,637)
Interest Rate Cap
Derivative Instruments, Gain (Loss) [Line Items]
Realized gain on interest rate derivatives recorded in interest expense, net	(1,505)	(13,233)	(33,094)
Embedded derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized (gain) loss on embedded derivatives recorded in other income, net	(863)	2,213	(1,637)
Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Realized (gain) loss on foreign currency forward contracts recorded in foreign exchange loss	(6,033)	18,055	(2,025)
Unrealized (gain) loss on foreign currency forward contracts recorded in foreign exchange loss	$ (110)	$ 249	$ (412)

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 182
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-182

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(6)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CCC
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4CC
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4C
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4D

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E

+ Details

- Definition

The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.

+ References + Details

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 344,621	$ 277,242
Restricted cash short-term	1,835	1,623
Accounts receivable, net of allowance for uncollectible accounts of $2,968 and $2,532 as of December 31, 2025 and 2024, respectively	139,329	140,327
Inventories, net	54,375	49,158
Prepaid expenses and other current assets	65,250	51,031
Income taxes receivable	8,000	6,656
Total current assets	613,410	526,037
Property, plant, and equipment, net	1,130,564	1,036,892
Operating lease assets	33,393	27,551
Deferred income taxes	3,853	2,865
Post-retirement assets	53,817	42,524
Other assets	36,694	37,053
Other intangible assets, net	288,227	317,653
Goodwill	1,103,232	1,081,073
Total assets	3,263,190	3,071,648
Current liabilities:
Accounts payable	77,963	55,098
Accrued liabilities	124,736	90,463
Deferred revenue	17,999	15,100
Current portion of long-term debt	13,973	14,803
Current portion of finance lease obligations	3,465	2,923
Current portion of operating lease obligations	5,755	5,056
Income taxes payable	5,693	7,559
Total current liabilities	249,584	191,002
Long-term debt	2,126,724	2,208,100
Finance lease obligations, less current portion	93,835	95,286
Operating lease obligations, less current portion	29,901	24,465
Noncurrent asset retirement obligations	53,496	49,319
Deferred lease income	17,057	16,784
Post-retirement obligations	8,123	7,863
Noncurrent liabilities	7,360	4,418
Deferred income taxes	71,075	69,500
Total liabilities	2,657,155	2,666,737
See Commitments and contingencies note
Equity:
Common stock, with $0.01 par value, 1,200,000 shares authorized; 286,037 shares issued at December 31, 2025 and 2024	2,860	2,860
Preferred stock, with $0.01 par value, 120,000 shares authorized; no shares issued at December 31, 2025 and 2024	0	0
Treasury stock, at cost (1,666 and 2,571 shares at December 31, 2025 and 2024, respectively)	(17,013)	(23,434)
Additional paid-in capital	1,262,119	1,243,778
Retained deficit	(532,093)	(610,042)
Accumulated other comprehensive loss	(109,838)	(208,251)
Total equity	606,035	404,911
Total liabilities and equity	$ 3,263,190	$ 3,071,648

Income Taxes

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Income Taxes

The geographic sources of income before income taxes were as follows:


(thousands of U.S. dollars)
Year ended December 31,	2025		2024		2023
U.S.	$	(69,357)	$	(116,049)	$	(100,635)
Foreign	216,863		229,923		206,662
Income before income taxes	$	147,506	$	113,874	$	106,027

Provision for income taxes consisted of the following:


(thousands of U.S. dollars)
Year ended December 31,	2025		2024		2023
Current
Federal U.S.	$	8,975	$	708	$	(3,809)
State U.S.	1,108		1,100		924
Foreign	59,452		58,235		54,087
Total current provision	69,535		60,043		51,202
Deferred
Federal U.S.	(328)		13,645		6,933
State U.S.	670		(837)		(619)
Foreign	(320)		(3,375)		(2,865)
Total deferred provision	22		9,433		3,449
Total provision for income taxes	$	69,557	$	69,476	$	54,651

The provision for income taxes for the year ended December 31, 2025 is reconciled with the U.S. federal statutory rate as follows:


Year ended December 31,	2025
(thousands of U.S. dollars)	Amount		Percent
U.S. Federal Statutory Tax Rate	$	30,976	21.0	%
Increase (decrease) in taxes as a result of:
State and Local Income Taxes, Net of Federal Income Tax Effect (a)	2,495		1.7
Foreign Tax Effects
Canada
State taxes, net of federal income tax effect	12,637		8.6
Foreign rate differential	(6,891)		(4.7)
Withholding tax	15,259		10.3
Other	1,058		0.7
Brazil
Foreign rate differential	1,887		1.3
Nontaxable income from application of presumed profits method	(2,301)		(1.6)
Other	1,903		1.3
Belgium
Changes in valuation allowance	1,807		1.2
Prior year differences	(1,990)		(1.3)
Other	1,960		1.3
Other Foreign Jurisdictions	3,522		2.4
Effect of Cross Border Tax Laws
Global intangible low-taxed income	1,800		1.2
Changes in Valuation Allowance	3,128		2.1
Nontaxable or Nondeductible Items
Non-deductible equity compensation	2,256		1.5
Other Adjustments	51		—
Total provision for income taxes	$	69,557	47.2	%

(a)State taxes in California, Illinois and Utah made up the majority (greater than 50 percent) of the tax effect in this category.

The provision for income taxes for the years ended December 31, 2024 and 2023 is reconciled with the U.S. federal statutory rate as follows:


(thousands of U.S. dollars)
Year ended December 31,	2024		2023
Provision computed at federal statutory rate	$	23,914	$	22,265
Increase (decrease) in taxes as a result of:
State taxes, net of federal benefit	(2,840)		(2,889)
Valuation allowance	35,660		19,494
Global intangible low-tax income	1,691		4,861
Nondeductible share-based compensation	3,859		3,192
Foreign tax rate differential	11,893		10,595
Impact of rate changes on deferred tax balances	(914)		(92)
Tax holiday	(1,335)		(1,082)
Audit settlement	17		739
Tax credits	(259)		—
Other	(2,210)		(2,432)
Total provision for income taxes	$	69,476	$	54,651

The components of the tax effects of temporary differences and carryforwards that gave rise to significant portions of the deferred tax assets and liabilities are as follows:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Net operating loss carryforwards	$	57,210	$	56,097
Net capital loss carryforwards	3,652		2,890
Reserves and accruals	16,532		8,187
Employee benefits and compensation	12,636		10,481
Asset retirement obligations	12,432		11,506
Lease liability	16,462		14,381
Disallowed interest carryforward	186,937		167,369
Other	10,690		8,804
Deferred tax assets before valuation allowance	316,551		279,715
Valuation allowance	(172,294)		(160,595)
Net deferred tax assets	144,257		119,120

Depreciation and amortization	(188,522)		(170,646)
Reserves and accruals	(15,207)		(11,240)
Other	(7,750)		(3,869)
Total deferred tax liabilities	(211,479)		(185,755)
Net deferred tax liabilities	$	(67,222)	$	(66,635)
Noncurrent net deferred tax assets	$	3,853	$	2,865
Noncurrent net deferred tax liabilities	(71,075)		(69,500)
Noncurrent net deferred tax liabilities	$	(67,222)	$	(66,635)

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. The OBBBA includes a broad range of tax reform provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act of 2017, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The Company has included the impact of the provisions effective in its 2025 consolidated financial statements, recording a

$16.6 million tax benefit related to the reduction of the valuation allowance attributable to the change in the limitation on the deductibility of interest expense. There were no other material impacts to the Company’s results of operations or financial condition.

At December 31, 2025 and 2024, the Company had available U.S. federal net operating loss carryforwards of $155.4 million and $164.1 million, respectively, which have no expiration date. At December 31, 2025 and 2024, the Company had available state net operating loss carryforwards of $299.5 million and $293.8 million, respectively, of which $64.1 million and $89.6 million have no expiration date, and foreign net operating loss carryforwards of approximately $32.6 million and $21.4 million, respectively, the majority of which have no expiration date. At December 31, 2025 and 2024, a valuation allowance was established against foreign net operating loss carryforwards for $5.4 million and $3.6 million, respectively. At December 31, 2025 we established a valuation allowance against U.S. federal net operating loss carryforwards of $0.8 million. At December 31, 2025 and 2024, we also established a valuation allowance against U.S. state net operating loss carryforwards for $17.2 million and $12.5 million, respectively. Based on management’s assessment, it is not more likely than not that these deferred tax assets will be realized through future taxable income.

At December 31, 2025 and 2024, the deferred tax liability balance related to repatriation of earnings not deemed to be indefinitely reinvested was $7.8 million and $3.8 million, respectively. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings not subject to the transition tax and additional outside basis difference in these entities (i.e., basis difference in excess of that subject to the one-time transition tax) is not practicable.

The Company recognizes interest and penalties as part of the provision for income taxes. For the years ended December 31, 2025, 2024 and 2023, interest and penalties related to uncertain income tax positions that were recognized in the Consolidated Statements of Operations and Comprehensive Income (Loss) were not material.

The Company, which represents all of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. The Company is no longer subject to U.S. federal, state, and local tax examinations before 2016, and non-U.S. income tax examinations by tax authorities for years before 2012. Tax years through December 31, 2018 have been audited by the Internal Revenue Service and are effectively closed for U.S. federal income tax purposes and no other fiscal years are currently under audit. For Nordion’s Canadian tax, all tax years through October 31, 2018 have been closed through audit or statute, and no other fiscal years are currently under audit.

A portion of the Company’s foreign operations benefit from a tax holiday, which is set to expire in 2030. This tax holiday may be terminated early if certain conditions are not met. The tax benefit attributable to this holiday was $1.1 million and $1.3 million for the fiscal years ended December 31, 2025 and 2024, respectively.

The amounts of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes for the year ended December 31, 2025 were as follows:


Year ended December 31,	2025
(thousands of US dollars)	Amount		Percent
Federal U.S.	$	1,570	2.6	%
State U.S.	369		0.6
Foreign
Canada	34,597		56.8
Belgium	7,477		12.3
United Kingdom	3,958		6.5
Mexico	3,310		5.4
All other foreign countries	9,592		15.8
Total cash paid for income taxes, net of refunds received	$	60,873

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2025
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We depend on a limited number of suppliers and our agreements with these suppliers account for material portions of our supply and direct material costs. These costs include obligations under various supply agreements in our Nordion segment for Co-60 that are enforceable and legally binding on us. As of December 31, 2025, we had minimum purchase commitments primarily with domestic and international suppliers of raw materials for the Nordion business totaling $2,379.5 million, $53.1 million to $72.9 million in each of the next five years. The terms of these long-term supply or service arrangements range from 1 to 39 years. In addition, our Sterigenics segment has obligations to purchase ethylene oxide (“EO”). Our contract to purchase EO in the U.S. requires us to purchase all of our requirements from one supplier, and our contracts to purchase EO outside the U.S. generally require that we purchase a specified percentage of our requirements for our operations in the countries covered by those contracts. We expect to utilize the Co-60 and EO encompassed by these agreements in the normal course of our business and therefore our commitments under these agreements are not recognized on the consolidated balance sheets as a liability. From time to time, we may be or are subject to various lawsuits and other claims, as well as gain contingencies, in the ordinary course of our business. In addition, from time to time, we receive communications from government or regulatory agencies concerning investigations or allegations of noncompliance with laws or regulations in jurisdictions in which we operate. We assess these regulatory and legal actions to determine if a contingent liability should be recorded. In making these determinations, we may, depending on the nature of the matter, consult with internal and external legal counsel and technical experts. We establish reserves for specific liabilities in connection with regulatory and legal actions that we determine to be both probable and reasonably estimable. The outcomes of regulatory and legal actions can be difficult to predict and are often resolved over long periods of time, making our probability and estimability determinations highly judgmental. Probability determinations require the analysis of various possible outcomes, assessments of potential damages and the impact of multiple factors beyond our control, including potential actions by others, interpretations of the law, and changes and developments in relevant facts, circumstances, regulations and other laws. If a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability is disclosed, together with an estimate of the range of possible loss if the range is determinable and material. In certain of the matters described below, we are not able to estimate potential liability because of the uncertainties related to the outcome(s) and/or the amount(s) or range(s) of loss. The ultimate resolution of pending regulatory and legal matters in future periods, including the matters described below, may have a material adverse effect on our financial condition, results of operations and/or liquidity. The Company may also incur material defense and settlement costs, diversion of management resources and other adverse effects on our business, financial condition, and/or results of operations. The information regarding those lawsuits set forth below, including the number of claims, is as of December 31, 2025, except as otherwise indicated. Ethylene Oxide Tort Litigation Sterigenics U.S., LLC (“Sterigenics”) and other medical supply sterilization companies have been subjected to tort lawsuits alleging various injuries caused by low-level environmental exposure to EO used at or emitted or released from sterilization facilities. Those lawsuits, as detailed further below, are individual claims, as opposed to class actions. California As of February 20, 2026, subsidiaries of the Company and other parties are defendants in Los Angeles County Superior Court in which the plaintiffs assert approximately 120 claims for personal injury or wrongful death allegedly resulting from use, emissions and releases of EO from Sterigenics’ Vernon facilities (the “Vernon Cases”). The Vernon Cases have been assigned to one judge, with initial trials scheduled for January and April 2027. Eight individual claims have been selected as the “First Plaintiff Group” and are being prioritized for discovery. Georgia Subsidiaries of the Company and other parties are defendants in lawsuits in Georgia in which plaintiffs allege personal injuries, wrongful death and property devaluation resulting from use, emissions and releases of EO from or at Sterigenics’ Atlanta facility. As of February 20, 2026, approximately 450 personal injury and wrongful death claims pending in the State Court of Cobb County (the “Georgia Trial Court”) are assigned to a single judge (the “Georgia Personal Injury Cases”). The Georgia Personal Injury Cases are governed by case management orders pursuant to which general causation issues in a pool of eight cases are to be adjudicated in Phase 1 and specific causation issues in those pool cases are to be adjudicated in Phase 2; the remaining Georgia Personal Injury Cases, including 15 cases that include both personal injury and property claims and one personal injury lawsuit that is pending before a different judge, are stayed. On November 22, 2024, the Georgia Trial Court issued a Phase 1 ruling on general causation issues granting in part and denying in part defendants’ motions to exclude certain Phase 1 expert testimony and defendants’ motions for summary judgment on Phase 1 issues (the “General Causation Ruling”). Plaintiffs and defendants appealed the General Causation Ruling to the Court of Appeals of Georgia (the “Phase 1 General Causation Appeals”). While the Phase 1 General Causation Appeals were pending, three of the pool cases selected by plaintiffs’ counsel proceeded to Phase 2 (the “Phase 2 Cases”). On October 17, 2025, the Georgia Trial Court issued its Phase 2 rulings on specific causation issues granting Sterigenics’ motions to exclude three of plaintiffs’ specific causation expert witnesses and granting Sterigenics’ motions for summary judgment in all three Phase 2 Cases (“the “Specific Causation Ruling”). On October 28, 2025, the Georgia Trial Court entered an order also adopting its Specific Causation Ruling with respect to our subsidiary Sotera Health LLC. Plaintiffs in the Phase 2 Cases appealed the Specific Causation Ruling to the Court of Appeals of Georgia (the “Phase 2 Specific Causation Appeals”). On October 31, 2025, the Court of Appeals of Georgia ruled on the Phase 1 General Causation Appeals, finding that, as Sterigenics contended on appeal, the General Causation Ruling failed to apply the proper standard for determining the admissibility of expert testimony on general causation, vacating the General Causation Ruling and remanding the pool cases to the Georgia Trial Court with instructions to apply the proper standard in ruling on general causation issues. The Court of Appeals also instructed the Georgia Trial Court to consider whether plaintiffs can prove general causation through epidemiological evidence and background risks of the diseases at issue. The Georgia Trial Court is conducting further Phase 1 proceedings in the five remanded pool cases that are not involved in the Phase 2 Specific Causation Appeals. Subsidiaries of the Company and other parties are also defendants in a lawsuit filed in May 2020 in which employees of a sterilization customer of Sterigenics allege they were injured while working at the customer’s distribution facility by exposure to residual EO allegedly emanating from products of the customer that had been sterilized by Sterigenics. The case has been transferred from the Georgia Trial Court to the Superior Court of Cobb County and is proceeding on plaintiffs’ Fifth Amended Complaint. Pursuant to the customer’s contract with Sterigenics, the customer is indemnifying Sterigenics against this lawsuit. As of February 20, 2026, approximately 305 lawsuits have been filed in the Georgia Trial Court against subsidiaries of the Company and other parties in which plaintiffs allege property devaluation resulting from use, emissions and releases of EO from or at Sterigenics’ Atlanta facility. These cases have been consolidated for pretrial purposes (the “Consolidated Property Cases”). Proceedings in a pool of nine of the Consolidated Property Cases are governed by case management orders pursuant to which the parties completed discovery and defendants filed motions to exclude certain plaintiffs’ expert testimony and motions for summary judgment, which remain pending. The remaining cases are stayed. Illinois Lawsuits against subsidiaries of the Company and other parties have been filed in the Circuit Court of Cook County, Illinois, by plaintiffs alleging personal injury or wrongful death resulting from use, emissions and releases of EO from Sterigenics’ former Willowbrook facility (the “Willowbrook Cases”). As of February 20, 2026, subsidiaries of the Company and other parties are defendants in one Willowbrook Case in which two plaintiffs are asserting claims for personal injuries. In April 2025, Sterigenics entered into a binding term sheet to pay $30.9 million to resolve 97 claims, including claimants with pending lawsuits and claimants who asserted claims but had yet to file lawsuits. The settlement was finalized in September 2025. In July 2025, Sterigenics entered into a binding term sheet to pay $34.0 million to resolve 129 additional claims, including claimants with pending lawsuits and claimants who asserted claims but had yet to file. The settlement was finalized in February 2026. New Mexico The Company and certain subsidiaries are defendants in a lawsuit filed in the Third Judicial District Court, Doña Ana County, New Mexico (the “Trial Court”) in which the New Mexico Attorney General (“NMAG”) alleges that use, emissions and releases of EO from Sterigenics’ facility in Santa Teresa have deteriorated the air quality in surrounding communities and materially contributed to increased health risks for residents of those communities and seeks declaratory and permanent injunctive relief and damages. In April 2024, the Court of Appeals of the State of New Mexico denied the NMAG’s petition for leave to file an interlocutory appeal of the Trial Court’s August 2023 order granting Sterigenics’ motion for summary judgment on strict liability, the Unfair Practices Act claim, and the claims for decreased property values, increased healthcare costs and medical monitoring costs, and remanded the case to the District Court of Doña Ana County for further proceedings on the remaining claims. In January 2026, the Trial Court denied NMAG’s May 2025 motion to modify the Trial Court’s August 2023 summary judgment order to reinstate the NMAG’s claim for recovery of healthcare cost damages. The case is set for trial in July 2026. * * * Additional EO lawsuits have been threatened relating to Sterigenics’ current and former EO sterilization facilities in the United States and may be filed in the future. These threats of additional EO lawsuits are comparable to threats that have similarly been made against other companies within our industry. Based on our view of the strength of the science and related evidence that emissions of EO from Sterigenics’ operations have not caused and could not have caused the harms alleged in such lawsuits, we believe that losses in the remaining or future EO cases through trials and any appeals that may prove necessary are not probable. Although the Company is vigorously defending against the EO tort claims, future settlements of EO tort claims are reasonably possible. The previously disclosed settlements of certain cases related to our facilities in Willowbrook and Atlanta were driven by dynamics unique to the claims that were settled and thus should not give rise to presumptions that the Company will settle additional EO tort claims and/or that any such settlements will be for comparable amounts. Potential trial and settlement outcomes can vary widely based on a host of factors. EO tort lawsuits will be presided over by different judges, tried by different counsel presenting different evidence and decided by different juries. The substantive and procedural laws of jurisdictions vary and can meaningfully impact the litigation process and outcome of a case. Each plaintiff’s claim involves unique facts and evidence, including the circumstances of the plaintiff’s alleged exposure, the type and severity of the plaintiff’s disease, the plaintiff’s medical history and course of treatment, the location of and other factors related to the plaintiff’s real property, and other circumstances. The outcomes of trials before juries are rarely certain and a judgment rendered or settlement reached in one case is not necessarily representative of potential outcomes of other seemingly comparable cases. As a result, it is not possible to estimate a reasonably possible loss or range of loss with respect to any future EO tort lawsuit, trial or settlement. We are vigorously defending the EO tort lawsuits. Insurance Coverage for Environmental Liabilities An environmental liability insurance policy under which we have received coverage for the EO tort lawsuits in Georgia, Illinois and New Mexico described above had limits of $10.0 million per occurrence and $20.0 million in the aggregate. Those per occurrence and aggregate limits were fully utilized in the defense of the Georgia, Illinois and New Mexico litigation. Our insurance for future alleged environmental liabilities excludes coverage for EO claims. We are pursuing additional insurance coverage for our legal expenses related to EO tort lawsuits. On August 27, 2021, Sterigenics filed an insurance coverage lawsuit in the U.S. District Court for the Northern District of Illinois (the “Illinois District Court”) relating to two commercial general liability policies issued in the 1980s (the “Northern District of Illinois Coverage Lawsuit”). The Illinois District Court issued an order declaring that the defendant insurer owes a duty to Sterigenics and another insured party to defend the Willowbrook Cases (the “Duty to Defend Order”) and entered judgment for Sterigenics in January 2024 in the amount of $110.2 million for certain defense costs incurred in the Willowbrook Cases as of August 2022 (the “Defense Costs Judgment”). The defendant insurer appealed the Duty to Defend Order and Defense Costs Judgment to the United States Court of Appeals for the Seventh Circuit. On January 23, 2026 the Illinois Supreme Court issued an opinion answering a question of Illinois law certified to it by the Seventh Circuit Court of Appeals, holding that a permit or regulation authorizing emissions plays no role in assessing the application of a pollution exclusion in a standard form commercial general liability policy. The Seventh Circuit Court of Appeals is conducting further proceedings in light of the Illinois Supreme Court’s opinion. Sterigenics is also a party in insurance coverage lawsuits instituted on March 27, 2023 in the Delaware Superior Court, on February 3, 2025 in the Los Angeles County Superior Court and, in January 2023, in the Circuit Court of Cook County, Illinois (after being granted leave to intervene on May 6, 2024), relating to insurance coverage from various historical commercial general liability policies for certain EO litigation settlement amounts and defense costs that the defendant insurer in the Northern District of Illinois Coverage Lawsuit may fail to fund. The Delaware Superior Court case has been stayed pending resolution of the coverage lawsuit in the Circuit Court of Cook County. The coverage lawsuits in the Circuit Court of Cook County lawsuit and the Los Angeles County Superior Court have been stayed pending resolution of the question certified to the Illinois Supreme Court. It is not possible to predict how much, if any, of the insurance proceeds sought will ultimately be recovered. Sotera Health Company Securities Litigation and Related Matters In January 2023, a stockholder class action was filed in the U.S. District Court for the Northern District of Ohio (the “Ohio District Court”) against the Company, certain past and present directors and senior executives, the Company’s private equity stockholders and the underwriters of the Company’s IPO in November 2020 and the Company’s secondary public offering (“SPO”) in March 2021 (the “Michigan Funds Litigation”). In April 2023, the Ohio District Court appointed the Oakland County Employees’ Retirement System, Oakland County Voluntary Employees’ Beneficiary Association, and Wayne County Employees’ Retirement System (the “Michigan Funds”) to serve as lead plaintiff to prosecute claims on behalf of a proposed class of stockholders who acquired shares of the Company in connection with our IPO or SPO between November 20, 2020 and September 19, 2022 (the “Proposed Class”). The Michigan Funds allege that certain statements made regarding the safety of the Company’s use of EO and/or the EO tort lawsuits and other risks of its EO operations violated Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (when made in the registration statements for the IPO and SPO) and Sections 10(b), Section 20(a) and Rule 10b-5 of the Exchange Act (when made in subsequent securities filings and other contexts) and seek compensatory, rescissory or statutory damages. On March 19, 2025, the Ohio District Court issued a Memorandum Opinion and Order granting the Company’s motion to dismiss the Amended Complaint and entered judgment dismissing the Michigan Funds Litigation with prejudice (the “Dismissal Order and Judgment”). The Michigan Funds appealed the Dismissal Order and Judgment to the United States Court of Appeals for the Sixth Circuit (the “Michigan Funds Appeal”). On February 24, 2026, the United States Court of Appeals for the Sixth Circuit affirmed the Dismissal Order and Judgment. In May 2024, a stockholder derivative lawsuit was filed in the Court of Chancery of the State of Delaware (the “Delaware Chancery Court”) for the benefit of the Company as the nominal defendant (the “May 2024 Derivative Litigation”). The plaintiffs allege breaches of fiduciary duties, insider trading, unjust enrichment and other violations by certain past and present directors and senior executives of the Company and the Company’s private equity stockholders, and seek damages sustained by the Company and other forms of relief including restitution, rescission and disgorgement. On June 25, 2024, the Delaware Chancery Court stayed the May 2024 Derivative Litigation pending a ruling on the merits on the motion to dismiss the Amended Complaint in the Michigan Funds Litigation and that stay has been extended by agreement of the parties until the Sixth Circuit Court of Appeals decides the Michigan Funds Appeal. The Company plans to vigorously defend the May 2024 Derivative Litigation. The Company has also received demands pursuant to 8 Del. C. §220 for inspections of its books and records (“220 Demands”) from shareholders purporting to investigate potential wrongdoing by Company fiduciaries and other issues relating to the Company’s statements regarding the safety of its use of EO and/or the EO tort lawsuits and other risks of its EO operations. The Company has produced documents in response to the 220 Demands and may produce additional documents.

Inventories

12 Months Ended

Dec. 31, 2025

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Raw materials and supplies	$	45,569	$	42,408
Work-in-process	2,436		929
Finished goods	6,622		6,039
	54,627		49,376
Reserve for excess and obsolete inventory	(252)		(218)
Inventories, net	$	54,375	$	49,158

Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ 404,911	$ 443,734	$ 350,238
Other comprehensive income (loss) before reclassifications	99,604	(105,554)	36,307
Amounts reclassified from accumulated other comprehensive income (loss)	(1,191)	(10,015)	(22,336)
Net current-period other comprehensive income (loss)	98,413	(115,569)	13,971
Ending Balance	606,035	404,911	443,734
Defined Benefit Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	1,165	(7,297)	3,209
Other comprehensive income (loss) before reclassifications	2,455	8,632	(10,308)
Amounts reclassified from accumulated other comprehensive income (loss)	(69)	(170)	(198)
Net current-period other comprehensive income (loss)	2,386	8,462	(10,506)
Ending Balance	3,551	1,165	(7,297)
Foreign Currency Translation
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(209,666)	(91,031)	(131,205)
Other comprehensive income (loss) before reclassifications	98,115	(118,635)	40,174
Amounts reclassified from accumulated other comprehensive income (loss)	0	0	0
Net current-period other comprehensive income (loss)	98,115	(118,635)	40,174
Ending Balance	(111,551)	(209,666)	(91,031)
Interest Rate Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	250	5,646	21,343
Other comprehensive income (loss) before reclassifications	(966)	4,449	6,441
Amounts reclassified from accumulated other comprehensive income (loss)	(1,122)	(9,845)	(22,138)
Net current-period other comprehensive income (loss)	(2,088)	(5,396)	(15,697)
Ending Balance	(1,838)	250	5,646
AOCI Attributable to Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(208,251)	(92,682)	(106,653)
Ending Balance	$ (109,838)	$ (208,251)	$ (92,682)

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480870/815-30-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

Other Comprehensive Income (Loss)

Amounts in accumulated other comprehensive income (loss) are presented net of the related tax. Foreign currency translation is not adjusted for income taxes.

Changes in our accumulated other comprehensive income (loss) balances, net of applicable tax, were as follows:


(thousands of U.S. dollars)	Defined Benefit Plans			Foreign Currency Translation		Interest Rate Derivatives			Total
Beginning balance – January 1, 2023	$	3,209		$	(131,205)	$	21,343		$	(106,653)
Other comprehensive income (loss) before reclassifications	(10,308)			40,174		6,441			36,307
Amounts reclassified from accumulated other comprehensive income (loss)	(198)		(a)	—		(22,138)		(b)	(22,336)
Net current-period other comprehensive income (loss)	(10,506)			40,174		(15,697)			13,971
Ending balance – December 31, 2023	$	(7,297)		$	(91,031)	$	5,646		$	(92,682)

Beginning balance – January 1, 2024	$	(7,297)		$	(91,031)	$	5,646		$	(92,682)
Other comprehensive income (loss) before reclassifications	8,632			(118,635)		4,449			(105,554)
Amounts reclassified from accumulated other comprehensive income (loss)	(170)		(a)	—		(9,845)		(b)	(10,015)
Net current-period other comprehensive income (loss)	8,462			(118,635)		(5,396)			(115,569)
Ending balance – December 31, 2024	$	1,165		$	(209,666)	$	250		$	(208,251)

Beginning balance – January 1, 2025	$	1,165		$	(209,666)	$	250		$	(208,251)
Other comprehensive income (loss) before reclassifications	2,455			98,115		(966)			99,604
Amounts reclassified from accumulated other comprehensive income (loss)	(69)		(a)	—		(1,122)		(b)	(1,191)
Net current-period other comprehensive income (loss)	2,386			98,115		(2,088)			98,413
Ending balance – December 31, 2025	$	3,551		$	(111,551)	$	(1,838)		$	(109,838)

(a)For defined benefit pension and other post-retirement plans, amounts reclassified from accumulated other comprehensive income (loss) are recorded to “Other income, net” within the Consolidated Statements of Operations and Comprehensive Income (Loss).

(b)For interest rate derivatives, amounts reclassified from accumulated other comprehensive income (loss) are recorded to “Interest expense, net” within the Consolidated Statements of Operations and Comprehensive Income (Loss)

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid taxes	$ 5,212	$ 4,993
Prepaid business insurance	3,974	6,993
Prepaid rent	4,466	1,223
Customer contract assets	24,410	15,213
Current deposits	283	807
Prepaid maintenance contracts	490	638
Value added tax receivable	4,527	3,614
Prepaid software licensing	2,661	2,590
Stock supplies	5,012	4,025
Embedded derivatives	1,162	2,689
Other	13,053	8,246
Prepaid expenses and other current assets	$ 65,250	$ 51,031

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

Changes to goodwill during the years ended December 31, 2025 and 2024 were as follows:


(thousands of U.S. dollars)	Sterigenics		Nordion		Nelson Labs		Total
Goodwill at January 1, 2024	$	659,888	$	276,929	$	174,373	$	1,111,190
Changes due to foreign currency exchange rates	(6,666)		(21,444)		(2,007)		(30,117)
Goodwill at December 31, 2024	653,222		255,485		172,366		1,081,073
Changes due to foreign currency exchange rates	5,697		12,286		4,176		22,159
Goodwill at December 31, 2025	$	658,919	$	267,771	$	176,542	$	1,103,232

Other intangible assets consisted of the following:


(thousands of U.S. dollars)	Gross Carrying Amount		Accumulated Amortization
As of December 31, 2025
Finite-lived intangible assets
Customer relationships	$	167,313	$	84,083
Proprietary technology	37,775		19,253
Trade names	2,400		2,000
Land-use rights	8,861		2,313
Sealed source and supply agreements	168,740		91,405
Other	900		790
Total finite-lived intangible assets	385,989		199,844

Indefinite-lived intangible assets
Regulatory licenses and other(a)	76,064		—
Trade names / trademarks	26,018		—
Total indefinite-lived intangible assets	102,082		—
Total	$	488,071	$	199,844


As of December 31, 2024	Gross Carrying Amount		Accumulated Amortization
Finite-lived intangible assets
Customer relationships	$	646,965	$	537,871
Proprietary technology	73,464		52,976
Trade names	2,531		1,651
Land-use rights	8,493		2,008
Sealed source and supply agreements	192,630		110,668
Other	4,344		3,655
Total finite-lived intangible assets	928,427		708,829

Indefinite-lived intangible assets
Regulatory licenses and other(a)	72,550		—
Trade names / trademarks	25,505		—
Total indefinite-lived intangible assets	98,055		—
Total	$	1,026,482	$	708,829

Amounts include the impact of foreign currency translation. Fully amortized amounts are written off.

Amortization expense for finite-lived intangible assets was $41.8 million, $79.4 million and $81.3 million for the years ended December 31, 2025, 2024 and 2023, respectively. $30.7 million, $62.0 million, and $63.8 million was included in “Amortization of intangible assets” in the Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2025, 2024 and 2023, whereas the remainder was included in “Cost of revenues.”

The estimated aggregate amortization expense for finite-lived intangible assets for each of the next five years and thereafter is as follows:


(thousands of U.S. dollars)
2026	$	22,161
2027	21,084
2028	20,537
2029	20,427
2030	20,427
Thereafter	81,509
Total	$	186,145

The weighted-average remaining amortization periods of the finite-lived intangible assets by major intangible asset class as of December 31, 2025 were as follows:


(in years)			Weighted average remaining amortization period
Customer relationships			9.3
Proprietary technology			9.8
Trade names			0.8
Land-use rights			30.7
Sealed source and supply agreements			9.0
Other			0.8

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Provision computed at federal statutory rate	$ 30,976	$ 23,914	$ 22,265
State taxes, net of federal benefit		(2,840)	(2,889)
Valuation allowance		35,660	19,494
Global intangible low-tax income	1,800	1,691	4,861
Nondeductible share-based compensation	2,256	3,859	3,192
Foreign tax rate differential		11,893	10,595
Impact of rate changes on deferred tax balances		(914)	(92)
Tax holiday		(1,335)	(1,082)
Audit settlement		17	739
Tax credits		(259)	0
Other		(2,210)	(2,432)
Total provision for income taxes	$ 69,557	$ 69,476	$ 54,651

Significant Accounting Policies - Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Undepreciated software costs	$ 17,100	$ 11,400
Property, Plant and Equipment [Line Items]
Undepreciated software costs	17,100	11,400
Depreciation	$ 94,908	84,260	$ 76,577
Co-60
Property, Plant and Equipment [Line Items]
Useful life	20 years
Software purchases and software development \| Minimum
Property, Plant and Equipment [Line Items]
Useful life	1 year
Software purchases and software development \| Maximum
Property, Plant and Equipment [Line Items]
Useful life	5 years
Buildings and building improvements \| Minimum
Property, Plant and Equipment [Line Items]
Useful life	15 years
Buildings and building improvements \| Maximum
Property, Plant and Equipment [Line Items]
Useful life	44 years
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Useful life	3 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Useful life	30 years
Leasehold improvements \| Minimum
Property, Plant and Equipment [Line Items]
Useful life	2 years
Leasehold improvements \| Maximum
Property, Plant and Equipment [Line Items]
Useful life	20 years
Furniture and fixtures \| Minimum
Property, Plant and Equipment [Line Items]
Useful life	3 years
Furniture and fixtures \| Maximum
Property, Plant and Equipment [Line Items]
Useful life	10 years
Computer hardware and software
Property, Plant and Equipment [Line Items]
Depreciation	$ 4,800	$ 4,200	$ 3,300
Computer hardware and software \| Minimum
Property, Plant and Equipment [Line Items]
Useful life	1 year
Computer hardware and software \| Maximum
Property, Plant and Equipment [Line Items]
Useful life	7 years

Accrued Liabilities

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Accrued Liabilities

Accrued liabilities consisted of the following:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Accrued employee compensation	$	43,543	$	37,018
Reserve for Illinois EO litigation settlements	34,000		—
Accrued interest expense	20,543		25,321
Embedded derivatives	1,872		4,098
Professional fees	10,483		12,572
Accrued utilities	1,786		1,651
Insurance accrual	2,131		2,326
Accrued taxes	3,287		3,923
Other	7,091		3,554
Accrued liabilities	$	124,736	$	90,463

Share-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Details) - Restricted Stock - shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Restricted Stock - Pre-IPO B-1
Number of Shares
Beginning balance (in shares)	71,451	352,447	716,091
Forfeited (in shares)		(2,651)	(16,243)
Vested (in shares)	(71,451)	(278,345)	(347,401)
Ending balance (in shares)	0	71,451	352,447
Restricted Stock - Pre-IPO B-2
Number of Shares
Beginning balance (in shares)	0	987,111	1,098,415
Forfeited (in shares)		0	(111,304)
Vested (in shares)	0	(987,111)	0
Ending balance (in shares)	0	0	987,111

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Schedule of Income Before Income Taxes

The geographic sources of income before income taxes were as follows:


(thousands of U.S. dollars)
Year ended December 31,	2025		2024		2023
U.S.	$	(69,357)	$	(116,049)	$	(100,635)
Foreign	216,863		229,923		206,662
Income before income taxes	$	147,506	$	113,874	$	106,027

Schedule of Total Provision for Income Taxes

Provision for income taxes consisted of the following:


(thousands of U.S. dollars)
Year ended December 31,	2025		2024		2023
Current
Federal U.S.	$	8,975	$	708	$	(3,809)
State U.S.	1,108		1,100		924
Foreign	59,452		58,235		54,087
Total current provision	69,535		60,043		51,202
Deferred
Federal U.S.	(328)		13,645		6,933
State U.S.	670		(837)		(619)
Foreign	(320)		(3,375)		(2,865)
Total deferred provision	22		9,433		3,449
Total provision for income taxes	$	69,557	$	69,476	$	54,651

Schedule of Effective Income Tax Rate Reconciliation

The provision for income taxes for the year ended December 31, 2025 is reconciled with the U.S. federal statutory rate as follows:


Year ended December 31,	2025
(thousands of U.S. dollars)	Amount		Percent
U.S. Federal Statutory Tax Rate	$	30,976	21.0	%
Increase (decrease) in taxes as a result of:
State and Local Income Taxes, Net of Federal Income Tax Effect (a)	2,495		1.7
Foreign Tax Effects
Canada
State taxes, net of federal income tax effect	12,637		8.6
Foreign rate differential	(6,891)		(4.7)
Withholding tax	15,259		10.3
Other	1,058		0.7
Brazil
Foreign rate differential	1,887		1.3
Nontaxable income from application of presumed profits method	(2,301)		(1.6)
Other	1,903		1.3
Belgium
Changes in valuation allowance	1,807		1.2
Prior year differences	(1,990)		(1.3)
Other	1,960		1.3
Other Foreign Jurisdictions	3,522		2.4
Effect of Cross Border Tax Laws
Global intangible low-taxed income	1,800		1.2
Changes in Valuation Allowance	3,128		2.1
Nontaxable or Nondeductible Items
Non-deductible equity compensation	2,256		1.5
Other Adjustments	51		—
Total provision for income taxes	$	69,557	47.2	%

(a)State taxes in California, Illinois and Utah made up the majority (greater than 50 percent) of the tax effect in this category.

The provision for income taxes for the years ended December 31, 2024 and 2023 is reconciled with the U.S. federal statutory rate as follows:


(thousands of U.S. dollars)
Year ended December 31,	2024		2023
Provision computed at federal statutory rate	$	23,914	$	22,265
Increase (decrease) in taxes as a result of:
State taxes, net of federal benefit	(2,840)		(2,889)
Valuation allowance	35,660		19,494
Global intangible low-tax income	1,691		4,861
Nondeductible share-based compensation	3,859		3,192
Foreign tax rate differential	11,893		10,595
Impact of rate changes on deferred tax balances	(914)		(92)
Tax holiday	(1,335)		(1,082)
Audit settlement	17		739
Tax credits	(259)		—
Other	(2,210)		(2,432)
Total provision for income taxes	$	69,476	$	54,651

Schedule of Deferred Tax Assets and Liabilities

The components of the tax effects of temporary differences and carryforwards that gave rise to significant portions of the deferred tax assets and liabilities are as follows:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Net operating loss carryforwards	$	57,210	$	56,097
Net capital loss carryforwards	3,652		2,890
Reserves and accruals	16,532		8,187
Employee benefits and compensation	12,636		10,481
Asset retirement obligations	12,432		11,506
Lease liability	16,462		14,381
Disallowed interest carryforward	186,937		167,369
Other	10,690		8,804
Deferred tax assets before valuation allowance	316,551		279,715
Valuation allowance	(172,294)		(160,595)
Net deferred tax assets	144,257		119,120

Depreciation and amortization	(188,522)		(170,646)
Reserves and accruals	(15,207)		(11,240)
Other	(7,750)		(3,869)
Total deferred tax liabilities	(211,479)		(185,755)
Net deferred tax liabilities	$	(67,222)	$	(66,635)
Noncurrent net deferred tax assets	$	3,853	$	2,865
Noncurrent net deferred tax liabilities	(71,075)		(69,500)
Noncurrent net deferred tax liabilities	$	(67,222)	$	(66,635)

Schedule of Income Taxes Paid

The amounts of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes for the year ended December 31, 2025 were as follows:


Year ended December 31,	2025
(thousands of US dollars)	Amount		Percent
Federal U.S.	$	1,570	2.6	%
State U.S.	369		0.6
Foreign
Canada	34,597		56.8
Belgium	7,477		12.3
United Kingdom	3,958		6.5
Mexico	3,310		5.4
All other foreign countries	9,592		15.8
Total cash paid for income taxes, net of refunds received	$	60,873

Income Taxes - Schedule of Income Taxes Paid (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Amount
Federal U.S.	$ 1,570
State U.S.	369
Total cash paid for income taxes, net of refunds received	$ 60,873	$ 65,829	$ 50,210
Percent
Federal U.S.	2.60%
State U.S.	0.60%
Canada
Amount
Foreign	$ 34,597
Percent
Foreign	56.80%
Belgium
Amount
Foreign	$ 7,477
Percent
Foreign	12.30%
United Kingdom
Amount
Foreign	$ 3,958
Percent
Foreign	6.50%
Mexico
Amount
Foreign	$ 3,310
Percent
Foreign	5.40%
Other Foreign Jurisdictions
Amount
Foreign	$ 9,592
Percent
Foreign	15.80%

Segment and Geographic Information - Schedule of Long-Lived Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Segment Reporting Information [Line Items]
Total	$ 1,130,564	$ 1,036,892
United States
Segment Reporting Information [Line Items]
Total	620,410	587,707
Canada
Segment Reporting Information [Line Items]
Total	212,350	188,498
Europe
Segment Reporting Information [Line Items]
Total	204,453	174,227
Other
Segment Reporting Information [Line Items]
Total	$ 93,351	$ 86,460
Asia
Segment Reporting Information [Line Items]
Percent of total long-lived assets	3.00%	3.00%
Latin America
Segment Reporting Information [Line Items]
Percent of total long-lived assets	3.00%	3.00%

Employee Benefits

12 Months Ended

Dec. 31, 2025

Postemployment Benefits [Abstract]

Employee Benefits

Employee Retirement Benefits in the U.S.

We have a defined-contribution retirement plan that covers all U.S. employees upon date of hire. Contributions are directed by each participant into various investment options. Under this plan, we match participants’ contributions based on plan provisions. The Company’s contributions, which are expensed as incurred, were $6.0 million, $6.0 million, and $5.7 million for the years ended December 31, 2025, 2024 and 2023, respectively, and are recorded in the same line as the respective employee’s wages. Administrative expenses related to the plan are paid by the Company and are not material.

Employee Retirement Benefits Outside the U.S.

The Company participates in qualified supplemental retirement and savings plans in various countries outside the U.S. where we operate. Under these defined-contribution plans, funding and costs are generally based upon a predetermined percentage of employee compensation. The Company’s contributions, which are expensed as incurred and recorded in the same line as the respective employee’s wages, were $2.0 million, $1.7 million and $1.7 million for the years ended December 31, 2025, 2024 and 2023, respectively.

Defined Benefit Pension Plans

The Company also sponsors various post-employment benefit plans including, in certain countries outside the U.S., defined benefit and defined contribution plans, retirement compensation arrangements, and plans that provide extended health care coverage to retired employees, the majority of which relate to Nordion.

Defined benefit pension plan

The following defined benefit pension plan disclosure relates to Nordion. Certain immaterial foreign defined benefit pension plans have been excluded from the table below. The interest cost, expected return on plan assets and amortization of net actuarial loss are recorded in “Other income, net” and the service cost component is included in the same financial statement line item as the applicable employee’s wages in the Consolidated Statements of Operations and Comprehensive Income (Loss). The components of net periodic pension benefit for the defined benefit plans were as follows:


Year ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Service cost	$	495	$	570	$	525
Interest cost	9,478		10,435		10,917
Expected return on plan assets	(15,825)		(15,823)		(16,108)

Net periodic benefit	$	(5,852)	$	(4,818)	$	(4,666)

The following weighted average assumptions were used in the determination of the PBO and the net periodic benefit:


Year ended December 31,	2025		2024
Projected benefit obligation
Discount rate	4.82	%	4.65	%
Rate of compensation increase	3.00	%	3.00	%
Periodic benefit
Discount rate	4.65	%	4.65	%
Expected return on plan assets	6.00	%	6.25	%
Rate of compensation increase	3.00	%	3.00	%

The changes in the PBO, fair value of plan assets, and the funded status of the plans are as follows:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Change in projected benefit obligation:
Projected benefit obligation, as of beginning of the year	$	220,633	$	239,947
Service cost	635		732
Interest cost	9,478		10,435
Benefits paid	(12,468)		(12,737)
Actuarial (gain) loss	(4,105)		935

Foreign currency exchange rate changes	10,561		(18,679)

Projected benefit obligation, end of year	$	224,734	$	220,633

Change in fair value of plan assets:
Fair value of plan assets as of the beginning of the year	$	262,703	$	268,424
Actual return on plan assets	13,764		27,925
Benefits paid	(12,468)		(12,737)
Employer contributions	515		604
Employee contributions	140		162
Foreign currency exchange rate changes	12,766		(21,675)

Fair value of plan assets, end of year	$	277,420	$	262,703

Funded status at end of year	$	52,686	$	42,070

Accumulated benefit obligation, end of year	$	222,331	$	218,122

The Nordion defined benefit pension plan was overfunded as of December 31, 2025 and December 31, 2024.

The funded status, measured as the difference between the fair value of the plan assets and the PBO, are included in “Post-retirement assets” for overfunded plans and “Post-retirement obligations” for underfunded plans in the Consolidated Balance Sheets.

A reconciliation of the funded status to amounts recognized in the Consolidated Balance Sheets is as follows:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Projected benefit obligation	$	224,734	$	220,633
Fair value of plan assets	277,420		262,703
Plan assets greater than projected benefit obligation (noncurrent assets)	52,686		42,070
Unrecognized net actuarial gain	2,196		107

The following table illustrates the amounts in accumulated other comprehensive income (loss) that have not yet been recognized as components of pension expense:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Net actuarial gain	$	2,196	$	107
Deferred income taxes	(510)		(27)
Accumulated other comprehensive income – net of tax	$	1,686	$	80

We do not expect to reclassify any of the net actuarial gain in accumulated other comprehensive income to net periodic pension income in the next twelve months.

The weighted average asset allocation of the Company’s pension plans was as follows:


Asset Category	Target		2025		2024
Cash	0.0	%	0.6	%	0.6	%
Fixed income	54.0	%	53.1	%	52.3	%
Equities	27.0	%	25.9	%	25.9	%
Hedge funds	19.0	%	20.4	%	21.2	%
Total	100.0	%	100.0	%	100.0	%

The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans, which are designed to maximize the total rate of return (income and appreciation) after inflation, within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments. Such investment strategies have adopted an equity-based philosophy to achieve their long-term investment goals by investing in assets that often have uncertain returns, such as Canadian and other foreign equities, and non-government bonds, although the Company also attempts to reduce the overall level of risk by diversifying the asset classes and further diversifying within each individual asset class.

The Company’s expected return on asset assumptions are derived from studies conducted by actuaries and investment advisors. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study considers recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate.

Valuation Methodologies

Below is a description of the composition and valuation methodologies for pension plan assets. Refer to the discussion of fair value hierarchy in Note 20, “Financial Instruments and Financial Risk.”

Cash and cash equivalents – Consists of deposits with financial institutions and other short-term highly liquid investments with an original maturity of three months or less. Cash and cash equivalents are categorized as Level 1 instruments in the fair value hierarchy.

Fixed income securities, equity securities and hedge fund assets – These assets are invested in managed funds that are measured at fair value using the net asset value per share practical expedient and, therefore, are not categorized in the fair value hierarchy.

Expected future benefit payments from plan assets are as follows:


(thousands of U.S. dollars)
Year Ended December 31,
2026	$	13,813
2027	14,168
2028	14,339
2029	14,506
2030	14,617
2031 - 2035	74,377
	$	145,820

Other benefit plans

Other benefit plans disclosed below relate to Nordion and include a supplemental retirement arrangement, a retirement and termination allowance, and post-retirement benefit plans, which include contributory health and dental care benefits and contributory life insurance coverage. Certain immaterial other foreign benefit plans have been excluded from the table below. All non-pension post-employment benefit plans are unfunded. All other non-pension post-employment benefit plans are immaterial.

The interest cost and amortization of net actuarial gain are recorded in “Other income, net” and the service cost component is included in the same financial statement line item as the applicable employee’s wages in the Consolidated Statements of Operations and Comprehensive Income (Loss). The components of net periodic benefit cost for the other benefit plans were as follows:


(thousands of U.S. dollars)
Year Ended December 31,	2025		2024		2023
Service cost	$	5	$	10	$	9
Interest cost	343		371		398
Amortization of net actuarial gain	(69)		(170)		(197)
Net periodic benefit cost	$	279	$	211	$	210

The weighted average assumptions used to determine the PBO and net periodic pension cost for these plans were as follows:


Year Ended December 31,	2025		2024
Projected benefit obligation:
Discount rate	4.82	%	4.65	%
Rate of compensation increase	3.00	%	3.00	%
Initial health care cost trend rate	7.00	%	7.00	%
Ultimate health care cost trend rate	4.00	%	4.00	%
Years until ultimate trend rate is reached	15		15
Benefit cost:
Discount rate	4.65	%	4.65	%
Rate of compensation increase	3.00	%	3.00	%

Assumed health care cost trend rates have a significant effect on the amounts reported for the health care plans. A one-percentage point change in assumed health care cost trend rates would have had the following impact on our consolidated financial statements in 2025:


(thousands of U.S. dollars)	1% Increase		1% Decrease
Change in net periodic benefit cost	$	21	$	(18)
Change in projected benefit obligation	510		(434)

The changes in the projected benefit obligation and the funded status of the other post-retirement plans were as follows:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Change in projected benefit obligation:
Projected benefit obligation	$	8,375	$	8,964
Service cost	5		10
Interest cost	343		371
Benefits paid	(512)		(609)
Actuarial (gain) loss	(311)		211
Plan participant contributions	131		132
Foreign currency exchange rate changes	398		(704)

Projected benefit obligation, end of year	$	8,429	$	8,375

Change in fair value of plan assets:
Fair value of plan assets as of the beginning of the year	$	512	$	525
Benefits paid	(188)		(187)
Employer (refunds) contributions	(38)		216
Foreign currency exchange rate changes	20		(42)

Fair value of plan assets, end of year	$	306	$	512

Underfunded status at end of year	$	(8,123)	$	(7,863)

Accumulated benefit obligation, end of year	$	8,410	$	8,364

The Nordion post-retirement benefit pension plans are underfunded as of December 31, 2025 and 2024.

A reconciliation of the funded status to the net plan liabilities recognized in the Consolidated Balance Sheets is as follows:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Projected benefit obligation	$	8,429	$	8,375
Fair value of plan assets	306		512
Plan assets less than projected benefit obligation (noncurrent liabilities)	(8,123)		(7,863)
Unrecognized actuarial gains	1,870		1,549

The other benefit plan liabilities are presented on the Consolidated Balance Sheets as “Post retirement obligations.”

The following table illustrates the amounts in accumulated other comprehensive income (loss) that have not yet been recognized as components of other benefit plan expense:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Net actuarial gain	$	1,870	$	1,549
Deferred income taxes	(593)		(444)
Accumulated other comprehensive income – net of tax	$	1,277	$	1,105

Based on the actuarial assumptions used to develop the Company’s benefit obligations as of December 31, 2025, the following benefit payments are expected to be made to plan participants:


(thousands of U.S. dollars)
Years ended December 31
2026	$	550
2027	585
2028	510
2029	511
2030	514
2031 - 2035	2,628
Total	$	5,298

The Company currently has no funding requirements as the Nordion pension plan had a going concern surplus as of January 1, 2025, as defined by Canadian federal regulations, which require solvency testing on defined benefit pension plans on an annual basis.

The Company may obtain a qualifying letter of credit for solvency payments, up to 15% of the market value of solvency liabilities as determined on the valuation date, instead of cash payment into the pension fund. As of December 31, 2025 we had no letters of credit outstanding relating to the defined benefit plans. As of December 31, 2024 we had $6.4 million of letters of credit outstanding relating to the defined benefit plans. The actual funding requirements over the five-year period will be dependent on subsequent annual actuarial valuations. These amounts are estimates, which may change with actual investment performance, changes in interest rates, any pertinent changes in Canadian government regulations, and any voluntary contributions.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

+ Details

Earnings Per Share

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Abstract]

Earnings Per Share

Basic earnings per share represents the amount of income attributable to each common share outstanding. Diluted earnings per share represents the amount of income attributable to each common share outstanding adjusted for the effects of potentially dilutive common shares. Potentially dilutive common shares include stock options and other stock-based awards. In the periods where the effect would be antidilutive, potentially dilutive common shares are excluded from the calculation of diluted earnings per share.

In periods in which the Company has net income, earnings per share is calculated using the two-class method. This method is required as unvested pre-IPO restricted stock awards have the right to receive non-forfeitable dividends or dividend equivalents if the Company were to declare dividends on its common stock. Pursuant to the two-class method, earnings for each period are allocated on a pro-rata basis to common stockholders and unvested pre-IPO restricted stock awards. Diluted earnings per share is computed using the more dilutive of (a) the two-class method, or (b) treasury stock method, as applicable, to the potentially dilutive instruments.

Our basic and diluted earnings per common share are calculated as follows:


	Year Ended December 31,
in thousands of U.S. dollars and share amounts (except per share amounts)	2025		2024		2023
Earnings:
Net income	$	77,949	$	44,398	$	51,376
Less: Allocation to participating securities	4		59		287
Net income attributable to Sotera Health Company common stockholders	$	77,945	$	44,339	$	51,089
Weighted Average Common Shares:
Weighted-average common shares outstanding - basic	283,956		282,784		281,008
Dilutive effect of potential common shares	2,465		2,122		2,213
Weighted-average common shares outstanding - diluted	286,421		284,906		283,222
Earnings per Common Share:
Net income per common share attributable to Sotera Health Company common stockholders - basic	$	0.27	$	0.16	$	0.18
Net income per common share attributable to Sotera Health Company common stockholders - diluted	0.27		0.16		0.18

Diluted earnings per shares does not consider the following potential common shares as the effect would be anti-dilutive:


	Year Ended December 31,
in thousands of share amounts	2025	2024	2023
RSUs	9	34	291
Stock options	5,550	5,469	4,108
Total anti-dilutive securities	5,559	5,503	4,399

Asset Retirement Obligations (“ARO”)

12 Months Ended

Dec. 31, 2025

Asset Retirement Obligation Disclosure [Abstract]

Asset Retirement Obligations (“ARO”)

Our ARO represent the present value of future remediation costs. The associated asset retirement costs are also capitalized as part of the carrying amounts of the related long-lived assets in property, plant and equipment in the Consolidated Balance Sheets. The capitalized future site remediation costs are depreciated and the ARO are accreted over the life of the related assets. These amounts are included in depreciation and amortization expense, respectively, within cost of revenues in the Consolidated Statements of Operations and Comprehensive Income (Loss).

The fair value of the ARO is determined based on estimates requiring management judgment. Key assumptions include the timing and estimated decommissioning costs of the remediation activities and credit adjusted risk free interest rates. Changes in the assumptions based on future information may result in adjustments to the estimated obligations over time. No market risk premium has been included in the calculation for the ARO since no reliable estimate can be made by the Company. Any difference between costs incurred upon settlement of an ARO and the liability recognized for the estimated cost of asset retirements will be recognized as a gain or loss in our current period operating results.

Each year, we review decommissioning costs and consider changes in marketplace rates. The following table describes changes to our ARO liability during the years presented:


(thousands of U.S. dollars)
For the years ended December 31,	2025		2024
ARO – beginning of period	$	49,319	$	47,944
Changes in estimates	191		1,240
Accretion expense	2,321		2,638
Foreign currency exchange and other	1,665		(2,503)
ARO – end of period	$	53,496	$	49,319

We recorded depreciation expense on the ARO of $0.6 million, $0.4 million and $0.4 million, for the years ended December 31, 2025, 2024, and 2023 respectively.

We are obligated to provide financial assurance to local and state licensing authorities for possible future decommissioning costs associated with the various facilities that hold Co-60. At December 31, 2025 and 2024, $50.3 million and $49.1 million, respectively, of the standby letters of credit referenced above and surety bonds were outstanding in favor of the various local and state licensing authorities in the event we defaulted on our decommissioning obligation.

Financial Instruments and Financial Risk (Tables)

12 Months Ended

Dec. 31, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments

The following table provides a summary of the notional and fair values of our derivative instruments:


	December 31, 2025							December 31, 2024
(in U.S. dollars; notional in millions, fair value in thousands)				Fair Value							Fair Value
	Notional Amount			Derivative Assets		Derivative Liabilities		Notional Amount			Derivative Assets		Derivative Liabilities
Derivatives designated as hedging instruments
Interest rate swaps	400.0			—		2,346		400.0			459		—
Derivatives not designated as hedging instruments
Foreign currency forward contracts	—			—		—		263.7			88		198
Embedded derivatives	264.4		(a)	1,162		1,872		230.8		(a)	2,689		4,098
Total	$	664.4		$	1,162	$	4,218	$	894.5		$	3,236	$	4,296

(a)Represents the total notional amounts for certain of the Company’s supply and sales contracts accounted for as embedded derivatives.

Schedule of Derivative Instruments, Gain (Loss)

The following table summarizes the activities of our derivative instruments for the periods presented, and the line item they are recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss):


(thousands of U.S. dollars)
Year Ended December 31,	2025		2024		2023
Realized gain on interest rate derivatives recorded in interest expense, net(a)	$	(1,505)	$	(13,233)	$	(33,094)
Unrealized (gain) loss on embedded derivatives recorded in other income, net	(863)		2,213		(1,637)
Realized (gain) loss on foreign currency forward contracts recorded in foreign exchange loss	(6,033)		18,055		(2,025)
Unrealized (gain) loss on foreign currency forward contracts recorded in foreign exchange loss	(110)		249		(412)

(a) Amounts represent periodic settlement of interest rate caps and swaps.

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table discloses the fair value our financial assets and liabilities:


As of December 31, 2025		Fair Value
(thousands of U.S. dollars)	Carrying Amount	Level 1	Level 2	Level 3
Derivatives designated as hedging instruments(a)
Interest rate swap liability	2,346	—	2,346	—
Derivatives not designated as hedging instruments(b)
Embedded derivative assets	1,162	—	1,162	—
Embedded derivative liabilities	1,872	—	1,872	—
Current portion of long-term debt(c)
Term Loan, due 2031	13,973	—	14,327	—
Long-Term Debt(c)
Senior secured Notes, due 2031	746,871	—	789,375	—
Term loan, due 2031	1,379,853	—	1,410,539	—
Finance Lease Obligations (with current portion)(d)	97,300	—	97,300	—


As of December 31, 2024			Fair Value
(thousands of U.S. dollars)	Carrying Amount		Level 1		Level 2		Level 3
Derivatives designated as hedging instruments(a)
Interest rate swap	$	459	$	—	$	459	$	—
Derivatives not designated as hedging instruments(b)
Foreign currency forward contracts assets	88		—		88		—
Foreign currency forward contracts liabilities	198		$	—	$	198	$	—
Embedded derivative assets	2,689		—		2,689		—
Embedded derivative liabilities	4,098		—		4,098		—
Current portion of long-term debt(c)
Term loan, due 2031	14,803		—		15,123		—
Long-Term Debt(c)
Secured Notes, due 2031	746,293		—		759,375		—
Term loan, due 2031	1,461,807		—		1,493,314		—
Finance Lease Obligations (with current portion)(d)	98,209		—		98,209		—

(a)Derivatives designated as hedging instruments are measured at fair value with changes in fair value recorded as a component of accumulated other comprehensive income (loss). Interest rate swaps are valued using pricing models that

incorporate observable market inputs including interest rate curves and yield curves. Additional information is provided in Note 1, “Significant Accounting Policies.”

(b)Derivatives that are not designated as hedging instruments are measured at fair value with gains or losses recognized immediately in the Consolidated Statements of Operations and Comprehensive Income (Loss). Refer also to Note 1, “Significant Accounting Policies.” Embedded derivatives are valued using internally developed models that rely on observable market inputs, including foreign currency forward curves. Foreign currency forward contracts are valued by reference to changes in foreign currency exchange rate over the life of the contract.

(c)Carrying amounts of current portion of long-term debt and long-term debt instruments are reported net of discounts and debt issuance costs. The estimated fair value of these instruments are based upon quoted prices for the Term Loan and the Secured Notes in inactive markets as provided by an independent fixed income security pricing service.

(d)Refer to Note 17, “Leases.” Fair value approximates carrying value.

Long-Term Debt - Senior Secured Credit Facilities (Narrative) (Details)				12 Months Ended
	Sep. 17, 2025 USD ($)	Apr. 30, 2025 USD ($)	May 30, 2024 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 13, 2019 USD ($)
Debt Instrument [Line Items]
Payments of long-term borrowings				$ 86,104,000	$ 2,264,373,000	$ 2,500,000
Total long-term debt				$ 2,169,472,000	$ 2,255,577,000
Illinois EO litigation settlements \| Pending Litigation
Debt Instrument [Line Items]
Basis spread adjustment				30.00%
Base amount for default				$ 162,600,000
Triggering period for default				60 days
Senior Secured Credit Facilities \| Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 1,509,400,000				$ 600,000,000.0
Debt instrument, applicable floor interest rate			0.0000
Soft call premium			1.00%
Increase in borrowing capacity		$ 176,200,000
Debt instrument, pricing step-down, percent			0.25%
Leverage ratio			3.30
Letters of credit outstanding, amount				$ 8,200,000
Unused borrowing capacity				$ 591,800,000
Senior Secured Credit Facilities \| Revolving Credit Facility \| Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Basis spread on variable rate			3.25%
Senior Secured Credit Facilities \| Revolving Credit Facility \| Alternative Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate			2.25%
Senior Secured Credit Facilities \| Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 186,300,000
Senior Secured Credit Facilities \| Secured Debt
Debt Instrument [Line Items]
Face amount	$ 1,419,500,000
Basis spread adjustment	0.50%
Contractual pricing step-down	0.25%
Soft call premium	1.00%
Weighted average interest rate				7.25%	8.29%
Senior Secured Credit Facilities \| Secured Debt \| Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Basis spread on variable rate	2.50%
Senior Secured Credit Facilities \| Secured Debt \| Alternative Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
Senior secured Notes, due 2031 \| Secured Debt
Debt Instrument [Line Items]
Total long-term debt				$ 750,000,000	$ 750,000,000
Senior secured Notes, due 2031 \| Senior Notes
Debt Instrument [Line Items]
Face amount			$ 750,000,000.0
Stated percentage			7.375%
Redemption price, as percent of principal, proceeds from equity offerings			107.375%
Senior secured Notes, due 2031 \| Senior Notes \| Maximum
Debt Instrument [Line Items]
Percentage of original principal that may be redeemed			40.00%
Redemption as percent of outstanding principal amount			10.00%
Senior secured Notes, due 2031 \| Senior Notes \| Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Redemption price, percentage			100.00%
Senior secured Notes, due 2031 \| Senior Notes \| Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Redemption price, percentage			103.00%
Secured notes due 2031 \| Secured Debt
Debt Instrument [Line Items]
Payments of long-term borrowings	$ 75,000,000.0
Total long-term debt				1,763,100,000
Term loan due 2031 \| Secured Debt
Debt Instrument [Line Items]
Total long-term debt				$ 496,300,000

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Accounts Payable and Accrued Liabilities [Line Items]
Accrued employee compensation	$ 43,543	$ 37,018
Accrued interest expense	20,543	25,321
Embedded derivatives	1,872	4,098
Professional fees	10,483	12,572
Accrued utilities	1,786	1,651
Insurance accrual	2,131	2,326
Accrued taxes	3,287	3,923
Other	7,091	3,554
Accrued liabilities	124,736	90,463
Reserve for Illinois EO litigation settlements
Accounts Payable and Accrued Liabilities [Line Items]
Litigation settlement reserve	$ 34,000	$ 0

Income Taxes - Schedule of Provision for Effective Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Amount
U.S. Federal Statutory Tax Rate	$ 30,976	$ 23,914	$ 22,265
State and Local Income Taxes, Net of Federal Income Tax Effect		(2,840)	(2,889)
Foreign tax rate differential		11,893	10,595
Withholding tax	15,259
Nontaxable income from application of presumed profits method	(2,301)
Valuation allowance		35,660	19,494
Prior year differences	(1,990)
Global intangible low-taxed income	1,800	1,691	4,861
Nondeductible share-based compensation	2,256	3,859	3,192
Total provision for income taxes	$ 69,557	$ 69,476	$ 54,651
Percent
U.S. Federal Statutory Tax Rate	21.00%
Withholding tax	10.30%
Nontaxable income from application of presumed profits method	(1.60%)
Prior year differences	(1.30%)
Global intangible low-taxed income	1.20%
Non-deductible equity compensation	1.50%
Total provision for income taxes	47.20%
United States
Amount
State and Local Income Taxes, Net of Federal Income Tax Effect	$ 2,495
Other	51
Valuation allowance	$ 3,128
Percent
State and Local Income Taxes, Net of Federal Income Tax Effect	1.70%
Other	0.00%
Changes in valuation allowance	2.10%
Canada
Amount
State and Local Income Taxes, Net of Federal Income Tax Effect	$ 12,637
Foreign tax rate differential	(6,891)
Other	$ 1,058
Percent
State and Local Income Taxes, Net of Federal Income Tax Effect	8.60%
Foreign rate differential	(4.70%)
Other	0.70%
Brazil
Amount
Foreign tax rate differential	$ 1,887
Other	$ 1,903
Percent
Foreign rate differential	1.30%
Other	1.30%
Belgium
Amount
Other	$ 1,960
Valuation allowance	$ 1,807
Percent
Other	1.30%
Changes in valuation allowance	1.20%
Other Foreign Jurisdictions
Amount
Foreign tax rate differential	$ 3,522
Percent
Foreign rate differential	2.40%

Segment and Geographic Information - Schedule of Revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Net revenues	$ 1,163,617	$ 1,100,441	$ 1,049,288
United States
Segment Reporting Information [Line Items]
Net revenues	629,543	616,684	590,967
Canada
Segment Reporting Information [Line Items]
Net revenues	221,948	208,886	192,050
Europe
Segment Reporting Information [Line Items]
Net revenues	232,179	196,011	187,542
Other
Segment Reporting Information [Line Items]
Net revenues	$ 79,947	$ 78,860	$ 78,729
Asia
Segment Reporting Information [Line Items]
Percent of total revenues	2.00%	2.00%	2.00%
Latin America
Segment Reporting Information [Line Items]
Percent of total revenues	2.00%	2.00%	2.00%

- Definition

+ References

+ Details

Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Goodwill [Roll Forward]
Beginning balance	$ 1,081,073	$ 1,111,190
Changes due to foreign currency exchange rates	22,159	(30,117)
Ending balance	1,103,232	1,081,073
Sterigenics
Goodwill [Roll Forward]
Beginning balance	653,222	659,888
Changes due to foreign currency exchange rates	5,697	(6,666)
Ending balance	658,919	653,222
Nordion
Goodwill [Roll Forward]
Beginning balance	255,485	276,929
Changes due to foreign currency exchange rates	12,286	(21,444)
Ending balance	267,771	255,485
Nelson Labs
Goodwill [Roll Forward]
Beginning balance	172,366	174,373
Changes due to foreign currency exchange rates	4,176	(2,007)
Ending balance	$ 176,542	$ 172,366

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 740
-Name Accounting Standards Codification
-Section 55
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478064/805-740-55-13

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-39

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

+ Details

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Depreciation is computed using the assets’ estimated useful lives as presented below:


Buildings and building improvements			15–44 years
Machinery and equipment			3–30 years
Leasehold improvements			2–20 years
Furniture and fixtures			3–10 years
Computer hardware and software			1–7 years

Property, plant, and equipment, net, consisted of the following:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Land and buildings	$	470,905	$	418,038
Leasehold improvements	128,313		98,028
Machinery, equipment, including Co-60	853,195		757,568
Furniture and fixtures	9,472		9,118
Computer hardware and software	72,694		58,767
Asset retirement costs	7,925		7,368
Construction-in-progress	259,919		250,418
	1,802,423		1,599,305
Less accumulated depreciation	(671,859)		(562,413)
Property, plant and equipment, net	$	1,130,564	$	1,036,892

Long-Term Debt - Schedule of Long term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Debt Instrument [Line Items]
Gross Amount	$ 2,169,472	$ 2,255,577
Less current portion	14,230	15,094
Long-term debt	2,155,242	2,240,483
Unamortized Debt Issuance Costs	(9,747)	(10,215)
Less current portion	(66)	(65)
Long-term debt	(9,681)	(10,150)
Unamortized Debt Discount	(18,837)	(22,233)
Unamortized discount, excluding current portion	(19,028)	(22,459)
Less current portion	(191)	(226)
Net Amount	2,140,697	2,222,903
Less current portion	13,973	14,803
Long-term debt	2,126,724	2,208,100
Secured Debt \| Secured notes due 2031
Debt Instrument [Line Items]
Gross Amount	750,000	750,000
Unamortized Debt Issuance Costs	(3,129)	(3,707)
Unamortized Debt Discount	0	0
Net Amount	746,871	746,293
Secured Debt \| Term loan due 2031
Debt Instrument [Line Items]
Gross Amount	1,419,472	1,505,577
Unamortized Debt Issuance Costs	(6,618)	(6,508)
Unamortized Debt Discount	(19,028)	(22,459)
Net Amount	$ 1,393,826	$ 1,476,610

Related Parties (Details) - USD ($)	12 Months Ended
Related Parties (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Related Party Transactions [Abstract]
Related party transaction	$ 0	$ 0	$ 0

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2025
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	Cleveland, Ohio
Auditor Firm ID	42

Segment and Geographic Information

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Segment and Geographic Information

We identify our operating segments based on the way we manage, evaluate and internally report our business activities for purposes of allocating resources and assessing performance. We have three reportable segments: Sterigenics, Nordion and Nelson Labs. We have determined our reportable segments based upon an assessment of organizational structure, service types, and internally prepared financial statements. Our chief operating decision maker, the Chairman and Chief Executive Officer of Sotera Health Company (“CODM”), evaluates performance and allocates resources based on segment income after the elimination of intercompany activities. The CODM uses these performance measures to inform decisions about the operations of the business and dedication of resources to selling and general administrative matters pertinent to the Company. The accounting policies of our reportable segments are the same as those described in Note 1, “Significant Accounting Policies.”

Sterigenics

Sterigenics provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three major technologies: gamma irradiation, EO processing and E-beam irradiation.

Nordion

Nordion is a leading global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a leading global provider of gamma irradiation systems.

Nelson Labs

Nelson Labs provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

Segment Revenue Concentrations

For the year ended December 31, 2025, two customers reported within the Nordion segment individually represented 10% or more of the segment’s total net revenues. These customers represented 34.8% and 11.0% of the total segment’s external net revenues for the year ended December 31, 2025. For the year ended December 31, 2024, one customer reported within the Nordion segment individually represented 10% or more of the segment’s total net revenues. This customer represented 34.3% of the total segment’s external net revenues for the year ended December 31, 2024. For the year ended December 31, 2023, two customers reported within the Nordion segment individually represented 10% or more of the segment’s total net revenues. These customers represented 34.9% and 13.9% of the total segment’s external net revenues for the year ended December 31, 2023.

Financial information for each of our segments is presented in the following table:


	Year Ended December 31, 2025
(thousands of U.S. dollars)	Sterigenics		Nordion		Nelson Labs		Total
Net revenues(a)	$	755,780	$	187,618	$	220,219	$	1,163,617
Segment expenses(b)	306,621		74,533		141,477		522,631
Corporate expense allocation(c)	36,266		5,507		5,412		47,185
Segment income	$	412,893	$	107,578	$	73,330	$	593,801


	Year Ended December 31, 2024
(thousands of U.S. dollars)	Sterigenics		Nordion		Nelson Labs		Total
Net revenues(a)	$	697,853	$	173,355	$	229,233	$	1,100,441
Segment expenses(b)	286,434		67,087		155,088		508,609
Corporate expense allocation(c)	33,248		5,048		4,962		43,258
Segment income	$	378,171	$	101,220	$	69,183	$	548,574


	Year Ended December 31, 2023
(thousands of U.S. dollars)	Sterigenics		Nordion		Nelson Labs		Total
Net revenues(a)	$	667,130	$	160,459	$	221,699	$	1,049,288
Segment expenses(b)	275,424		59,399		148,209		483,032
Corporate expense allocation(c)	29,494		4,382		4,351		38,227
Segment income	$	362,212	$	96,678	$	69,139	$	528,029

(a)Revenues are reported net of intersegment sales. Our Nordion segment recognized $25.9 million, $58.7 million and $43.9 million in revenues from sales to our Sterigenics segment for the years ended December 31, 2025, 2024 and 2023, respectively, that is not reflected in net revenues in the table above. Intersegment sales for Sterigenics and Nelson Labs are immaterial for all periods presented.

(b)Segment expenses are comprised of direct materials, labor, utilities, other costs of revenues, SG&A, and other non-operating expense (income) attributable to each segment.

(c)Corporate operating expenses that are directly incurred by a segment are reflected in each segment’s income. The remaining Corporate operating expenses for executive management, accounting, IT, legal, human resources, treasury, investor relations, corporate development, tax, purchasing, and marketing not directly incurred by a segment are allocated to the segments primarily based on total net revenue.

Capital expenditures by segment for the years ended December 31, 2025, 2024 and 2023 were as follows:


	Year Ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Sterigenics	$	99,383	$	131,258	$	163,043
Nordion	21,832		34,928		38,351
Nelson Labs	16,803		12,884		13,581
Total capital expenditures	$	138,018	$	179,070	$	214,975

Total assets and depreciation and amortization expense by segment are not readily available and are not reported separately to the CODM.

A reconciliation of segment income to consolidated income (loss) before taxes is as follows:


(thousands of U.S. dollars)
Year Ended December 31,	2025		2024		2023
Segment income	$	593,801	$	548,574	$	528,029
Less adjustments:
Interest expense, net	155,722		164,691		142,878
Depreciation and amortization(a)	136,428		161,797		157,925
Share-based compensation(b)	31,068		36,896		32,364
Loss on refinancing of debt(c)	1,462		24,168		—
Loss (gain) on foreign currency and derivatives not designated as hedging instruments, net(d)	58		2,448		(1,552)
Business optimization expenses(e)	8,068		9,368		7,662
Professional services relating to EO sterilization facilities(f)	46,225		32,694		45,312
Illinois EO litigation settlements(g)	64,943		—		—
Georgia EO litigation settlement(h)	—		—		35,000
Accretion of asset retirement obligation(i)	2,321		2,638		2,413
Consolidated income before taxes	$	147,506	$	113,874	$	106,027

(a)Includes depreciation of Co-60 held at gamma irradiation sites, and excludes accelerated depreciation associated with business optimization activities.

(b)Represents share-based compensation expense related to employees and Non-Employee Directors. See Note 15, “Share-Based Compensation” for further information.

(c)Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the refinancing activity for the Term Loans, the Secured Notes and the Revolving Credit Facility.

(d)Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.

(e)Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with secondary offerings and shareholder engagement.

(f)Represents litigation and other professional fees associated with our EO sterilization facilities.

(g)Represents (i) the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025 and (ii) the cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on July 23, 2025. See Note 19, “Commitments and Contingencies.”

(h)Represents the cost to settle 79 pending EO claims in Georgia under a settlement entered into on December 21, 2023. See Note 19, “Commitments and Contingencies.”

(i)Represents non-cash accretion of ARO related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.

Geographic Information

Net revenues for geographic area are reported by the country’s origin of the revenues.


(thousands of U.S. dollars)
Year Ended December 31,	2025		2024		2023
United States	$	629,543	$	616,684	$	590,967
Canada	221,948		208,886		192,050
Europe	232,179		196,011		187,542
Other	79,947		78,860		78,729
Total	$	1,163,617	$	1,100,441	$	1,049,288

The ‘Other’ category above is primarily comprised of net revenues from Asian and Latin American countries that individually represent 2% or less of our total net revenues.

Long-lived assets are based on physical locations and are comprised of the net book value of property, plant, and equipment.


(thousands of U.S. dollars)
As of December 31,	2025		2024
United States	$	620,410	$	587,707
Canada	212,350		188,498
Europe	204,453		174,227
Other	93,351		86,460
Total	$	1,130,564	$	1,036,892

The ‘Other’ category above is primarily comprised of long-lived assets in Asian and Latin American countries that individually represent 3% or less of our total long-lived assets.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Recent Accounting Standards	12 Months Ended
Recent Accounting Standards	Dec. 31, 2025
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Standards	Recent Accounting Standards Adoption of Accounting Standard Updates In the year ended December 31, 2025, we adopted Accounting Standards Update (“ASU”) 2023-09-Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this ASU require entities to disclose, on an annual basis, specific categories in the reconciliation of the provision (benefit) for income taxes to the statutory rate and provide additional information for reconciling items that meet a quantitative threshold. Additionally, the ASU requires entities to disclose a disaggregation of taxes paid by category (federal, state and foreign taxes) as well as individual jurisdictions. ASUs Issued But Not Yet Adopted In November 2024, the FASB issued ASU 2024-03-Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in this ASU requires entities to disaggregate certain expense captions into specified categories in disclosures within the footnotes to the financial statements. In January 2025, the FASB issued ASU 2025-01, which revises the effective date of ASU 2024-03 and clarifies that entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. The Company expects that this ASU will increase disclosures in the annual and interim periods when adopted.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476173/280-10-65-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org/250/tableOfContent

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

+ Details

Employee Benefits - Schedule of Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Defined benefit pension plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 635	$ 732
Interest cost	9,478	10,435
Defined benefit pension plan \| Nordion
Defined Benefit Plan Disclosure [Line Items]
Service cost	495	570	$ 525
Interest cost	9,478	10,435	10,917
Expected return on plan assets	(15,825)	(15,823)	(16,108)
Net periodic benefit cost	(5,852)	(4,818)	(4,666)
Other post-retirement benefits plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	5	10
Interest cost	343	371
Other post-retirement benefits plans \| Nordion
Defined Benefit Plan Disclosure [Line Items]
Service cost	5	10	9
Interest cost	343	371	398
Amortization of net actuarial gain	(69)	(170)	(197)
Net periodic benefit cost	$ 279	$ 211	$ 210

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Leases - Schedule of Cash Flows (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 7,917	$ 7,382	$ 10,067
Operating cash flows for finance leases	6,332	6,277	3,988
Finance cash flows for finance leases	$ 3,903	$ 8,088	$ 1,823

Related Parties	12 Months Ended
Related Parties	Dec. 31, 2025
Related Party Transactions [Abstract]
Related Parties	Related Parties For the years ended December 31, 2025, 2024 and 2023, the Company did not engage in any material related party transactions.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Leases - Schedule of Maturities (Details) $ in Thousands	Dec. 31, 2025 USD ($)
Operating Leases
2026	$ 8,134
2027	7,187
2028	5,760
2029	4,717
2030	3,767
2031 and Thereafter	22,069
Total lease payments	51,634
Less imputed interest	(15,978)
Total lease liabilities	35,656
Finance Leases
2026	9,689
2027	9,968
2028	10,263
2029	9,933
2030	9,634
2031 and Thereafter	108,811
Total lease payments	158,298
Less imputed interest	(60,998)
Total lease liabilities	97,300
Total
2026	17,823
2027	17,155
2028	16,023
2029	14,650
2030	13,401
2031 and Thereafter	130,880
Total lease payments	209,932
Less imputed interest	(76,976)
Total lease liabilities	$ 132,956

Commitments and Contingencies (Details) $ in Millions						1 Months Ended	12 Months Ended
Commitments and Contingencies (Details) $ in Millions	Feb. 20, 2026 claim case plaintiffs	Oct. 31, 2025 case	Oct. 17, 2025 case	Apr. 30, 2025 USD ($) claim	Aug. 31, 2022 USD ($)	Jul. 31, 2025 USD ($) case	Dec. 31, 2025 USD ($) claim case	Dec. 31, 2024 claim
Gain Contingencies [Line Items]
Loss contingency, insurance limits per occurrence							$ 10.0
Loss contingency, insurance limits							$ 20.0
Pending Litigation
Gain Contingencies [Line Items]
Number of cases that will proceed to judicial determination (in cases) \| case							1
Gross settlement					$ 110.2
CALIFORNIA \| Pending Litigation \| Subsequent Event \| Personal Injury And Wrongful Death
Gain Contingencies [Line Items]
Number of pending claims \| claim	120
CALIFORNIA \| Pending Litigation \| Subsequent Event \| Selected as the First Plaintiff Group \| Personal Injury And Wrongful Death
Gain Contingencies [Line Items]
Number of pending claims \| claim	8
GEORGIA \| Property Devaluation \| Georgia EO litigation settlement
Gain Contingencies [Line Items]
Number of new claims filed \| case							9
GEORGIA \| Pending Litigation \| Asset Transfer Case
Gain Contingencies [Line Items]
Number of pending claims \| claim							305
GEORGIA \| Pending Litigation \| Personal Injury And Wrongful Death
Gain Contingencies [Line Items]
Number of pending claims \| claim								79
GEORGIA \| Pending Litigation \| Personal Injury
Gain Contingencies [Line Items]
Number of cases that will proceed to judicial determination (in cases) \| case			3
Number of cases including personal injury and property claims (in cases) \| case		1
GEORGIA \| Pending Litigation \| Exclude Certain Expert Witnesses \| Personal Injury
Gain Contingencies [Line Items]
Number of cases that will proceed to judicial determination (in cases) \| case			3
Number of plaintiffs \| case			3
GEORGIA \| Pending Litigation \| Subsequent Event \| Personal Injury And Wrongful Death
Gain Contingencies [Line Items]
Number of pending claims \| claim	450
GEORGIA \| Pending Litigation \| Subsequent Event \| Personal Injury
Gain Contingencies [Line Items]
Number of cases that will proceed to judicial determination (in cases) \| case	15
GEORGIA \| Pending Litigation \| Subsequent Event \| Consolidated for Pretrial Purposes \| Personal Injury And Wrongful Death
Gain Contingencies [Line Items]
Number of pending claims \| claim	8
ILLINOIS \| Subsequent Event \| Willowbrook Cases
Gain Contingencies [Line Items]
Number of pending claims \| plaintiffs	2
ILLINOIS \| Pending Litigation
Gain Contingencies [Line Items]
Number of pending claims \| claim				97
Damages sought				$ 30.9		$ 34.0
ILLINOIS \| Pending Litigation \| Other Claims
Gain Contingencies [Line Items]
Number of plaintiffs \| case						129
ILLINOIS \| Pending Litigation \| Subsequent Event
Gain Contingencies [Line Items]
Number of cases that will proceed to judicial determination (in cases) \| case	1
Minimum
Gain Contingencies [Line Items]
Purchase commitment, period							1 year
Maximum
Gain Contingencies [Line Items]
Purchase commitment, period							39 years
Nordion
Gain Contingencies [Line Items]
Minimum purchase commitments							$ 2,379.5
Nordion \| Minimum
Gain Contingencies [Line Items]
To be paid, year one							53.1
To be paid, year two							53.1
To be paid, year three							53.1
To be paid, year four							53.1
To be paid, year five							53.1
Nordion \| Maximum
Gain Contingencies [Line Items]
To be paid, year one							72.9
To be paid, year two							72.9
To be paid, year three							72.9
To be paid, year four							72.9
To be paid, year five							$ 72.9

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2025

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Deferred Costs, Capitalized, Prepaid, and Other Assets

Prepaid expenses and other current assets consisted of the following:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Prepaid taxes	$	5,212	$	4,993
Prepaid business insurance	3,974		6,993
Prepaid rent	4,466		1,223
Customer contract assets	24,410		15,213
Current deposits	283		807
Prepaid maintenance contracts	490		638
Value added tax receivable	4,527		3,614
Prepaid software licensing	2,661		2,590
Stock supplies	5,012		4,025
Embedded derivatives	1,162		2,689
Other	13,053		8,246
Prepaid expenses and other current assets	$	65,250	$	51,031

Significant Accounting Policies - Additional Information (Details)		12 Months Ended
	Oct. 01, 2023 USD ($)	Dec. 31, 2025 segment	Dec. 31, 2023
Accounting Policies [Abstract]
Number of reportable segments		3
Number of operating segments		3
Goodwill impairment \| $	$ 0
Performance Shares \| Minimum \| 2020 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Performance Shares \| Maximum \| 2020 Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Restricted Stock - Pre-IPO B-1 \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			5 years

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Cybersecurity Risk Management and Strategy The Company has an enterprise risk management (“ERM”) program that includes the processes used to identify, assess, and manage our most significant enterprise risks and uncertainties that could materially impact the long-term health of the Company or prevent the achievement of strategic objectives. These risks are identified, measured, monitored, and managed across key risk categories, which include the consideration of cybersecurity risks. The Company develops and maintains cybersecurity processes that protect the confidentiality, integrity and availability of Company, employee, customer and partner information against a growing number of cybersecurity threats and threat actors. Our cybersecurity program is designed to protect our infrastructure from potential threats, including threats associated with our third party business partners, to allow us to assess, identify and manage material risks from cybersecurity threats and to endeavor to secure the integrity of our data and IT systems using techniques, hardware, and software typical of companies of our size and scope, which are described further below. For example, we leverage the National Institute of Standards and Technology Cybersecurity Framework’s (“NIST CSF”) principles in developing our cybersecurity program to monitor our security environment and manage risk. However, this does not mean that we meet any particular technical standards, specifications, or requirements, but rather that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks and threats relevant to our business. The Company has adopted a risk-based strategy designed to achieve a targeted and cost-effective approach to managing cybersecurity risks that strengthens our abilities to prevent, detect, and respond to cybersecurity incidents. The Company has configured its IT environment, where possible, to restrict access using a least privileged methodology. We use various technologies and monitoring capabilities to detect anomalies and track information and assets. We have implemented a cybersecurity awareness program consisting of frequent training, phishing exercises, and bulletins regarding pertinent cybersecurity developments. We maintain and regularly update incident response, disaster recovery and business continuity plans and procedures. Our IT specialists subscribe to threat intelligence feeds and are members of cybersecurity-related associations such as the Information Systems Audit and Control Association, the Computing Technology Industry Association and the Cloud Security Alliance. We also maintain insurance coverage for cyber and data security risks of an amount and subject to conditions and exceptions that we believe are customary for companies like ours, but there can be no assurance that our levels of coverage are adequate or that we will be able to continue to maintain our existing insurance or obtain comparable insurance at a reasonable cost or at all. As of the date of this filing, we do not believe that any risks from cybersecurity threats, including as a result of past cybersecurity incidents have had, or are reasonably likely to have, a material effect on our business strategy, results of operations or financial condition, but we cannot assure that our business strategy, results of operations and financial condition will not be materially affected in the future by cybersecurity risks or future cybersecurity incidents. Although we have taken and will continue to take significant steps to protect the security and integrity of our information and although we have implemented policies and procedures to enhance data privacy and security, there can be no assurance that our efforts will prevent breakdowns, system failures, breaches of our systems or other cybersecurity incidents or otherwise be fully effective. Any such breakdown, breach or cybersecurity incident could adversely affect our business strategy, prospects, financial condition or results of operations, and any insurance that we may have for cybersecurity incidents may not cover such risks or be sufficient to compensate us for losses that may occur.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	The Company has an enterprise risk management (“ERM”) program that includes the processes used to identify, assess, and manage our most significant enterprise risks and uncertainties that could materially impact the long-term health of the Company or prevent the achievement of strategic objectives. These risks are identified, measured, monitored, and managed across key risk categories, which include the consideration of cybersecurity risks. The Company develops and maintains cybersecurity processes that protect the confidentiality, integrity and availability of Company, employee, customer and partner information against a growing number of cybersecurity threats and threat actors. Our cybersecurity program is designed to protect our infrastructure from potential threats, including threats associated with our third party business partners, to allow us to assess, identify and manage material risks from cybersecurity threats and to endeavor to secure the integrity of our data and IT systems using techniques, hardware, and software typical of companies of our size and scope, which are described further below. For example, we leverage the National Institute of Standards and Technology Cybersecurity Framework’s (“NIST CSF”) principles in developing our cybersecurity program to monitor our security environment and manage risk. However, this does not mean that we meet any particular technical standards, specifications, or requirements, but rather that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks and threats relevant to our business.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	When detected, suspected cybersecurity threats are escalated to the CIO and incident response team. The CIO then creates a Cybersecurity Incident Response Team (“CSIRT”) which, depending on the incident, comprises the incident coordinator, cybersecurity staff, legal counsel and other stakeholders as appropriate. The CSIRT investigates and manages the impact of cybersecurity incidents in accordance with our security incident response procedures. Our board of directors and its audit committee oversee the Company’s ERM program, and the steps management has taken to monitor and mitigate such risks, including the Company’s procedures and any related policies with respect to enterprise risk assessment and risk management. The board of directors bears principal responsibility for overseeing the Company’s principal current and future risk exposures, and, on an annual basis, the board of directors reviews them, including cybersecurity risks and exposures. The board of directors’ review includes an annual session with our CIO on the Company’s procedures and policies for assessing and managing cybersecurity risks and disclosing any material cybersecurity incidents. In performing these oversight functions, the board of directors relies on advice, reports and opinions of management, counsel and our internal and external auditors, including mid-year and year-end cybersecurity inquiries by our external auditors on various aspects of the Company’s cybersecurity program, processes and training.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our board of directors and its audit committee oversee the Company’s ERM program, and the steps management has taken to monitor and mitigate such risks, including the Company’s procedures and any related policies with respect to enterprise risk assessment and risk management. The board of directors bears principal responsibility
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	In performing these oversight functions, the board of directors relies on advice, reports and opinions of management, counsel and our internal and external auditors, including mid-year and year-end cybersecurity inquiries by our external auditors on various aspects of the Company’s cybersecurity program, processes and training.
Cybersecurity Risk Role of Management [Text Block]	Our board of directors and its audit committee oversee the Company’s ERM program, and the steps management has taken to monitor and mitigate such risks, including the Company’s procedures and any related policies with respect to enterprise risk assessment and risk management. The board of directors bears principal responsibility for overseeing the Company’s principal current and future risk exposures, and, on an annual basis, the board of directors reviews them, including cybersecurity risks and exposures. The board of directors’ review includes an annual session with our CIO on the Company’s procedures and policies for assessing and managing cybersecurity risks and disclosing any material cybersecurity incidents. In performing these oversight functions, the board of directors relies on advice, reports and opinions of management, counsel and our internal and external auditors, including mid-year and year-end cybersecurity inquiries by our external auditors on various aspects of the Company’s cybersecurity program, processes and training.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our board of directors and its audit committee oversee the Company’s ERM program, and the steps management has taken to monitor and mitigate such risks, including the Company’s procedures and any related policies with respect to enterprise risk assessment and risk management. The board of directors bears principal responsibility
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our CIO has over 12 years of professional experience in various roles involving managing information security, developing cybersecurity strategy, implementing cybersecurity programs, and managing multiple industry and regulatory compliance environments. Our CIO also holds a certificate in Cyber-Risk Oversight issued by the National Association of Corporate Directors. Our Senior Director of IT Governance, Security, and Service Delivery has over 15 years of professional experience in various roles involving managing information security, developing cybersecurity strategy, implementing cybersecurity programs, and managing industry and regulatory compliance environments. Our Senior Information Security Architect has over 20 years of professional experience designing secure architecture, conducting threat and risk assessments, incident response, cyber forensics, and teaching college and university level cybersecurity program courses. Our Senior Information Security Architect also holds a diverse set of certifications, including CISSP, CISCO Security +, CISA, CEH, CompTIA Sec +, and others.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The CIO is supported by the Senior Director of IT Governance, Security, and Service Delivery and the Senior Director of Global Infrastructure, and Senior Information Security Architect, who manage our day-to-day cybersecurity-related matters and keep abreast of cybersecurity news, events and incidents through regular course monitoring and updates.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Segment and Geographic Information - Schedule of Segment Operating Results (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Net revenues	$ 1,163,617	$ 1,100,441	$ 1,049,288
Total capital expenditures	138,018	179,070	214,975
Sterigenics
Segment Reporting Information [Line Items]
Net revenues	755,780	697,853	667,130
Nordion
Segment Reporting Information [Line Items]
Net revenues	187,618	173,355	160,459
Nelson Labs
Segment Reporting Information [Line Items]
Net revenues	220,219	229,233	221,699
Operating Segments
Segment Reporting Information [Line Items]
Net revenues	1,163,617	1,100,441	1,049,288
Segment expenses	522,631	508,609	483,032
Segment income	593,801	548,574	528,029
Operating Segments \| Sterigenics
Segment Reporting Information [Line Items]
Net revenues	755,780	697,853	667,130
Segment expenses	306,621	286,434	275,424
Segment income	412,893	378,171	362,212
Total capital expenditures	99,383	131,258	163,043
Operating Segments \| Nordion
Segment Reporting Information [Line Items]
Net revenues	187,618	173,355	160,459
Segment expenses	74,533	67,087	59,399
Segment income	107,578	101,220	96,678
Total capital expenditures	21,832	34,928	38,351
Operating Segments \| Nelson Labs
Segment Reporting Information [Line Items]
Net revenues	220,219	229,233	221,699
Segment expenses	141,477	155,088	148,209
Segment income	73,330	69,183	69,139
Total capital expenditures	16,803	12,884	13,581
Corporate Nonsegment
Segment Reporting Information [Line Items]
Segment income	47,185	43,258	38,227
Corporate Nonsegment \| Sterigenics
Segment Reporting Information [Line Items]
Segment income	36,266	33,248	29,494
Corporate Nonsegment \| Nordion
Segment Reporting Information [Line Items]
Segment income	5,507	5,048	4,382
Corporate Nonsegment \| Nelson Labs
Segment Reporting Information [Line Items]
Segment income	5,412	4,962	4,351
Intersegment
Segment Reporting Information [Line Items]
Net revenues	$ (25,900)	$ (58,700)	$ (43,900)

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant, and equipment, net, consisted of the following:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Land and buildings	$	470,905	$	418,038
Leasehold improvements	128,313		98,028
Machinery, equipment, including Co-60	853,195		757,568
Furniture and fixtures	9,472		9,118
Computer hardware and software	72,694		58,767
Asset retirement costs	7,925		7,368
Construction-in-progress	259,919		250,418
	1,802,423		1,599,305
Less accumulated depreciation	(671,859)		(562,413)
Property, plant and equipment, net	$	1,130,564	$	1,036,892

Depreciation and amortization expense for property, plant, and equipment, including property under finance leases, was $94.9 million, $84.3 million and $76.6 million for the years ended December 31, 2025, 2024 and 2023, respectively. Capitalized interest totaled $12.6 million, $16.2 million and $12.2 million for the years ended December 31, 2025, 2024 and 2023, respectively, and was recorded as a reduction in “Interest expense, net” in the Consolidated Statements of Operations and Comprehensive Income (Loss).

Goodwill and Other Intangible Assets - Schedule of Acquired Finite-Lived and Indefinite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Intangible Asset, Acquired, Finite-Lived [Line Items]
Gross Carrying Amount	$ 385,989	$ 928,427
Accumulated Amortization	199,844	708,829
Acquired Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount	102,082	98,055
Total	488,071	1,026,482
Regulatory licenses and other
Acquired Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 76,064	72,550
Renewal term	25 years
Trade names / trademarks
Acquired Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 26,018	25,505
Customer relationships
Intangible Asset, Acquired, Finite-Lived [Line Items]
Gross Carrying Amount	167,313	646,965
Accumulated Amortization	84,083	537,871
Proprietary technology
Intangible Asset, Acquired, Finite-Lived [Line Items]
Gross Carrying Amount	37,775	73,464
Accumulated Amortization	19,253	52,976
Trade names
Intangible Asset, Acquired, Finite-Lived [Line Items]
Gross Carrying Amount	2,400	2,531
Accumulated Amortization	2,000	1,651
Land-use rights
Intangible Asset, Acquired, Finite-Lived [Line Items]
Gross Carrying Amount	8,861	8,493
Accumulated Amortization	2,313	2,008
Sealed source and supply agreements
Intangible Asset, Acquired, Finite-Lived [Line Items]
Gross Carrying Amount	168,740	192,630
Accumulated Amortization	91,405	110,668
Other
Intangible Asset, Acquired, Finite-Lived [Line Items]
Gross Carrying Amount	900	4,344
Accumulated Amortization	$ 790	$ 3,655

Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in our accumulated other comprehensive income (loss) balances, net of applicable tax, were as follows:


(thousands of U.S. dollars)	Defined Benefit Plans			Foreign Currency Translation		Interest Rate Derivatives			Total
Beginning balance – January 1, 2023	$	3,209		$	(131,205)	$	21,343		$	(106,653)
Other comprehensive income (loss) before reclassifications	(10,308)			40,174		6,441			36,307
Amounts reclassified from accumulated other comprehensive income (loss)	(198)		(a)	—		(22,138)		(b)	(22,336)
Net current-period other comprehensive income (loss)	(10,506)			40,174		(15,697)			13,971
Ending balance – December 31, 2023	$	(7,297)		$	(91,031)	$	5,646		$	(92,682)

Beginning balance – January 1, 2024	$	(7,297)		$	(91,031)	$	5,646		$	(92,682)
Other comprehensive income (loss) before reclassifications	8,632			(118,635)		4,449			(105,554)
Amounts reclassified from accumulated other comprehensive income (loss)	(170)		(a)	—		(9,845)		(b)	(10,015)
Net current-period other comprehensive income (loss)	8,462			(118,635)		(5,396)			(115,569)
Ending balance – December 31, 2024	$	1,165		$	(209,666)	$	250		$	(208,251)

Beginning balance – January 1, 2025	$	1,165		$	(209,666)	$	250		$	(208,251)
Other comprehensive income (loss) before reclassifications	2,455			98,115		(966)			99,604
Amounts reclassified from accumulated other comprehensive income (loss)	(69)		(a)	—		(1,122)		(b)	(1,191)
Net current-period other comprehensive income (loss)	2,386			98,115		(2,088)			98,413
Ending balance – December 31, 2025	$	3,551		$	(111,551)	$	(1,838)		$	(109,838)

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Net deferred tax assets
Net operating loss carryforwards	$ 57,210	$ 56,097
Net capital loss carryforwards	3,652	2,890
Reserves and accruals	16,532	8,187
Employee benefits and compensation	12,636	10,481
Asset retirement obligations	12,432	11,506
Lease liability	16,462	14,381
Disallowed interest carryforward	186,937	167,369
Other	10,690	8,804
Deferred tax assets before valuation allowance	316,551	279,715
Valuation allowance	(172,294)	(160,595)
Net deferred tax assets	144,257	119,120
Net deferred tax liabilities
Depreciation and amortization	(188,522)	(170,646)
Reserves and accruals	(15,207)	(11,240)
Other	(7,750)	(3,869)
Total deferred tax liabilities	(211,479)	(185,755)
Net deferred tax liabilities	(67,222)	(66,635)
Noncurrent net deferred tax assets	3,853	2,865
Noncurrent net deferred tax liabilities	$ (71,075)	$ (69,500)

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Allowance for uncollectible accounts receivable
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 2,532	$ 4,689	$ 1,871
Charges (credits) to costs and expense	2,119	(435)	4,313
Deductions	(1,746)	(1,580)	(1,502)
Translation Adjustments	63	(142)	7
Balance at End of Period	2,968	2,532	4,689
Deferred tax asset valuation allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	160,595	125,435	105,600
Charges (credits) to costs and expense	11,135	35,660	19,682
Deductions	0	0	0
Translation Adjustments	564	(500)	153
Balance at End of Period	$ 172,294	$ 160,595	$ 125,435

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Statement of Financial Position [Abstract]
Allowance for uncollectible accounts	$ 2,968	$ 2,532
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	1,200,000,000	1,200,000,000
Common stock, shares issued (in shares)	286,037,000	286,037,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	120,000,000	120,000,000
Preferred stock, shares issued (in shares)	0	0
Treasury stock (in shares)	1,666,000	2,571,000

Share-Based Compensation - Schedule of Unvested RSUs (Details) - RSUs - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Number of Shares
Beginning balance (in shares)	2,278,537
Granted (in shares)	1,583,130
Forfeited (in shares)	(89,892)
Vested (in shares)	(1,365,684)
Ending balance (in shares)	2,406,091	2,278,537
Weighted-average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 13.73
Granted (in dollars per share)	13.48	$ 14.05	$ 16.95
Forfeited (in dollars per share)	12.87
Vested (in dollars per share)	12.74
Ending balance (in dollars per share)	$ 14.16	$ 13.73

Employee Benefits - Schedule of Pension Plan Weighted Average Asset Allocations (Details) - Defined benefit pension plan	Dec. 31, 2025	Dec. 31, 2024
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target	100.00%
Defined benefit plan securities	100.00%	100.00%
Cash
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target	0.00%
Defined benefit plan securities	0.60%	0.60%
Fixed income
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target	54.00%
Defined benefit plan securities	53.10%	52.30%
Equities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target	27.00%
Defined benefit plan securities	25.90%	25.90%
Hedge funds
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target	19.00%
Defined benefit plan securities	20.40%	21.20%

Goodwill and Other Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 41,798	$ 79,377	$ 81,348
Other
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	41,800	79,400	81,300
Other \| Amortization Of Intangible Assets, Nonproduction
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 30,700	$ 62,000	$ 63,800

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-29

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-29

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 24: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 26: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 27: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 28: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-3

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483154/926-20-50-5

+ Details

Employee Benefits -Schedule of Reconciliation of Changes in Benefit Obligations and Fair Value of Plan Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Defined benefit pension plan
Change in projected benefit obligation:
Projected benefit obligation, as of beginning of the year	$ 220,633	$ 239,947
Service cost	635	732
Interest cost	9,478	10,435
Benefits paid	(12,468)	(12,737)
Actuarial (gain) loss	(4,105)	935
Foreign currency exchange rate changes	10,561	(18,679)
Projected benefit obligation, end of year	224,734	220,633
Change in fair value of plan assets:
Fair value of plan assets as of the beginning of the year	262,703	268,424
Actual return on plan assets	13,764	27,925
Benefits paid	(12,468)	(12,737)
Employer contributions	515	604
Employee contributions	140	162
Foreign currency exchange rate changes	12,766	(21,675)
Fair value of plan assets, end of year	277,420	262,703
Funded status at end of year	52,686	42,070
Accumulated benefit obligation, end of year	222,331	218,122
Other post-retirement benefits plans
Change in projected benefit obligation:
Projected benefit obligation, as of beginning of the year	8,375	8,964
Service cost	5	10
Interest cost	343	371
Benefits paid	(512)	(609)
Actuarial (gain) loss	(311)	211
Plan participant contributions	131	132
Foreign currency exchange rate changes	398	(704)
Projected benefit obligation, end of year	8,429	8,375
Change in fair value of plan assets:
Fair value of plan assets as of the beginning of the year	512	525
Benefits paid	(188)	(187)
Employer (refunds) contributions	(38)	216
Foreign currency exchange rate changes	20	(42)
Fair value of plan assets, end of year	306	512
Funded status at end of year	(8,123)	(7,863)
Accumulated benefit obligation, end of year	$ 8,410	$ 8,364

Employee Benefits (Tables)

12 Months Ended

Dec. 31, 2025

Postemployment Benefits [Abstract]

Schedule of Net Benefit Costs

The components of net periodic pension benefit for the defined benefit plans were as follows:


Year ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Service cost	$	495	$	570	$	525
Interest cost	9,478		10,435		10,917
Expected return on plan assets	(15,825)		(15,823)		(16,108)

Net periodic benefit	$	(5,852)	$	(4,818)	$	(4,666)

The components of net periodic benefit cost for the other benefit plans were as follows:


(thousands of U.S. dollars)
Year Ended December 31,	2025		2024		2023
Service cost	$	5	$	10	$	9
Interest cost	343		371		398
Amortization of net actuarial gain	(69)		(170)		(197)
Net periodic benefit cost	$	279	$	211	$	210

Schedule of Defined Benefit Plan Assumptions

The following weighted average assumptions were used in the determination of the PBO and the net periodic benefit:


Year ended December 31,	2025		2024
Projected benefit obligation
Discount rate	4.82	%	4.65	%
Rate of compensation increase	3.00	%	3.00	%
Periodic benefit
Discount rate	4.65	%	4.65	%
Expected return on plan assets	6.00	%	6.25	%
Rate of compensation increase	3.00	%	3.00	%

The weighted average assumptions used to determine the PBO and net periodic pension cost for these plans were as follows:


Year Ended December 31,	2025		2024
Projected benefit obligation:
Discount rate	4.82	%	4.65	%
Rate of compensation increase	3.00	%	3.00	%
Initial health care cost trend rate	7.00	%	7.00	%
Ultimate health care cost trend rate	4.00	%	4.00	%
Years until ultimate trend rate is reached	15		15
Benefit cost:
Discount rate	4.65	%	4.65	%
Rate of compensation increase	3.00	%	3.00	%

Schedule of Defined Benefit Plans Disclosures

The changes in the PBO, fair value of plan assets, and the funded status of the plans are as follows:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Change in projected benefit obligation:
Projected benefit obligation, as of beginning of the year	$	220,633	$	239,947
Service cost	635		732
Interest cost	9,478		10,435
Benefits paid	(12,468)		(12,737)
Actuarial (gain) loss	(4,105)		935

Foreign currency exchange rate changes	10,561		(18,679)

Projected benefit obligation, end of year	$	224,734	$	220,633

Change in fair value of plan assets:
Fair value of plan assets as of the beginning of the year	$	262,703	$	268,424
Actual return on plan assets	13,764		27,925
Benefits paid	(12,468)		(12,737)
Employer contributions	515		604
Employee contributions	140		162
Foreign currency exchange rate changes	12,766		(21,675)

Fair value of plan assets, end of year	$	277,420	$	262,703

Funded status at end of year	$	52,686	$	42,070

Accumulated benefit obligation, end of year	$	222,331	$	218,122

Expected future benefit payments from plan assets are as follows:


(thousands of U.S. dollars)
Year Ended December 31,
2026	$	13,813
2027	14,168
2028	14,339
2029	14,506
2030	14,617
2031 - 2035	74,377
	$	145,820

The changes in the projected benefit obligation and the funded status of the other post-retirement plans were as follows:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Change in projected benefit obligation:
Projected benefit obligation	$	8,375	$	8,964
Service cost	5		10
Interest cost	343		371
Benefits paid	(512)		(609)
Actuarial (gain) loss	(311)		211
Plan participant contributions	131		132
Foreign currency exchange rate changes	398		(704)

Projected benefit obligation, end of year	$	8,429	$	8,375

Change in fair value of plan assets:
Fair value of plan assets as of the beginning of the year	$	512	$	525
Benefits paid	(188)		(187)
Employer (refunds) contributions	(38)		216
Foreign currency exchange rate changes	20		(42)

Fair value of plan assets, end of year	$	306	$	512

Underfunded status at end of year	$	(8,123)	$	(7,863)

Accumulated benefit obligation, end of year	$	8,410	$	8,364

Based on the actuarial assumptions used to develop the Company’s benefit obligations as of December 31, 2025, the following benefit payments are expected to be made to plan participants:


(thousands of U.S. dollars)
Years ended December 31
2026	$	550
2027	585
2028	510
2029	511
2030	514
2031 - 2035	2,628
Total	$	5,298

Schedule of Net Funded Status

A reconciliation of the funded status to amounts recognized in the Consolidated Balance Sheets is as follows:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Projected benefit obligation	$	224,734	$	220,633
Fair value of plan assets	277,420		262,703
Plan assets greater than projected benefit obligation (noncurrent assets)	52,686		42,070
Unrecognized net actuarial gain	2,196		107

A reconciliation of the funded status to the net plan liabilities recognized in the Consolidated Balance Sheets is as follows:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Projected benefit obligation	$	8,429	$	8,375
Fair value of plan assets	306		512
Plan assets less than projected benefit obligation (noncurrent liabilities)	(8,123)		(7,863)
Unrecognized actuarial gains	1,870		1,549

Schedule of Amounts Recognized in Other Comprehensive Income (Loss)

The following table illustrates the amounts in accumulated other comprehensive income (loss) that have not yet been recognized as components of pension expense:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Net actuarial gain	$	2,196	$	107
Deferred income taxes	(510)		(27)
Accumulated other comprehensive income – net of tax	$	1,686	$	80

The following table illustrates the amounts in accumulated other comprehensive income (loss) that have not yet been recognized as components of other benefit plan expense:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Net actuarial gain	$	1,870	$	1,549
Deferred income taxes	(593)		(444)
Accumulated other comprehensive income – net of tax	$	1,277	$	1,105

Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates


(thousands of U.S. dollars)	1% Increase		1% Decrease
Change in net periodic benefit cost	$	21	$	(18)
Change in projected benefit obligation	510		(434)

Schedule of Allocation of Plan Assets

The weighted average asset allocation of the Company’s pension plans was as follows:


Asset Category	Target		2025		2024
Cash	0.0	%	0.6	%	0.6	%
Fixed income	54.0	%	53.1	%	52.3	%
Equities	27.0	%	25.9	%	25.9	%
Hedge funds	19.0	%	20.4	%	21.2	%
Total	100.0	%	100.0	%	100.0	%

Financial Instruments and Financial Risk - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Derivative [Line Items]
Derivative assets	$ 1,162	$ 3,236
Derivative liability	4,218	4,296
Derivatives designated as hedging instruments \| Interest rate swap
Derivative [Line Items]
Derivative assets	0	459
Derivative liability	2,346	0
Derivatives designated as hedging instruments \| Interest rate swap \| Level 1
Derivative [Line Items]
Derivative assets		0
Derivative liability	0
Derivatives designated as hedging instruments \| Interest rate swap \| Level 2
Derivative [Line Items]
Derivative assets		459
Derivative liability	2,346
Derivatives designated as hedging instruments \| Interest rate swap \| Level 3
Derivative [Line Items]
Derivative assets		0
Derivative liability	0
Derivatives designated as hedging instruments \| Carrying Amount \| Interest rate swap
Derivative [Line Items]
Derivative assets		459
Derivative liability	2,346
Derivatives not designated as hedging instruments \| Term loan due 2031 \| Level 1
Derivative [Line Items]
Long-term debt	0	0
Current portion of long-term debt	0	0
Derivatives not designated as hedging instruments \| Term loan due 2031 \| Level 2
Derivative [Line Items]
Long-term debt	14,327	15,123
Current portion of long-term debt	1,410,539	1,493,314
Derivatives not designated as hedging instruments \| Term loan due 2031 \| Level 3
Derivative [Line Items]
Long-term debt	0	0
Current portion of long-term debt	0	0
Derivatives not designated as hedging instruments \| Senior secured Notes, due 2031 \| Level 1
Derivative [Line Items]
Current portion of long-term debt	0	0
Derivatives not designated as hedging instruments \| Senior secured Notes, due 2031 \| Level 2
Derivative [Line Items]
Current portion of long-term debt	789,375	759,375
Derivatives not designated as hedging instruments \| Senior secured Notes, due 2031 \| Level 3
Derivative [Line Items]
Current portion of long-term debt	0	0
Derivatives not designated as hedging instruments \| Finance Lease Obligations (with current portion) \| Level 1
Derivative [Line Items]
Current portion of long-term debt	0	0
Derivatives not designated as hedging instruments \| Finance Lease Obligations (with current portion) \| Level 2
Derivative [Line Items]
Current portion of long-term debt	97,300	98,209
Derivatives not designated as hedging instruments \| Finance Lease Obligations (with current portion) \| Level 3
Derivative [Line Items]
Current portion of long-term debt	0	0
Derivatives not designated as hedging instruments \| Foreign currency forward \| Level 1
Derivative [Line Items]
Derivative assets		0
Derivative liability		0
Derivatives not designated as hedging instruments \| Foreign currency forward \| Level 2
Derivative [Line Items]
Derivative assets		88
Derivative liability		198
Derivatives not designated as hedging instruments \| Foreign currency forward \| Level 3
Derivative [Line Items]
Derivative assets		0
Derivative liability		0
Derivatives not designated as hedging instruments \| Embedded Derivative Assets and Liabilities
Derivative [Line Items]
Derivative assets	1,162	2,689
Derivative liability	1,872	4,098
Derivatives not designated as hedging instruments \| Embedded Derivative Assets and Liabilities \| Level 1
Derivative [Line Items]
Derivative assets	0	0
Derivative liability	0	0
Derivatives not designated as hedging instruments \| Embedded Derivative Assets and Liabilities \| Level 2
Derivative [Line Items]
Derivative assets	1,162	2,689
Derivative liability	1,872	4,098
Derivatives not designated as hedging instruments \| Embedded Derivative Assets and Liabilities \| Level 3
Derivative [Line Items]
Derivative assets	0	0
Derivative liability	0	0
Derivatives not designated as hedging instruments \| Carrying Amount \| Term loan due 2031
Derivative [Line Items]
Long-term debt	13,973	14,803
Current portion of long-term debt	1,379,853	1,461,807
Derivatives not designated as hedging instruments \| Carrying Amount \| Senior secured Notes, due 2031
Derivative [Line Items]
Current portion of long-term debt	746,871	746,293
Derivatives not designated as hedging instruments \| Carrying Amount \| Finance Lease Obligations (with current portion)
Derivative [Line Items]
Current portion of long-term debt	97,300	98,209
Derivatives not designated as hedging instruments \| Carrying Amount \| Foreign currency forward
Derivative [Line Items]
Derivative assets		88
Derivative liability		198
Derivatives not designated as hedging instruments \| Carrying Amount \| Embedded Derivative Assets and Liabilities
Derivative [Line Items]
Derivative assets	1,162	2,689
Derivative liability	$ 1,872	$ 4,098

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Accrued employee compensation	$	43,543	$	37,018
Reserve for Illinois EO litigation settlements	34,000		—
Accrued interest expense	20,543		25,321
Embedded derivatives	1,872		4,098
Professional fees	10,483		12,572
Accrued utilities	1,786		1,651
Insurance accrual	2,131		2,326
Accrued taxes	3,287		3,923
Other	7,091		3,554
Accrued liabilities	$	124,736	$	90,463

Segment and Geographic Information (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Financial information for each of our segments is presented in the following table:


	Year Ended December 31, 2025
(thousands of U.S. dollars)	Sterigenics		Nordion		Nelson Labs		Total
Net revenues(a)	$	755,780	$	187,618	$	220,219	$	1,163,617
Segment expenses(b)	306,621		74,533		141,477		522,631
Corporate expense allocation(c)	36,266		5,507		5,412		47,185
Segment income	$	412,893	$	107,578	$	73,330	$	593,801


	Year Ended December 31, 2024
(thousands of U.S. dollars)	Sterigenics		Nordion		Nelson Labs		Total
Net revenues(a)	$	697,853	$	173,355	$	229,233	$	1,100,441
Segment expenses(b)	286,434		67,087		155,088		508,609
Corporate expense allocation(c)	33,248		5,048		4,962		43,258
Segment income	$	378,171	$	101,220	$	69,183	$	548,574


	Year Ended December 31, 2023
(thousands of U.S. dollars)	Sterigenics		Nordion		Nelson Labs		Total
Net revenues(a)	$	667,130	$	160,459	$	221,699	$	1,049,288
Segment expenses(b)	275,424		59,399		148,209		483,032
Corporate expense allocation(c)	29,494		4,382		4,351		38,227
Segment income	$	362,212	$	96,678	$	69,139	$	528,029

(b)Segment expenses are comprised of direct materials, labor, utilities, other costs of revenues, SG&A, and other non-operating expense (income) attributable to each segment.

Capital expenditures by segment for the years ended December 31, 2025, 2024 and 2023 were as follows:


	Year Ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Sterigenics	$	99,383	$	131,258	$	163,043
Nordion	21,832		34,928		38,351
Nelson Labs	16,803		12,884		13,581
Total capital expenditures	$	138,018	$	179,070	$	214,975

Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated

A reconciliation of segment income to consolidated income (loss) before taxes is as follows:


(thousands of U.S. dollars)
Year Ended December 31,	2025		2024		2023
Segment income	$	593,801	$	548,574	$	528,029
Less adjustments:
Interest expense, net	155,722		164,691		142,878
Depreciation and amortization(a)	136,428		161,797		157,925
Share-based compensation(b)	31,068		36,896		32,364
Loss on refinancing of debt(c)	1,462		24,168		—
Loss (gain) on foreign currency and derivatives not designated as hedging instruments, net(d)	58		2,448		(1,552)
Business optimization expenses(e)	8,068		9,368		7,662
Professional services relating to EO sterilization facilities(f)	46,225		32,694		45,312
Illinois EO litigation settlements(g)	64,943		—		—
Georgia EO litigation settlement(h)	—		—		35,000
Accretion of asset retirement obligation(i)	2,321		2,638		2,413
Consolidated income before taxes	$	147,506	$	113,874	$	106,027

(a)Includes depreciation of Co-60 held at gamma irradiation sites, and excludes accelerated depreciation associated with business optimization activities.

(b)Represents share-based compensation expense related to employees and Non-Employee Directors. See Note 15, “Share-Based Compensation” for further information.

(f)Represents litigation and other professional fees associated with our EO sterilization facilities.

(h)Represents the cost to settle 79 pending EO claims in Georgia under a settlement entered into on December 21, 2023. See Note 19, “Commitments and Contingencies.”

Schedule of Revenue from External Customers by Geographic Areas

Net revenues for geographic area are reported by the country’s origin of the revenues.


(thousands of U.S. dollars)
Year Ended December 31,	2025		2024		2023
United States	$	629,543	$	616,684	$	590,967
Canada	221,948		208,886		192,050
Europe	232,179		196,011		187,542
Other	79,947		78,860		78,729
Total	$	1,163,617	$	1,100,441	$	1,049,288

Schedule of Long-lived Assets by Geographic Areas

Long-lived assets are based on physical locations and are comprised of the net book value of property, plant, and equipment.


(thousands of U.S. dollars)
As of December 31,	2025		2024
United States	$	620,410	$	587,707
Canada	212,350		188,498
Europe	204,453		174,227
Other	93,351		86,460
Total	$	1,130,564	$	1,036,892

Inventories (Tables)

12 Months Ended

Dec. 31, 2025

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consisted of the following:


(thousands of U.S. dollars)
As of December 31,	2025		2024
Raw materials and supplies	$	45,569	$	42,408
Work-in-process	2,436		929
Finished goods	6,622		6,039
	54,627		49,376
Reserve for excess and obsolete inventory	(252)		(218)
Inventories, net	$	54,375	$	49,158

Stockholders’ Equity (Details)	12 Months Ended
Stockholders’ Equity (Details)	Dec. 31, 2025 vote $ / shares shares	Dec. 31, 2024 $ / shares shares	Dec. 17, 2020 $ / shares	Nov. 19, 2020 shares	Nov. 18, 2020 shares	Nov. 17, 2020 $ / shares shares
Equity [Abstract]
Common stock, shares authorized (in shares)	1,200,000,000	1,200,000,000				1,200,000,000
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01	$ 0.01				$ 0.01
Common stock, shares outstanding (in shares)				284,421,755	3,000	232,400,200
Number of vote \| vote	1
Preferred stock, shares authorized (in shares)	120,000,000	120,000,000				120,000,000
Preferred stock, par value (in dollars per share) \| $ / shares	$ 0.01	$ 0.01	$ 0.01

Financial Instruments and Financial Risk

12 Months Ended

Dec. 31, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments and Financial Risk

Derivative Instruments

We do not use derivatives for trading or speculative purposes and are not a party to leveraged derivatives.

Derivatives Designated in Hedge Relationships

From time to time, the Company utilizes interest rate derivatives designated in hedge relationships to manage interest rate risk associated with our variable rate borrowings. These instruments are measured at fair value with changes in fair value recorded as a component of “Accumulated other comprehensive loss” on our Consolidated Balance Sheets.

In March 2025, we entered into an interest rate swap agreement with a notional amount of $400.0 million. The interest rate swap became effective on August 31, 2025 and expires on August 31, 2027. We have designated the interest swap as a cash

flow hedge designed to hedge the variability of cash flows attributable to changes in the SOFR benchmark interest rate of our Term Loan (or any successor thereto). We receive interest at the one-month Term SOFR rate and pay a fixed interest rate under

the terms of the swap agreement.

In March 2023, we entered into an interest rate swap agreement with a notional amount of $400.0 million. The interest rate swap was effective on August 23, 2023 and expired on August 23, 2025. We designated the interest rate swap as a cash flow hedge designed to hedge the variability of cash flows attributable to changes in the SOFR benchmark interest rate of our Term Loan (or any successor thereto). We received interest at the one-month Term SOFR rate and paid a fixed interest rate under the terms of the swap agreement.

Derivatives Not Designated in Hedge Relationships

The Company also enters into foreign currency forward contracts to manage foreign currency exchange rate risk of our intercompany loans in certain of our international subsidiaries and non-functional currency assets and liabilities. The foreign currency forward contracts expire on a monthly basis. These foreign currency derivatives are not designated in hedge relationships.

Embedded Derivatives

We have embedded derivatives in certain of our customer and supply contracts as a result of the currency of the contract being different from the functional currency of the parties involved. Changes in the fair value of the embedded derivatives are recognized in “Other income, net” in the Consolidated Statements of Operations and Comprehensive Income (Loss).

The following table provides a summary of the notional and fair values of our derivative instruments:


	December 31, 2025							December 31, 2024
(in U.S. dollars; notional in millions, fair value in thousands)				Fair Value							Fair Value
	Notional Amount			Derivative Assets		Derivative Liabilities		Notional Amount			Derivative Assets		Derivative Liabilities
Derivatives designated as hedging instruments
Interest rate swaps	400.0			—		2,346		400.0			459		—
Derivatives not designated as hedging instruments
Foreign currency forward contracts	—			—		—		263.7			88		198
Embedded derivatives	264.4		(a)	1,162		1,872		230.8		(a)	2,689		4,098
Total	$	664.4		$	1,162	$	4,218	$	894.5		$	3,236	$	4,296

(a)Represents the total notional amounts for certain of the Company’s supply and sales contracts accounted for as embedded derivatives.

Embedded derivatives assets/liabilities and foreign currency forward contracts are included in “Prepaid expenses and other current assets” and “Accrued Liabilities” on our Consolidated Balance Sheets depending upon their position at period end. Interest rate swaps are included in “Other assets” and “Noncurrent liabilities” on the Consolidated Balance Sheets depending upon their position at period end.


(thousands of U.S. dollars)
Year Ended December 31,	2025		2024		2023
Realized gain on interest rate derivatives recorded in interest expense, net(a)	$	(1,505)	$	(13,233)	$	(33,094)
Unrealized (gain) loss on embedded derivatives recorded in other income, net	(863)		2,213		(1,637)
Realized (gain) loss on foreign currency forward contracts recorded in foreign exchange loss	(6,033)		18,055		(2,025)
Unrealized (gain) loss on foreign currency forward contracts recorded in foreign exchange loss	(110)		249		(412)

(a) Amounts represent periodic settlement of interest rate caps and swaps.

We expect to reclassify approximately $1.0 million of after-tax net losses on derivative instruments from accumulated other comprehensive income (loss) to income during the next 12 months associated with our cash flow hedges. Refer to Note 13, “Other Comprehensive Income (Loss)” for unrealized gains on interest rate derivatives, net of applicable tax, recorded in other comprehensive income (loss) and amounts reclassified from accumulated other comprehensive income to interest expense, net of applicable tax, during the years ended December 31, 2025 and December 31, 2024.

Credit Risk

Certain of our financial assets, including cash and cash equivalents, are exposed to credit risk.

We are also exposed, in our normal course of business, to credit risk from our customers. As of December 31, 2025 and 2024, accounts receivable was net of an allowance for uncollectible accounts of $3.0 million and $2.5 million, respectively.

Credit risk on financial instruments arises from the potential for counterparties to default on their contractual obligations to us. We are exposed to credit risk in the event of non-performance, but do not anticipate non-performance by any of the counterparties to our financial instruments. We limit our credit risk by dealing with counterparties that are considered to be of high credit quality. In the event of non-performance by counterparties, the carrying value of our financial instruments represents the maximum amount of loss that would be incurred.

Our credit team evaluates and regularly monitors changes in the credit risk of our customers. We routinely assess the collectability of accounts receivable and maintain an adequate allowance for uncollectible accounts to address potential credit

losses. The process includes a review of customer financial information and credit ratings, current market conditions as well as the expected future economic conditions that may impact the collection of trade receivables. We regularly review our customers’ past due amounts through an analysis of aged accounts receivables, specific customer past due aging amounts, and the history of trade receivables written off. Upon concluding that a receivable balance is not collectible, the balance is written off against the allowance for uncollectible accounts.

Fair Value Hierarchy

The fair value of our financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The valuation techniques we would use to determine such fair values are described as follows: Level 1—fair values determined by inputs utilizing quoted prices in active markets for identical assets or liabilities; Level 2—fair values based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable; Level 3—fair values determined by unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants.

The following table discloses the fair value our financial assets and liabilities:


As of December 31, 2025		Fair Value
(thousands of U.S. dollars)	Carrying Amount	Level 1	Level 2	Level 3
Derivatives designated as hedging instruments(a)
Interest rate swap liability	2,346	—	2,346	—
Derivatives not designated as hedging instruments(b)
Embedded derivative assets	1,162	—	1,162	—
Embedded derivative liabilities	1,872	—	1,872	—
Current portion of long-term debt(c)
Term Loan, due 2031	13,973	—	14,327	—
Long-Term Debt(c)
Senior secured Notes, due 2031	746,871	—	789,375	—
Term loan, due 2031	1,379,853	—	1,410,539	—
Finance Lease Obligations (with current portion)(d)	97,300	—	97,300	—


As of December 31, 2024			Fair Value
(thousands of U.S. dollars)	Carrying Amount		Level 1		Level 2		Level 3
Derivatives designated as hedging instruments(a)
Interest rate swap	$	459	$	—	$	459	$	—
Derivatives not designated as hedging instruments(b)
Foreign currency forward contracts assets	88		—		88		—
Foreign currency forward contracts liabilities	198		$	—	$	198	$	—
Embedded derivative assets	2,689		—		2,689		—
Embedded derivative liabilities	4,098		—		4,098		—
Current portion of long-term debt(c)
Term loan, due 2031	14,803		—		15,123		—
Long-Term Debt(c)
Secured Notes, due 2031	746,293		—		759,375		—
Term loan, due 2031	1,461,807		—		1,493,314		—
Finance Lease Obligations (with current portion)(d)	98,209		—		98,209		—

incorporate observable market inputs including interest rate curves and yield curves. Additional information is provided in Note 1, “Significant Accounting Policies.”

(d)Refer to Note 17, “Leases.” Fair value approximates carrying value.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 182
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-182

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 185
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-185

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 184
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-184

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 181
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-181

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4H
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4H
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 15
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480960/815-15-50-3

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 183
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480401/815-10-55-183

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4K
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4I
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4I

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4F
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/815/tableOfContent

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C

+ Details

Employee Benefits - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Defined benefit pension plan
Defined Benefit Plan Disclosure [Line Items]
Letters of credit outstanding, amount	$ 0.0	$ 6.4
Period of actual funding requirements	5 years
Defined benefit pension plan \| Maximum
Defined Benefit Plan Disclosure [Line Items]
Solvency payment as percent of market value	15.00%
United States
Defined Benefit Plan Disclosure [Line Items]
Employer contributions	$ 6.0	6.0	$ 5.7
Outside the U.S.
Defined Benefit Plan Disclosure [Line Items]
Employer contributions	$ 2.0	$ 1.7	$ 1.7

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Employee Benefits - Schedule of Reconciliation of Funded Status (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Defined benefit pension plan
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	$ 224,734	$ 220,633
Fair value of plan assets	277,420	262,703
Plan assets greater than projected benefit obligation (noncurrent assets)	52,686	42,070
Unrecognized net actuarial gain	2,196	107
Other post-retirement benefits plans
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligation	8,429	8,375
Fair value of plan assets	306	512
Plan assets greater than projected benefit obligation (noncurrent assets)	(8,123)	(7,863)
Unrecognized net actuarial gain	$ 1,870	$ 1,549

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Goodwill and Other Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2025 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2026	$ 22,161
2027	21,084
2028	20,537
2029	20,427
2030	20,427
Thereafter	81,509
Total	$ 186,145

Leases

12 Months Ended

Dec. 31, 2025

Leases [Abstract]

Leases

We lease certain facilities and equipment under various non-cancelable leases. Most of our real property leases provide for renewal periods and rent escalations and stipulate that we pay taxes, maintenance, and certain other operating expenses applicable to the leased premises.

The components of lease expense were as follows:


	Year Ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Operating lease costs (a)	$	13,207	$	13,267	$	13,920
Finance lease costs:
Amortization of right of use assets	6,474		8,438		8,152
Interest on lease liabilities	6,105		6,064		4,394
Total finance lease costs	12,579		14,502		12,546
Total lease costs	$	25,786	$	27,769	$	26,466

(a)Includes $1.7 million, $1.5 million, and $1.4 million of short-term lease costs in the years ended December 31, 2025, 2024, and 2023, respectively.

Lease terms and discount rates were as follows:


	Year Ended December 31,
	2025		2024
Weighted average remaining lease term:
Operating leases	11.1 years		7.3 years
Finance leases	14.9 years		15.2 years
Weighted average discount rate:
Operating leases	6.90	%	6.57	%
Finance leases	6.55	%	6.55	%

Supplemental cash flow information related to leases was as follows:


	Year Ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	7,917	$	7,382	$	10,067
Operating cash flows for finance leases	6,332		6,277		3,988
Finance cash flows for finance leases	3,903		8,088		1,823

Supplemental non-cash information was as follows:


	Year Ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	10,822	$	10,550	$	4,559
Finance leases	431		36,016		14,770

Maturities of lease liabilities as of December 31, 2025 are as follows:


(thousands of U.S. dollars)	Operating Leases		Finance Leases		Total
2026	$	8,134	$	9,689	$	17,823
2027	7,187		9,968		17,155
2028	5,760		10,263		16,023
2029	4,717		9,933		14,650
2030	3,767		9,634		13,401
2031 and Thereafter	22,069		108,811		130,880
Total lease payments	51,634		158,298		209,932
Less imputed interest	(15,978)		(60,998)		(76,976)
Total lease liabilities	$	35,656	$	97,300	$	132,956

Leases

The components of lease expense were as follows:


	Year Ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Operating lease costs (a)	$	13,207	$	13,267	$	13,920
Finance lease costs:
Amortization of right of use assets	6,474		8,438		8,152
Interest on lease liabilities	6,105		6,064		4,394
Total finance lease costs	12,579		14,502		12,546
Total lease costs	$	25,786	$	27,769	$	26,466

(a)Includes $1.7 million, $1.5 million, and $1.4 million of short-term lease costs in the years ended December 31, 2025, 2024, and 2023, respectively.

Lease terms and discount rates were as follows:


	Year Ended December 31,
	2025		2024
Weighted average remaining lease term:
Operating leases	11.1 years		7.3 years
Finance leases	14.9 years		15.2 years
Weighted average discount rate:
Operating leases	6.90	%	6.57	%
Finance leases	6.55	%	6.55	%

Supplemental cash flow information related to leases was as follows:


	Year Ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	7,917	$	7,382	$	10,067
Operating cash flows for finance leases	6,332		6,277		3,988
Finance cash flows for finance leases	3,903		8,088		1,823

Supplemental non-cash information was as follows:


	Year Ended December 31,
(thousands of U.S. dollars)	2025		2024		2023
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	10,822	$	10,550	$	4,559
Finance leases	431		36,016		14,770

Maturities of lease liabilities as of December 31, 2025 are as follows:


(thousands of U.S. dollars)	Operating Leases		Finance Leases		Total
2026	$	8,134	$	9,689	$	17,823
2027	7,187		9,968		17,155
2028	5,760		10,263		16,023
2029	4,717		9,933		14,650
2030	3,767		9,634		13,401
2031 and Thereafter	22,069		108,811		130,880
Total lease payments	51,634		158,298		209,932
Less imputed interest	(15,978)		(60,998)		(76,976)
Total lease liabilities	$	35,656	$	97,300	$	132,956

Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Pension and post-retirement benefits, tax	$ 600	$ 2,804	$ (3,420)
Interest rate swaps, tax	$ (718)	$ (1,856)	$ (5,467)

Share-Based Compensation - Schedule of Stock Options Assumptions (Details) - Stock options - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value per share (in dollars per share)	$ 7.35	$ 7.13
Expected term (years)	6 years	6 years
Risk-free interest rate	4.20%	4.20%
Expected volatility	46.80%	50.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 45,569	$ 42,408
Work-in-process	2,436	929
Finished goods	6,622	6,039
Inventories, gross	54,627	49,376
Reserve for excess and obsolete inventory	(252)	(218)
Inventories, net	$ 54,375	$ 49,158

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Property, Plant and Equipment - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 94.9	$ 84.3	$ 76.6
Capitalized interest	$ 12.6	$ 16.2	$ 12.2

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References + Details

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2025	Feb. 17, 2026	Jun. 30, 2025
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2025
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-39729
Entity Registrant Name	SOTERA HEALTH COMPANY
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-3531161
Entity Address, Address Line One	9100 South Hills Blvd
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Broadview Heights
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44147
City Area Code	440
Local Phone Number	262-1410
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	SHC
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 1,714,111,104
Entity Common Stock, Shares Outstanding		284,392,079
Documents Incorporated by Reference	Portions of the Definitive Proxy Statement for the registrant’s 2026 Annual Meeting of Stockholders are incorporated by reference in Part III of this Annual Report on Form 10-K. Sotera Health Company intends to file the Definitive Proxy Statement with the Securities and Exchange Commission within 120 days after the end of the registrant’s fiscal year ended December 31, 2025.
Entity Central Index Key	0001822479
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2025
Amendment Flag	false

Significant Accounting Policies

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Significant Accounting Policies

Principles of Consolidation – Sotera Health Company (also referred to herein as the “Company,” “we,” “our,” “us” or “its”), is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry with operations primarily in the Americas, Europe and Asia.

The accompanying consolidated financial statements include the assets, liabilities, operating results, and cash flows of the Company and its wholly owned subsidiaries prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).

We operate and report in three segments, Sterigenics, Nordion and Nelson Labs. We describe our reportable segments in Note 21, “Segment and Geographic Information.” All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates – In preparing our consolidated financial statements in conformity with GAAP, we make estimates and assumptions that affect the amounts reported and the accompanying notes. We regularly evaluate the estimates and assumptions used and revise them as new information becomes available. Actual results may vary from those estimates.

Cash and Cash Equivalents – We consider all highly liquid investments purchased with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents may include various deposit accounts and money market funds.

Accounts Receivable – Accounts receivable consists of amounts billed and currently due from customers. The amounts due are stated net of the allowance for uncollectible accounts. The Company maintains an allowance for uncollectible receivables to provide for the estimated amount of receivables that will not be collected.

Allowance for Uncollectible Accounts Receivable – We maintain an allowance for uncollectible accounts receivable for estimated losses in the collection of amounts owed to us by customers. We estimate the allowance based on analyzing a number of factors, including amounts written off historically, customer payment practices, customer financial information and credit ratings, current market conditions as well as the expected future economic conditions that may impact the collection of accounts receivable. We also analyze significant customer accounts on a regular basis and record a specific allowance when we become aware of a specific customer’s inability to pay. We generally do not charge interest on accounts receivable or require collateral from our customers.

We record write-offs against the allowance for uncollectible accounts receivable when all reasonable efforts for collection have been exhausted. As a result, the related accounts receivable are reduced to an amount that we reasonably believe is collectible. These analyses require judgment. If the financial condition of our customers worsens, or economic conditions change, we may be required to make changes to our allowance for uncollectible accounts receivable.

Inventories – Inventories as of December 31, 2025 and 2024 are held at Nordion. Inventories are stated at the lower of cost or net realizable value. Cost of material, labor, and manufacturing overhead are determined using standard cost, which approximates average cost. We review inventory on an ongoing basis, considering factors such as deterioration and obsolescence. We record a reserve for excess and obsolete inventory, which was immaterial at December 31, 2025 and 2024, when the facts and circumstances indicate that particular inventories will not be usable. If future market conditions vary from those projected, and our estimates prove to be inaccurate, we may be required to write-down inventory values and record an adjustment to cost of revenues.

Property, Plant, and Equipment – Property, plant, and equipment is carried at cost, or initially at fair value if acquired in an acquisition, less accumulated depreciation and amortization. Except for Co-60, a radioactive isotope used in gamma radiation sterilization, all property, plant, and equipment depreciation is computed using the straight-line method over estimated useful lives. Leasehold improvements are amortized over their estimated useful lives or the term of the related lease, whichever is shorter. Co-60 is amortized using an accelerated method, which relates to the natural radioactive decay of the isotope over its estimated useful life which is approximately twenty years. Amortization of Co-60 is included within depreciation expense as a cost of revenue. Expenditures for major software purchases and software developed for internal use are capitalized and depreciated using the straight-line method over the estimated useful lives of the related assets, which are generally one to five years. For software obtained or developed for internal use, all external direct costs for materials and services and certain

personnel costs incurred to develop the software during the application development stage are capitalized. At December 31, 2025 and 2024, we had undepreciated software costs of $17.1 million and $11.4 million, respectively, included in property, plant, and equipment, net. We recognized $4.8 million, $4.2 million and $3.3 million, of depreciation expense related to software costs for the years ending December 31, 2025, 2024 and 2023, respectively.

Depreciation is computed using the assets’ estimated useful lives as presented below:


Buildings and building improvements			15–44 years
Machinery and equipment			3–30 years
Leasehold improvements			2–20 years
Furniture and fixtures			3–10 years
Computer hardware and software			1–7 years

From time to time, we build or expand facilities. The cost of construction of these facilities is reflected as construction-in-progress until the asset is ready for its intended use, at which time the costs are reclassified to the appropriate depreciable category of property, plant, and equipment and depreciation commences. Fixed asset projects requiring one or more years to complete construction qualify for capitalization of interest costs in accordance with our policy. Interest related to property, plant and equipment projects with a construction period of less than one year are not capitalized and are immaterial. Repairs and maintenance costs that do not extend the useful life of an asset are expensed as incurred.

Upon sale or retirement of assets, the cost and related accumulated depreciation is removed from the Consolidated Balance Sheets, and the resulting gain or loss is reflected as a component of operating income.

Leases – We determine if an agreement contains a lease and classify our leases as operating or finance at the lease commencement date. Leases with an initial term of twelve months or less are recognized as lease expense on a straight-line basis over the lease term and are not recorded on the Consolidated Balance Sheets. Non-lease components are accounted for separately from the lease components for all asset classes.

Finance leases are those in which we will pay substantially all the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. Lease assets arising from finance leases are included in “Property, plant and equipment, net” and the liabilities are included in “Finance lease obligations” on the Consolidated Balance Sheets. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the lease asset over the shorter of the lease term or the useful life of asset. Finance leases are accounted for as if the assets were owned and financed, with associated expense recognized in “Interest expense, net” and “Cost of revenues” or “Selling, general and administrative expenses” within the Consolidated Statements of Operations and Comprehensive Income (Loss) depending on the nature of the underlying asset.

Operating lease assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. As most leases do not provide an implicit interest rate, we estimate an incremental borrowing rate to determine the present value of lease payments. Our estimated incremental borrowing rate reflects a secured rate based on recent debt issuances, our estimated credit rating, and lease term. We recognize operating lease costs on a straight-line basis over the term of the lease in “Cost of revenues” or “Selling, general and administrative expenses” on the Consolidated Statements of Operations and Comprehensive Income (Loss) depending on the nature of the underlying asset.

Goodwill and Other Indefinite-Lived Intangibles – Goodwill and other indefinite-lived intangible assets, primarily certain regulatory licenses and tradenames, are tested for impairment annually as of October 1. If circumstances change during interim periods between annual tests that would indicate that the carrying amount of such assets may not be recoverable, the Company tests such assets at an interim date for impairment. Factors that necessitate an interim impairment assessment include prolonged negative industry or economic trends and significant underperformance relative to historical or projected future operating results.

We performed a quantitative assessment of all reporting units (Sterigenics, Nordion and Nelson Labs) as of October 1, 2025. The fair value of each reporting unit was calculated using a discounted cash flow analysis which was dependent on subjective

market participant assumptions determined by management. We further corroborated these discounted cash flow analyses utilizing a market approach to determine the estimated enterprise fair value. Assumptions used in the analyses included discount rates, revenue growth rates and projected operating cash flows. Estimates of future cash flows are based upon relevant data at a point-in-time, are subject to change, and could vary from actual results. The estimated fair value of each reporting unit exceeded its carrying amount by a sufficient margin to support a positive assertion that goodwill is not impaired. We performed a qualitative impairment assessment to evaluate any potential impairment to the indefinite-lived intangible assets. We considered significant events and circumstances that could affect the significant inputs used to determine the estimated fair value of the indefinite-lived intangible assets, and determined, after considering the totality of evidence that it is not more likely than not that the indefinite-lived intangible assets are impaired. There have been no other significant events or circumstances that occurred since the annual assessment date of October 1 that would change the conclusions reached above.

Derivative Instruments – We may enter into derivative instruments and hedging activities to manage, where possible and economically efficient, commodity price risk, foreign currency exchange rate risk and interest rate risk related to borrowings. We also have identified embedded derivatives in certain supply and customer contracts. Certain interest rate derivatives are designated as cash flow hedges allowing for changes in fair value to be recorded through “Other comprehensive income (loss).” Amounts in accumulated other comprehensive income (loss) will be reclassified into earnings in the same periods during which the hedged transaction affects earnings and are presented in “Interest expense, net” within the Consolidated Statements of Operations and Comprehensive Income (Loss). Derivatives not designated as hedges are recorded at fair value on the Consolidated Balance Sheets, with any changes in the value being recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss) in the same line item as the corresponding hedged item. We classify cash flows from derivative instruments and hedging activities as cash flows from operating activities in the Consolidated Statements of Cash Flows. To the extent derivative arrangements are with the same counterparty and contractual right of offset exists under applicable master agreements, we offset assets and liabilities for reporting on the Consolidated Balance Sheets.

Pension, Post-Retirement and Other Post-Employment Benefit Plans – We sponsor a defined-contribution retirement plan that covers substantially all U.S. employees. We also sponsor various post-employment benefit plans at our Nordion business in Canada, including defined benefit and defined contribution pension plans, retirement compensation arrangements and plans that provide extended health care coverage to retired employees. In addition, we provide other benefit plans at our foreign subsidiaries, including a supplemental retirement arrangement, a retirement and termination allowance and post-retirement benefit plans, which include contributory healthcare benefits and contributory life insurance coverage. All non-pension post-employment benefit plans are unfunded.

These costs and obligations are affected by assumptions including the discount rate, the expected long-term rate of return on plan assets, the annual rate of change in compensation for eligible employees, estimated changes in costs of healthcare benefits, and other demographic and economic factors. We review the assumptions used on an annual basis.

We recognize the over/under funded status of defined benefit pension and post-retirement benefits plans in our Consolidated Balance Sheets. This amount is measured as the difference between the fair value of plan assets and the projected benefit obligation (“PBO”). Changes in the funded status of the plans are recorded in other comprehensive income (loss) in the year they occur. We measure plan assets and obligations as of the balance sheet date. We provide additional information about our pension and other post-retirement benefits plans in Note 11, “Employee Benefits.”

Amortization of net gain or loss included in accumulated other comprehensive income (loss) is reclassified to net periodic pension cost if, as of the beginning of the year, that gain or loss exceeds 10% of the greater of the PBO or the market related value of the plan assets (the ‘corridor’). As most of the plan’s participants are no longer actively accruing benefits, the average remaining life expectancy is used.

Asset Retirement Obligations (“ARO”) – ARO are legal obligations associated with the retirement of long-lived assets or the exit of a leased facility. We recognize a liability for an ARO in the period in which it is incurred if a reasonable estimate of fair value can be made, and the associated asset retirement costs are then capitalized as part of the carrying amount of the long-lived asset. We lease various facilities where sterilization and ionization services are performed. Under the lease agreements, we are required to return the facilities to their original condition and to perform decommissioning activities. In addition, certain of our owned facilities are required to be decommissioned when we vacate the facility. Accretion expense is recognized in “Cost of Revenues” in the Consolidated Statements of Operations and Comprehensive Income (Loss) over time as the discounted liability is accreted to its expected settlement value.

Debt Issuance Costs, Premiums and Discounts – We have incurred costs in connection with obtaining financing as well as premiums and discounts associated with our long-term debt. The portion of these fees that are capitalized are recorded as a reduction of debt on the Consolidated Balance Sheets and amortized into interest expense over the term of the debt agreement. Debt issuance costs associated with the Company’s revolving credit facilities are classified as assets unless there are outstanding borrowings under such arrangements.

Concentration of Credit Risk, Other Risks and Uncertainties – We maintain cash and cash equivalents in the form of demand deposits in accounts with major financial institutions in the U.S. and in countries where our subsidiaries operate. Deposits in these institutions may exceed amounts of insurance provided on such accounts. We have not experienced any losses on our deposits of cash and cash equivalents.

Our net revenues and accounts receivable are derived from customers located primarily in North America and Europe.

No customer accounted for 10% or more of accounts receivable at December 31, 2025 and 2024, or 10% or more of net revenues for the years ended December 31, 2025, 2024 and 2023.

Income Taxes – We use the liability method of accounting for income taxes whereby we recognize deferred tax assets and liabilities for the future tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets will be reduced by a valuation allowance if, based on management’s estimate, it is more likely than not that a portion of the deferred tax assets will not be realized in a future period. The estimates used in the recognition of deferred tax assets are subject to revision in future periods based on new facts and circumstances.

We determine whether it is more likely than not that a tax position will be sustained upon examination, including resolution of related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, we presume that the position will be examined by the appropriate taxing authority and that the taxing authority will have full knowledge of all relevant information. A tax position that meets the more-likely-than-not recognition threshold is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Determining what constitutes an individual tax position and whether the more-likely-than-not recognition threshold is met for a tax position are matters of judgment based on the individual facts and circumstances of that position evaluated in light of all available evidence. We review and adjust tax estimates periodically because of ongoing examinations by, and settlements with, the various taxing authorities, as well as changes in tax laws, regulations, and precedent. We are subject to a tax on global intangible low taxed income (“GILTI”) which we record as a period cost.

Our policy is to recognize interest and penalties related to income tax matters as a component of the provision for income taxes in our Consolidated Statements of Operations and Comprehensive Income (Loss).

Foreign Currency Translation – The functional currency of our foreign subsidiaries is generally the local currency. Accordingly, assets and liabilities are generally translated into U.S. dollars at the current rates of exchange as of the balance sheet date, and revenues and expenses are translated using weighted-average rates prevailing during the period. Adjustments from foreign currency translation are included as a separate component of accumulated other comprehensive income (loss).

Gains or losses arising from foreign currency transactions are recognized in the Consolidated Statements of Operations and Comprehensive Income (Loss) as foreign exchange loss (gain). The Company routinely enters into foreign currency forward contracts to manage foreign currency exchange rate risk of our intercompany loans in certain of our international subsidiaries and non-functional currency assets and liabilities. The foreign currency forward contracts expire on a monthly basis. For the years ended December 31, 2025, 2024 and 2023, foreign exchange loss related primarily to short-term losses (offset by short-term gains) on sales denominated in currencies other than the functional currency of our operating entities.

Revenue Recognition – Revenue is recognized when control of promised goods or services is transferred to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The majority of our sales agreements contain performance obligations satisfied at a point-in-time when control of promised goods or services have transferred to our customers. Sales recognized over time are generally accounted for using an input measure to determine progress completed as of the end of the period.

Refunds, returns, warranties and other related obligations are not material to any of our segments and we do not incur material incremental costs to secure customer contracts.

Our Sterigenics segment provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets. We typically have multiyear service contracts with our significant customers, and these sales contracts are primarily based on customers’ purchase orders. Given the relatively short turnaround times, performance obligations are generally satisfied at a point-in-time upon the completion of sterilization or irradiation processing and approval by our quality assurance process. Sterigenics segment revenues are included in service revenues in our Consolidated Statements of Operations and Comprehensive Income (Loss).

Our Nordion segment is a global provider of Co-60 and gamma irradiation systems, which are key components to the gamma sterilization process. Revenue from the sale of Co-60 sources is recognized as product revenue at a point-in-time upon satisfaction of our performance obligations for delivery of existing sources. Revenue from the sale of gamma irradiation systems is recognized as product revenue over time using an input measure of costs incurred and is immaterial to the overall business. Revenues from Co-60 installation and disposal and gamma irradiation systems refurbishments and installations are recognized as service revenue.

Our Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. We provide our customers mission-critical lab testing services, which assess the product quality, effectiveness, patient safety and end-to-end sterility of products. These services are necessary for our customers’ regulatory approvals, product releases and ongoing product performance evaluations. Nelson Labs services are generally provided on a fee-for-service or project basis, and we recognize revenues over time using an input measure of time incurred to determine progress completed at the end of the period. Nelson Labs segment revenues are included in service revenues in our Consolidated Statements of Operations and Comprehensive Income (Loss).

We do not capitalize sales commissions because substantially all of our sales commission programs have an amortization period of one year or less. Furthermore, costs to fulfill a contract are not material.

Provisions for discounts, rebates to customers, and other adjustments are provided for as reductions in net revenues in the period the related sale is recorded. Shipping and handling charges billed to customers are included in net revenues, and the related shipping and handling costs are included in “Cost of Revenues” on the Consolidated Statements of Operations and Comprehensive Income (Loss). Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from net revenue.

Payment terms vary by the type and location of the customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.

Share-Based Compensation – Equity-based awards issued to employees under the Sotera Health Company 2020 Omnibus Incentive Plan (“2020 Plan”) include restricted stock units (“RSUs”), performance stock units (“PSUs”) and stock options that vest over time.

Prior to our initial public offering (the “IPO” as described in Note 14, “Stockholders' Equity”), equity-based awards were issued to employees and non-employee directors in the form of partnership interests in our predecessor, Sotera Health Topco Parent, L.P. (“Topco Parent”), which vested based on either time (“time vesting awards”) or the achievement of certain performance and market conditions (“performance awards” and, together with the time vesting awards, the “pre-IPO awards”). In connection with the IPO, Topco Parent made in-kind distributions of restricted shares of our common stock to holders of pre-IPO awards as described in Note 14, “Stockholders' Equity.” The restricted shares of our common stock distributed in respect of pre-IPO time vesting awards vested through August 2025; expense related to these unvested awards was recognized over the remaining vesting period. Expense attributable to the performance awards was recognized in its entirety in the year ended December 31, 2020 as the related performance conditions were considered probable of achievement and the implied service condition was met.

Share-based compensation expense is recognized in the Consolidated Statements of Operations and Comprehensive Income (Loss) within “Selling, general and administrative expenses” at the grant date fair value over the requisite service period (one to three years for awards granted under the 2020 Plan and five years for time vesting pre-IPO awards on a straight-line basis). We

use the Black-Scholes option pricing model to measure the grant date fair value of stock options awarded under the 2020 Plan using certain valuation assumptions. Certain RSUs and PSUs contain a performance modifier based on the achievement of growth targets of the market value of the Company’s common stock price. The fair value of these awards is estimated using a Monte Carlo simulation valuation model, as these awards are subject to a market condition. Share-based compensation expense for all awards recognizes forfeitures as they occur.

Earnings Per Share – In periods in which the Company has net income, earnings per share information is determined using the two-class method, which includes the weighted-average number of common shares outstanding during the period and securities that participate in dividends (“participating securities”). Our unvested restricted common stock distributed in respect of partnership interests in Topco Parent (“pre-IPO Class B-1 restricted stock awards”) has the right to receive non-forfeitable dividends or dividend equivalents if the Company declares dividends on its common stock. Under the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period. Diluted earnings per common share incorporates the dilutive effect of common stock equivalents on an average basis during the period, if dilutive, in which case the dilutive effect of such securities is calculated using the more dilutive of (a) the two-class method, or (b) treasury stock method, as applicable, to the potentially dilutive instruments. Unvested restricted common stock is not included in the weighted average common shares outstanding figure within earnings per share until the period in which the vesting condition is satisfied. In periods in which the Company has a net loss, the two-class method is not applicable because the pre-IPO Class B-1 restricted stock awards do not participate in losses. Refer to Note 16, “Earnings Per Share” for additional information.

Treasury Stock – The Company records repurchases of its own common stock at cost. Repurchased common stock is presented as a reduction of equity in the Consolidated Balance Sheets. The difference between the repurchase and reissue price of the Company’s own stock is added to or deducted from additional paid-in capital. The cost of treasury stock reissued is calculated using a weighted average cost method.

Commitments and Contingencies – Certain conditions may exist as of the date of the consolidated financial statements which may result in a loss to the Company but will only be resolved when one or more future events occur or fail to occur. Such liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, settlement agreements, and other sources, are recorded when management assesses that it is probable that a future liability has been incurred and the amount can be reasonably estimated. Recoveries of costs from third parties, which management assesses as being probable of realization, are recorded to the extent related contingent liabilities are accrued. Legal costs incurred in connection with matters relating to contingencies are expensed in the period incurred. We record gain contingencies when realized.

Share-Based Compensation

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Share-Based Compensation

Pre-IPO Awards

Prior to our IPO, the Company’s equity-based awards issued to service providers (including directors and employees) included partnership interests in our predecessor, Topco Parent (Class B-1 or B-2 Units), which vested based on either time or the achievement of certain performance and market conditions.

Restricted stock distributed in respect of pre-IPO Class B-1 time vesting units vested on a daily basis pro rata over a five-year vesting period (20% per year) beginning on the original vesting commencement date of the corresponding Class B-1 time vesting units, subject to the grantee’s continued services through each vesting date. All pre-IPO Class B-1 time vesting units were fully vested as of August 2025.

Restricted stock distributed in respect of pre-IPO Class B-2 Units were considered performance vesting units. The performance thresholds were satisfied on March 4, 2024 and, as a result, all outstanding B-2 Units were fully vested as of that date.

We recognized $0.5 million, $1.6 million and $2.0 million of share-based compensation expense related to the pre-IPO Class B-1 awards for the years ended December 31, 2025, 2024, and 2023, respectively.

A summary of the activity for the years ended December 31, 2025, 2024 and 2023 related to the restricted stock distributed in respect of the pre-IPO awards (Class B-1 and B-2) is presented below:


	Restricted Stock - Pre-IPO B-1	Restricted Stock - Pre-IPO B-2
At January 1, 2023	716,091	1,098,415
Forfeited	(16,243)	(111,304)
Vested	(347,401)	—
At December 31, 2023	352,447	987,111
Forfeited	(2,651)	—
Vested	(278,345)	(987,111)
At December 31, 2024	71,451	—

Vested	(71,451)	—
At December 31, 2025	—	—

2020 Omnibus Incentive Plan

We maintain the 2020 Plan that allows for grants of incentive stock options to employees (including employees of any of our subsidiaries), nonstatutory stock options, restricted stock awards (“RSAs”), RSUs, PSUs and other cash-based, equity-based or equity-related awards to employees, directors, and consultants, including employees or consultants of our subsidiaries. A maximum of 27.9 million shares of common stock were originally available for awards under the 2020 Plan. At December 31, 2025, 13.8 million shares were available for future awards. The Company plans to issue authorized but unissued shares under the 2020 Plan or shares from treasury to satisfy requirements of awards paid with shares.

In March 2025, we awarded PSUs to certain members of the Company’s senior executive team. PSUs are designed to vest based on a combination of financial performance factors and continued service through the end of a three-year performance period. The PSUs’ financial performance factors have a threshold, target and maximum level of achievement and vest according to the performance level achieved by the Company during the performance period. Upon issuance of PSUs, we assume the financial performance target will be reached for the measurement period when determining the amount of compensation expense. If information becomes available to indicate that achievement above the target level is probable, compensation expense is adjusted accordingly.

In addition, in March 2025, we awarded RSUs to certain members of the Company’s senior executive team with a performance modifier based on the achievement of growth targets for the market value of the Company’s common stock price. The amount of awards that vest at the end of a service period may exceed the target number of RSUs awarded based on the stock price growth achieved.

In March 2025, our CEO was awarded PSUs (also referred to as share appreciation units or “SAUs”) that vest according to the achievement of stock price increases over their three-year performance period.

We recognize share-based compensation expense at grant date fair value over the requisite service period on a straight-line basis in our Consolidated Statements of Operations and Comprehensive Income (Loss), in “Selling, general and administrative expenses.” We recognized $30.5 million ($7.3 million for stock options, $20.4 million for RSUs and $2.8 million for PSUs and SAUs), $35.2 million ($16.4 million for stock options and $18.8 million for RSUs) and $30.4 million ($14.4 million for stock options and $16.0 million for RSUs) of share-based compensation expense for these awards for the years ended December 31, 2025, 2024 and 2023, respectively.

Stock Options

We use a Black-Scholes option pricing model to estimate the fair value of stock options. The expected volatility is based on the volatility of similar publicly traded businesses within the same or similar industry as the Company in combination with our own volatility. We used the simplified method to estimate the expected term due to the limited quantity of historical stock option exercises. The risk-free rate is based on the U.S. Treasury yield in effect at the time of the grant.

Weighted-average grant-date fair values of stock options and the assumptions used in estimating the fair values are as follows. No stock options were granted during the year ended December 31, 2025.


For the year ended December 31,	2024			2023
Weighted average grant date fair value per option	$	7.35		$	7.13
Expected term (years)	6 years			6 years
Risk-free interest rate	4.2		%	4.2		%
Expected volatility	46.8		%	50.0		%

Stock options generally vest ratably over a period of two to four years. They have an exercise price equal to the fair market value of a share of common stock on the date of grant, and a contractual term of 10 years. The following table summarizes our stock option activity for the year ended December 31, 2025:


	Number of Shares	Weighted-average Exercise Price		Remaining Contractual Life	Aggregate Intrinsic Value (millions of U.S. dollars)
Outstanding at the beginning of the year	8,328,051	$	14.94

Forfeited	(113,221)	18.92
Exercised	(30,949)	14.59
Outstanding at the end of the year	8,183,881	$	14.89	6.6 years	$	35.3
Exercisable at the end of the year	6,841,193	$	14.80	6.3 years	$	32.2
Unvested at the end of the year	1,342,688	$	15.32	7.9 years	$	3.1

At December 31, 2025, the total unrecognized compensation expense related to stock options expected to be recognized over the weighted-average period of approximately 1.1 years is $4.9 million. The total fair value of stock options vested during the years ended December 31, 2025, 2024 and 2023 was $9.8 million, $16.3 million and $10.6 million, respectively.

RSUs

RSUs generally vest ratably over a period of one to four years and are valued based on the market price on the date of grant. For RSUs with performance modifiers, management estimated the fair value using a Monte Carlo simulation valuation model, as

these awards are subject to a market condition. The following table summarizes our unvested RSUs activity for the year ended December 31, 2025:


	Number of Shares	Weighted-average Grant Date Fair Value
Unvested at the beginning of the year	2,278,537	$	13.73
Granted	1,583,130	13.48
Forfeited	(89,892)	12.87
Vested	(1,365,684)	12.74
Unvested at the end of the year	2,406,091	$	14.16

As of December 31, 2025, total unrecognized compensation expense related to RSUs expected to be recognized over the weighted-average period of approximately 1.7 years is $18.6 million. The total fair value of RSUs vested during the years ended December 31, 2025, 2024 and 2023 was $17.3 million, $15.4 million and $14.1 million, respectively. The weighted average grant date fair value of RSUs awarded during the years ended December 31, 2024 and 2023 was $14.05 and $16.95, respectively.

PSUs

PSUs vest at the end of a three-year service period and are valued based on our market price on the date of grant. PSUs awarded to our CEO with vesting conditions dependent upon the achievement of stock price increases were valued using a Monte Carlo simulation valuation model. The following table summarizes our unvested PSUs for the year ended December 31, 2025:


	Number of Shares	Weighted-average Grant Date Fair Value
Unvested at December 31, 2024	—	—
Granted	865,256	10.86
Forfeited	(5,604)	$	11.68
Unvested at December 31, 2025	859,652	$	10.86

Asset Retirement Obligations (“ARO”) - Schedule of ARO liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
ARO – beginning of period	$ 49,319	$ 47,944
Changes in estimates	191	1,240
Accretion expense	2,321	2,638	$ 2,413
Foreign currency exchange and other	1,665	(2,503)
ARO – end of period	$ 53,496	$ 49,319	$ 47,944